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Pancreatic ductal adenocarcinoma (PDAC) is characterised by a complex tumour 
supportive microenvironment including a dense fibrotic stroma (Farrow et al., 2008). 
Embryonic signalling pathways such as the Hedgehog (Hh) and Wnt pathway are 
involved in the interactions between cancer-associated fibroblasts (CAFs) and 
pancreatic tumour cells as well as maintenance of the tumour supportive 
microenvironment (Bailey et al., 2008, Zhang et al., 2013). Prognosis for PDAC 
remains poor (global 5 year survival rate of less than 10% (Siegel et al., 2015)) owing, 
in part, to limited therapy options available and resistance to current therapies. The 
tumour microenvironment has been implicated in chemotherapy resistance (Dauer et 
al., 2017, Hessmann et al., 2017) which has led to a need for drug screening 
techniques which include elements of the tumour microenvironment. I therefore 
sought to develop a co-culture model incorporating CAFs and epithelial cells that 
would better represent the tumour microenvironment. This model would enable the 
study of embryonic signalling pathways and how these may be exploited in the 
treatment of PDAC. Mixed 3D cultures of CAFs and cancer cell lines showed a 
morphology close to that of a tumour with the presence of CAFs dispersed throughout 
the spheroid. The Hh pathway was found to be upregulated in CAFs in 2D co-cultures 
of CAFs and PDAC cancer cell lines. The Wnt pathway was found to be upregulated 
in PANC1 cells in a 2D co-culture of CAFs and PANC1 cells. This demonstrated that 
the embryonic signalling pathways (Hh and Wnt) are involved in the cross talk 
between CAFs and PDAC tumour cells. 2D, co-culture of CAFs with PANC1 cells 
reduced sensitivity to gemcitabine, dependent upon the number of CAFs when 
compared to the monoculture of the PANC1 cells. Furthermore, when SUIT2 and 
BXPC3 cell lines were cultured in a 3D model, the presence of CAFs significantly 
reduced the efficacy of gemcitabine effectively conferring resistance. Together these 
results demonstrate a complex interaction between CAFs and PDAC tumour cells in 
an in vitro model that is similar to the in vivo microenvironment. In addition the 
presence of CAFs within 2D and 3D co-culture models has a considerable impact on 
pancreatic cancer cell resistance to gemcitabine and thus better reflects the clinical 
response. The difference in gemcitabine sensitivity between mono- and co-culture 
together with the more physiologically relevant morphology in the co-cultured 
spheroids, highlights the importance of in vitro drug screening techniques which better 
represent the tumour microenvironment in order to more accurately predict a 
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‘Cancer’ is the term given to a large number of heterogeneous diseases which result 
from uncontrolled cell proliferation in various organs of the body (Hanahan and 
Weinberg, 2000, Hanahan and Weinberg, 2011). To date, more than 200 different 
types of cancer have been defined with each having a unique pathology and 
treatment approach. Cancer was responsible for the death of 8.2 million people 
worldwide in 2012 and in 2013, 352,000 new cases of cancer were diagnosed in the 
UK alone (CRUK, 2016). There are many factors which can increase the risk of 
developing cancer: age, genetics and lifestyle choices such as smoking, diet, stress 
and alcohol consumption (McGuire, 2016).  
1.1.2. Molecular mechanisms 
Twenty-five years of research has resulted in a large volume of information which has 
exposed cancer as a disease resulting from multiple changes in the genome. Cancer 
is a genetic disease as it is a consequence of mutations in genes which are involved 
with normal cellular processes such as DNA repair, division and apoptosis. These 
genetic changes have been categorised into two groups: a dominant form which are 
collectively known as oncogenes, or the recessive form known as tumour suppressor 
genes. Mutations in oncogenes generally result in gain of function whereas any 
mutation in a tumour suppressor gene are loss of function (Bishop, 1991). In 2000, 
Douglas Hanahan and Robert Weinberg revolutionised the way in which we regard 
the development of a malignant phenotype from normal cells. They theorised that in 
order for a cell to be considered malignant it must have undergone six changes in its 
biology (Hanahan and Weinberg, 2000). Firstly the cell must be self-sufficient and no 
longer require the necessary growth signals from the host. In healthy tissue growth 
signals are carefully regulated; cells enter the cell-cycle in a manner which ensures 
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maintenance of a certain number of cells thereby ensuring the stability of tissue 
architecture allowing the tissues to operate effectively. In cancer cells these signals 
become deregulated and this deregulation occur in a variety of ways: they can secrete 
ligands which can effect proliferation in an autocrine manner, they can signal to other 
cells within the tumour microenvironment to influence proliferative signals, and they 
can express higher than normal levels of various receptors and become extremely 
sensitive to normal signals. Secondly, the cancer cells will be immune to antigrowth 
signals which are well-regulated pathways, controlled by tumour suppressor genes. 
One example of a tumour suppressor gene is the retinoblastoma (RB) gene. In adult 
tissues the role of RB is the regulation of apoptosis, acting as a G1 checkpoint and it 
is involved in the maintenance of chromosomal stability. Loss of function mutations in 
this gene have been found to result in retinoblastoma; it can increase risk for 
osteosarcoma. Human papillomavirus is believed to inactivate RB resulting in cervical 
carcinoma and squamous cell carcinoma in the head and neck (Burkhart and Sage, 
2008). Cancer cells are able to evade apoptosis by avoiding the regulations in place 
for control of tissue homeostasis. One example of this is the neurofibromatosis type 
2 (NF2) gene and its product Merlin which is a cytoskeletal protein acting at the cell 
membrane to organise adherin junction stabilisation which co-ordinates contact 
inhibition between cells (Curto et al., 2007). In addition, it regulates epidermal growth 
factor (EGFR) by sequestering it in a membrane compartment and, loss of NF2 has 
been found to be linked to various cancers (Curto et al., 2007). This indicates an 
important role for contact mediated cell growth inhibition which is lost in various 
cancer cells. Furthermore, cancer cells must have the ability to undergo unlimited 
replications. In the lifespan of a normal cell, it is only able to go through a limited 
number of cycles before passing into senescence. In a malignant cell this process is 
dysregulated which is believed to be due to telomere alterations (Raynaud et al., 
2010). In the same way that tissues require a rich blood supply to deliver oxygen and 
nutrients a tumour also needs vasculature to sustain growth. Many factors can impact 
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angiogenesis; one example is the regulation of vascular endothelial growth factor-A 
(VEGF-A) which has been found to be upregulated by oncogenic signalling (Ferrara, 
2010). It has long been established that as a tumour progresses the likelihood of local 
invasion to healthy tissues and metastases increases (Yokota, 2000, Arvelo et al., 
2016). In PDAC, early precursor cells have been found in circulation in mice (Rhim et 
al., 2012) suggesting that metastases in PDAC is an early event in tumour 
progression. The term metastasis was first used by French gynaecologist Joseph-
Claude Recamier in 1829 to describe the spread of cancer throughout the body 
(Récamier, 1829). Metastasis is a critical clinical challenge which is difficult to predict 
and has a serious impact on the patient. In 1889, Stephen Paget investigated the 
interactions between the host and tumour, specifically how this relationship impacted 
the likelihood of metastasis and which organs would be involved (Paget, 1889). This 
work led to the “seed and soil” hypothesis which stated that in order for a tumour to 
successfully metastasise the circulating tumour cell or “seed” had to find an 
environment which was rich enough to support growth “soil.” This theory contradicted 
the current theory of the time which proposed that tumour cells were simply being 
obstructed and becoming stuck within the circulation system therefore metastases 
was dependant by mechanical factors (Virchow, 1989). Over 100 years since its 
conception the “seed” and “soil” hypothesis has been the subject of many studies and 
it is now accepted that the “seed” refers to progenitor cells or cancer stem cells and 
“soil” refers to a metastatic niche (Langley and Fidler, 2011, Plaks et al., 2015). In 
order for metastases to form, the tumour must undergo the following steps: progenitor 
cells must break off from the primary tumour and enter circulation both hematologic 
and lymphatic. These cells must survive conditions within circulation before resting in 
a capillary bed and, in a similar manner to the way a primary tumour will invade 
surrounding tissues, the progenitor cells will infiltrate tissues and proliferate. Once the 
progenitor cells are proliferating vascularisation forms and the metastases is 
established. (Talmadge and Fidler, 2010). The ability for cancers to metastasise 
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completes the acquired traits that Hanahan and Weinberg postulated were required 
for a tumour to be considered malignant (Figure 1.1.). This reductionist view of cancer 
as a mass of homogenous tumour cells has since been expanded to include a tumour 
promoting microenvironment.  
 
Figure 1.1. Therapeutic targeting of the hallmarks of cancer 
Image obtained from Douglas Hanahan and Robert A. Weinberg’s review article “Hallmarks of Cancer: 
The Next Generation” published in cell in 2011. (Hanahan and Weinberg, 2011) Copyright License 
from Elsevier. 
 
In 2011 it was established that four additional factors influenced cancer progression 
and they referred to these additional characteristics as “emerging hallmarks” 
(Hanahan and Weinberg, 2011)(Figure 1.1.). One of which is the capacity cancer cells 
have to reprogram their ability to metabolise nutrients in a way that supports 
continued cell growth. The first time this metabolic switch was observed was in the 
1930’s during the investigations by Otto Warburg. He discovered that even in aerobic 
conditions cancer cells tend to undergo a metabolic switch which became known as 
the “Warburg effect”, wherein they metabolise glucose using glycolysis (Warburg, 
12 
 
1931, Warburg, 1956). Glycolysis is considerably less efficient than mitochondrial 
oxidative phosphorylation, therefore they need to compensate for this deficit in ATP 
production per glucose molecule.  
1.2. The pancreas 
The pancreas is an organ that has both exocrine and endocrine functions, it is located 
posterior to the bottom half of the stomach. The head of the pancreas is the widest 
part and is located in the right side of the abdomen in close proximity to the 
duodenum. The neck is between the head and the body of the pancreas, the body is 
the middle section of the gland, the superior mesenteric artery and vein run behind 
the body. The tail is the thin tip of the pancreas which sits in the left side of the 
abdomen which is located next to the spleen. The vast majority of the pancreas 
(approximately 95%) is made up of pancreatic acinar cells and surrounding pancreatic 
ducts. Less than 5% of pancreatic cells are groups of endocrine cells which are 
referred to as islets of Langerhans (Figure 1.2.). 
 





1.2.1. The exocrine function of the pancreas 
The exocrine function of the pancreas is carried out by pancreatic acinar cells which 
secrete digestive enzymes into pancreatic ducts. The smaller pancreatic ducts 
increase in size until they form the main pancreatic duct. The acinar cells are 
pyramidal in shape and are filled with eosinophillic zymogen granules. These cells 
are arranged in “nests” with a central lumen. The function of these cells is the 
synthesis, storage and secretion of digestive enzymes, which become activated once 
they reach the duodenum. 
1.2.2. The endocrine function of the pancreas 
The islets of Langerhans are responsible for the endocrine function of the pancreas, 
they secrete the hormones insulin, glucagon, somatostatin and pancreatic 
polypeptide. There are four cell types which make up the islets of Langerhans: α-
cells, β-cells, δ-cells and γ-cells. α-cells make up around 20% of the islets, and their 
primary purpose is to produce glucagon (Quesada et al., 2008). Glucagon is involved 
in the regulation of blood glucose levels and is released when blood glucose levels 
are low. It has three mechanisms of action: firstly, it causes the liver to convert its 
glycogen stores back into glucose in a process referred to as glycogenolysis; 
secondly, it stimulates the uptake of amino acids from blood by the liver in order to 
produce glucose, this is known as gluconeogenesis; finally, it causes the breakdown 
of triglycerides into fatty acids and glycerol, this process is known as lipolysis. The 
combination of these processes result in an increase in blood glucose levels. 75% of 
the islets of Langerhans are β-cells which are responsible for the secretion of insulin 
(Hellerstrom, 1984). Insulin is secreted in response to an increased blood glucose 
level. The most important function of insulin is to cause the uptake of glucose from 
blood. 4% of islets are made up of δ-cells which secrete somatostatin, which is an 
inhibitor of insulin and glucagon secretion. The final cell type which make up the islets 
are the PP or γ-cell which secrete pancreatic polypeptide hormone which is believed 
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to effect appetite in addition to regulating the exocrine and endocrine functions of the 
pancreas. The islets of Langerhans secrete their hormones directly into the blood 
stream. 
1.3. Pancreatic cancer 
1.3.1. Incidence and risk factors 
Pancreatic cancer is the seventh most common cause of cancer-related mortality 
worldwide with approximately 330,000 deaths in 2012 accounting for 4% of total 
cancer related deaths. The pancreatic cancer mortality rate appears to be highest in 
North America however this could be an artefact of the ability to accurately collect 
data in the developing world. The incidence of pancreatic cancer is 12th worldwide 
with a mortality to incidence rate of 98% (Ferlay et al., 2015). Pancreatic ductal 
adenocarcinoma (PDAC) is the most common form of the malignancy accounting for 
more than 95% of cases (Becker et al., 2014). PDAC forms from the cells lining 
pancreatic ducts and is an exocrine tumour, most commonly found in the head of the 
pancreas (Hruban and Fukushima, 2007). Incidences of pancreatic cancer increase 
with age with the majority of cases appearing in the population in the 65-75 year age 
group. Median survival rate for metastatic pancreatic cancer is 3-5 months and in 
cases of locally advanced disease 6-10 months. Unfortunately due to the difficulties 
in diagnosis most cases are advanced upon diagnosis (Kaur et al., 2012, Oberstein 
and Olive, 2013). In the UK pancreatic cancer is the 11th most common form of cancer 
and in 2014 9,600 new cases were diagnosed which is approximately 26 per day. 
Over the past 10 years incidence of pancreatic cancer has increased by 10% and this 
is only predicted to increase. However it has been suggested that the apparent 
increase in incidence of pancreatic cancer could be due to more cases actually being 
identified as pancreatic cancer as advancements in diagnostics have developed 
(Kaur et al., 2012). Unfortunately this disease has a very poor prognosis with only a 
very small proportion of people diagnosed surviving with the disease for greater than 
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10 years which has not changed since the 1970’s. Less than 3% of individuals 
diagnosed will survive for 5 years or more; 20% of patients diagnosed will only survive 
for 1 year or more (CRUK, 2016). All of the cancer statistics reviewed above highlight 
the need for advances in tools to diagnose early disease and more sophisticated 
personalised treatment options. There are various risk factors which have been linked 
to the development of pancreatic cancer; age is a critical factor for the development 
of pancreatic cancer as only 5-10% of new cases occur in patients below 50 years of 
age. The median age for development of pancreatic cancer in the USA is 72 years 
which indicates that this is a disease which will continue to pose a risk as the aging 
population increases (Raimondi et al., 2009). It has been demonstrated that there is 
strong correlation between smoking and the development of pancreatic cancer and it 
has been estimated that smoking is responsible for up to 25% of pancreatic cancer 
cases despite the fact that this is the most preventable risk factor (Iodice et al., 2008). 
It has long been suggested that there is a link between alcohol and pancreatic cancer, 
however clear data around this risk factor is lacking due to a number of confounding 
variables. A recent meta-analysis of dose of alcohol versus pancreatic cancer 
indicates that high levels of alcohol intake leads to an increased risk of developing 
pancreatic cancer (Wang et al., 2016b). There is an indirect role for alcohol 
consumption, over 40g per day increases an individual’s risk of developing both acute 
and chronic pancreatitis (Samokhvalov et al., 2015) which in turn increases a patients 
risk of developing pancreatic cancer. Pancreatitis is a result of inflammation of the 
pancreas caused by the early activation and release of digestive enzymes. Chronic 
pancreatitis and hereditary pancreatitis have both been shown to dramatically 
increase a patient’s risk of developing pancreatic cancer (Lowenfels et al., 1993, 
Lowenfels et al., 1997). Many investigations have been undertaken to determine a 
role of obesity in the development of pancreatic cancer (Reeves et al., 2007, Patel et 
al., 2005) however, the precise mechanism of association has yet to be defined. 
Nevertheless, there appears to be a link between body mass index (BMI) and risk of 
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pancreatic cancer (Bracci, 2012). Diabetes is associated with increased risk, 
commonly type 2 (Hassan et al., 2007), specifically long term sufferers who have had 
diabetes for over 10 years (Huxley et al., 2005). A sudden and unexpected diabetes 
diagnosis can also be a symptom of pancreatic cancer and occurs in more than half 
of pancreatic cancer patients (Chari et al., 2008). 
1.3.2. Biology 
The most common form of pancreatic cancer is PDAC which develops from non-
invasive precursor lesions (PanIN) to an invasive cancer (Yachida et al., 2010). This 
tumour is a fibrotic white/yellow coloured mass invading neighbouring tissue which 
normally exhibits signs of fibrosis, atrophy and dilated ducts. All pancreatic lesions 
are classified based on the tumour node metastases (TNM) classification of malignant 
tumours staging system. This system takes into account the size of the primary 
tumour, lymph node status and the presence of distant metastases. Due to the lack 
of a screening test for pancreatic cancer, most patients are diagnosed already having 
distant metastases. Evidence suggests that if pancreatic cancer was detected at an 
earlier stage this would significantly increase the 5-year survival rate of patients (Chari 
et al., 2015).  
1.3.3. Genome instability 
1.3.3.1. KRAS 
KRAS encodes a GTPase which is approximately 21 kDa in size; it cycles between 
two forms: a GTP bound active form, and the inactive GDP-bound form. This cycling 
between inactive and active forms is mediated via guanine nucleoside exchange 
factors (GEFs) which are involved in the transition from GDP to GTP. Inactivation of 
KRAS protein is achieved through GTPase activating proteins (GAPs) which 
hydrolyse GTP. If the interaction which is required for the correct functioning of KRAS 
and GAPs is damaged in any way, constitutive activation of KRAS occurs. This leads 
to the constant stimulation of many downstream signalling pathways such as 
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RAF/MEK/ERK, PI3K/PDK1/AKT and MAPK (Eser et al., 2014). These pathways are 
involved in many of the processes which have been highlighted as important in the 
development of cancer as they are responsible for proliferation, apoptosis and 
metabolic reprogramming as well as other key functions which determine cell fate 
(Eser et al., 2014). Mutations in the KRAS oncogene are prevalent in PDAC and are 
found in greater than 80% of cases (Biankin et al., 2012, Waddell et al., 2015, 
Witkiewicz et al., 2015). The importance of mutations in this gene as an initiating 
event for PDAC are clear from the ability of KRAS to drive genetically engineered 
mouse models (GEMMs), which progress through the disease stages from early 
PanIN to an advanced state (Perez-Mancera et al., 2012). It is also one of the earliest 
genetic mutations to occur and has been found in the earliest instances of PanIN 1A 
lesions (Kanda et al., 2012).  
1.3.3.2. TP53 
Up to 75% of PDAC cases have an inactivating mutation in the tumour suppressor 
tumour protein (TP53) gene which encodes the p53 protein which is essential for the 
normal functioning of the cell cycle (Liu and Kulesz-Martin, 2000). In a healthy cell 
p53 has a role in the regulation of the G1-S cell cycle checkpoint and is involved in 
the induction of apoptosis in response to damaged DNA. A loss of function mutation 
in this gene allows cells to continue to divide and survive even in the presence of 
damaged DNA which eventually leads to the accumulation of genetic mutations 
(Vogelstein and Kinzler, 2004). 
1.3.3.3. DPC4/SMAD4 
Loss of function mutations in Deleted in pancreatic carcinoma (DPC4/SMAD4) are 
present in approximately 55% of pancreatic cancers. SMAD4 is a member of the 
transforming growth factor-β (TGF-β) signalling pathway. Activation of TGF-β 
signalling results in the nuclear localisation of SMAD2/3 in complex with SMAD4. The 
TGF-β signalling pathway controls cell fate by regulating the expression of specific 
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target genes, therefore mutations which prevent the inhibition of cell growth by TGF-
β confers a growth advantage on transformed cells (Siegel and Massague, 2003). 
Loss of SMAD4 expression is observed from PanIN-3 lesions and onwards in 
tumorigenesis (Wilentz et al., 2000).  
1.3.3.4. CDKN2A 
Loss of function mutations in Cyclin-dependant kinase inhibitor 2A (CDKN2A) are 
prevalent in over 50% of PDAC cases. It encodes two proteins, p16 and p14 which 
are both tumour suppressor proteins (Waddell et al., 2015, Barrett et al., 2017, 
Cicenas et al., 2017). p16 prevents phosphorylation of the retinoblastoma protein, 
which eventually results in inhibition of the E2F transcription factor which stops cells 
from progressing through the G1 cell cycle checkpoint. p14 is also involved in the 
regulation of cell growth as it stabilises p53. p53 once activated can arrest cyclin 
dependant kinases at G1 and G2 checkpoints which can trigger apoptosis (McWilliams 
et al., 2011). p16- and p14-related cell growth arrest is highly involved in the 
prevention of transformation from normal to neoplastic cells (Barrett et al., 2017). 
1.3.4. The PDAC tumour microenvironment 
One definition of the tumour microenvironment is the non-transformed components 
found in the immediate vicinity of a tumour which include stroma, vasculature and 
immune cells (Madar et al., 2013). PDAC is a unique type of solid tumour due to the 
dense desmoplastic reaction which is characteristic of this cancer, the desmoplastic 
reaction is composed of activated CAFs which deposit excessive amounts of 
extracellular matrix proteins The correlation between fibrosis and poorer outcomes 
has been reported (Nakatsura et al., 1997, Watanabe et al., 2003), specifically the 
relationship between fibrosis and metastases to the liver, bone or lung (Distant 
metastases). The tumour microenvironment is an important source of support for 
tumour cells; it contains cancer-associated fibroblasts (CAFs) including pancreatic 
stellate cells (PSCs) a subpopulation of CAFs, extracellular matrix proteins (ECM) 
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such as collagen and fibronectin and immune cells which all contribute to the chemo-
resistance of this aggressive tumour (Figure 1.3.). 
 
Figure 1.3. 
Components of the Pancreatic Tumour Microenvironment 
In an uninjured exocrine pancreas pancreatic ducts are lined by epithelial cells, quiescent fibroblasts 
with very few immune cells such as T and B lymphocytes and a very limited extra cellular matrix. In a 
PDAC cancer cells invade surrounding tissues and a large desmoplastic reaction is observed. The 
progression of tumorigenesis leads to the activation of CAFs which in turn leads to an increase in 
deposition of extra cellular matrix proteins. Immune cells infiltrate the stroma and can become part of 
the cancer supporting microenvironment. Angiogenesis increases due to the increased need to nutrients 
and oxygen to support the tumour. 
1.3.4.1. Cancer-associated fibroblasts 
The first description of fibroblasts was late in the 19th century (Virchow, 1989); they 
are not vascular, epithelial or immune cell derived but an elongated cell type found 
embedded within connective tissue (Kalluri and Zeisberg, 2006). Fibroblasts are 
responsible for maintaining the homeostasis of ECM. They produce many of the 
elements of ECM such as collagen (Type I, III and V) and fibronectin in addition to 
matrix metalloproteinases (MMPs) which have a role in the degradation of ECM 
proteins. In a damaged organ they have an important function in wound repair as they 
provide a scaffold for other cells types to infiltrate (Tomasek et al., 2002). Due to their 
role in the turnover of ECM they play an important role in scarring and tissue fibrosis. 
In an area of fibrosis or at the site of a healing wound, fibroblasts secrete higher levels 
of ECM and are found to be in an “activated” phenotype (Kendall and Feghali-
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Bostwick, 2014). CAFs are derived from different parental cells which include PSCs, 
pancreatic fibroblasts and bone marrow derived cells (Hinz et al., 2007, Erkan et al., 
2012a). PSCs are believed to be the most prevalent source of CAFs in the PDAC 
tumour microenvironment. PSCs were first identified in 1998 as star shaped cells 
which characteristically stored fat droplets and were rich in vitamin A; they were 
reminiscent of hepatic stellate cells (Apte et al., 1998, Bachem et al., 1998). 
Pancreatic injury results in a switch from quiescent PSC to myofibroblast with alpha 
smooth muscle actin (αSMA) expression, increased ECM secretion and loss of lipid 
droplets (Omary et al., 2007). The embryonic YAP-Hippo pathway was identified as 
a pathway involved in stem cell renewal and tissue regeneration (Cordenonsi et al., 
2011, Cai et al., 2010, Papaspyropoulos et al., 2018). This pathway has been found 
to be upregulated in the PDAC tumour microenvironment specifically in the stroma 
and is believed to be involved in the proliferation and activation of CAFs (Morvaridi et 
al., 2015). There is a theory that epithelial cells could also be a possible source for 
CAFs when they undergo Epithelial-to-Mesenchymal transition (EMT) (Iwano et al., 
2002). 
1.3.4.2. Extracellular matrix 
The PDAC tumour microenvironment contains an abundance of ECM, collagen, 
fibronectin, proteoglycans and hyaluronic acid. The presence of a large amount of 
ECM is believed to contribute to resistance to chemotherapy as it distorts the 
architecture of the pancreas, compressing capillaries and lymphatic vessels which 
leads to a reduced level of drug actually reaching tumour cells (Wehr et al., 2011, 
Mahadevan and Von Hoff, 2007). 
1.3.4.3. Immune cells 
Inflammatory cells are present in the PDAC tumour microenvironment and are 
believed to support the progression of PDAC. Inflammation of the pancreas in the 
form of chronic pancreatitis is a significant risk factor for PDAC (Lowenfels et al., 
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1993). The infiltrating immune cells present in the PDAC tumour microenvironment 
have been found to be immunosuppressive in nature such as regulatory T-cells and 
myeloid derived suppressor cells (MDSCs) with very few cytotoxic T lymphocytes 
present (CTLs) (Clark et al., 2007).  
1.3.4.4. Blood vessels 
The PDAC tumour microenvironment is very poorly vascularised which results in a 
hypoxic microenvironment; this is believed to contribute to its resistance to 
chemotherapy (Provenzano and Hingorani, 2013). Despite this, in vitro tumour cells 
have been shown to secrete vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF) (Koong et al., 2000, Erkan et al., 2009). Higher levels of VEGF 
in patients correlates with increased vascular density and a worse prognosis in 
patients (Carr and Fernandez-Zapico, 2016). Depleting the blood supply has not had 
much success in the clinic but remains an attractive target on the basis that if it is 
possible to deplete the blood supply further it could cause hypoxic necrosis within the 
tumour (Cook et al., 2012). 
1.3.4.5. Nerves 
In a healthy pancreas there is an extensive nerve supply which contains ganglia, 
myelinated and unmyelinated nerve cells. Peri-neural invasion of the tumour 
correlates with worse survival in patients after resection of the tumour which is 
mediated by CXCR1 (Shen, 2010, Marchesi et al., 2008). The reason for this effect 
on prognosis is not clear, though it has been suggested that it could be due to the 
degree of differentiation of the tumour (Bapat et al., 2011). The nerves present in the 
PDAC tumour microenvironment appear to be large and denser than in the normal 
pancreas, but their impact on tumour progression is not well understood. The 
presence of these nerves in the PDAC tumour microenvironment is believed to 




1.3.5. Chemotherapeutic treatment of PDAC 
Currently, only 15-20% of patients are diagnosed with disease that is eligible for 
surgical resection. A stage I PDAC tumour is present within the pancreas and does 
not have any blood vessel/lymph node involvement or distant metastases (Cid-
Arregui and Juarez, 2015). Unfortunately approximately 65% of patients have a 
tumour recurrence due to the presence of micro-metastases. Stage II PDAC involves 
local invasion of the tissue surrounding the pancreas such as the duodenum or bile 
ducts, but does not extend to lymph nodes or metastases (Cid-Arregui and Juarez, 
2015). Only stage I and II PDAC tumours are eligible for surgery. The majority of 
patients present with locally advanced or metastatic disease and are therefore not 
eligible for surgery (Neoptolemos et al., 2003). 
1.3.5.1. Gemcitabine 
Gemcitabine has been the standard of care for patients with PDAC for the last 20 
years (Burris et al., 1997). It increased the survival rate in patients treated with 
Fluorouracil (5-FU) the standard of care at that time from 2% to 18% in patients 
treated with Gemcitabine; it also had reduced disease related symptoms such as 
pain, Karnofsky performance status (KPS) and weight (Burris et al., 1997). The 
uptake of Gemcitabine depends on transporters primarily the human equilibrative 
nucleoside transporter-1 (hENT-1), which has been found to be overexpressed on 
pancreatic cancer cells (Damaraju et al., 2003, Fujita et al., 2010). Once it is within 
the cells, Gemcitabine is phosphorylated by deoxycytidine (dCK) to the 
monophosphate form of the molecule followed by its conversion to 
difluorodeoxycitidine (dFdCTP) which is the active metabolite responsible for the 
cytotoxic effects of Gemcitabine as it is a substrate for DNA and RNA polymerases 
(Huang et al., 1991).  
Unfortunately, not all patients respond to Gemcitabine due to mechanisms of 
chemotherapy resistance (Andersson et al., 2009). There are a variety of reasons a 
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patient may not respond to treatment with Gemcitabine. One study used 
transcriptional analysis of genes to determine the hENT-1 expression in patients, 
patients who were found to have high levels of hENT-1 responded significantly better 
to treatment with Gemcitabine (Giovannetti et al., 2006). Deficiencies in dCK have 
also been found to be associated with resistance to Gemcitabine (Kroep et al., 2002). 
High Mobility Group AT-Hook 1 (HMGA1) has been implicated in Gemcitabine 
resistance and has been found to be upregulated in PDAC patients (Liau and Whang, 
2008). It is involved in chemotherapy resistance through an Akt-dependant 
mechanism which is believed to have an impact on resistance to apoptosis (Liau et 
al., 2006). One other major factor in the resistance to chemotherapy is the PDAC 
tumour microenvironment which has a very low vascular density which impedes the 
delivery of chemotherapeutic agents (McCarroll et al., 2014).  
1.3.5.2. FOLFIRINOX 
FOLFIRINOX is a combination of oxaliplatin, irionotecan, fluorouracil and leucovorin; 
it showed a modest increase on patient survival compared to Gemcitabine alone. 
However the adverse effects associated with this treatment were increased compared 
to patients in the Gemcitabine only control group (Schober et al., 2015).  
1.3.5.3. Nab-Paclitaxel 
Albumin bound paclitaxel (Nab-paclitaxel) in combination with Gemcitabine 
increased the 1 and 2 year survival rates of patients compared with Gemcitabine 
alone (Von Hoff et al., 2013). This synergy was related to the increased drug 
delivery due to the presence of the albumin (Frese et al., 2012). Secreted protein, 
acidic and rich in cysteine (SPARC) which is present in abundance in the PDAC 
tumour microenvironment binds albumin and sequesters nab-paclitaxel leading to 
an increase in its concentration in the tumour (Frese et al., 2012). 
Unfortunately the current strategies to treat PDAC have not had a significant impact 
on the 5-year survival rate of patients compared to other gastrointestinal tumours 
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(Siegel et al., 2015), which highlights the need for the development of targeted 
therapies to treat PDAC. 
1.4. The Embryonic signalling pathways in PDAC 
1.4.1. The Hedgehog signalling pathway 
1.4.1.1. Hedgehog ligands 
The Hedgehog (Hh) family of signalling molecules are a highly conserved family of 
ligands with many roles within developing embryos. In adult organisms they have a 
diverse range of functions from controlling cell fate, maintaining stem cell populations, 
tissue repair and cellular differentiation (Michel et al., 2012, Matsumoto et al., 2016, 
Chen et al., 2016). Christiane Nusslein-Volhard and Eric Wieschaus first identified the 
Hedgehog gene during their investigations into the genes involved in the development 
and patterning of Drosophila Melanogaster (Nusslein-Volhard and Wieschaus, 1980). 
They won the Nobel Prize in Physiology or medicine for this work which gave new 
insight into the molecular mechanisms of early development in multicellular 
organisms. The Drosophila Hh gene was identified in the early 1990’s by three groups 
(Lee et al., 1992, Mohler and Vani, 1992, Tabata et al., 1992). In 1993 three murine 
homologs of the Hh gene had been identified they were named Sonic hh, Indian hh, 
and Desert hh (Shh, ihh, dhh) (Echelard et al., 1993). These genes were discovered 
to be incredibly well conserved between mouse and human (Marigo et al., 1995). 
1.4.1.2. Hedgehog post-translational modifications 
In order to become functionally active ligands, the Hh precursor proteins (Shh) must 
undergo various post translational modifications. Hh proteins are produced as 45kDa 
proteins which are autocatalytically cleaved to form a 19kDa NH2 fragment with all 
the signalling capacity and a 26kDa COOH- fragment which is responsible for the 
cleavage and has a role as a cholesterol transferase, which is the first lipid 
modification that the N-terminal fragment undergoes (Porter et al., 1996). The second 
lipid modification is the addition of a palmitic acid group, which is catalysed by the O-
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acetyltransferase skinny hedgehog (Figure 1.4.). The combination of these 
modifications make it a poorly soluble molecule, however they allow its association 
with cell membranes which are rich in sterols (Chen et al., 2004).  Shh ligands can 
signal as monomers short range (~40μm), but during development their role in limb 
patterning in vertebrates for example requires long range signalling (up to 300µm). In 
order for long range signalling to be possible the ligands must have undergone the 
lipid modifications described above as this it allows the formation of the large 
multimeric complexes that are required for this type of signalling (Koleva et al., 2015). 
 
Figure 1.4. Post translational modifications of Shh 
The 45kDa precursor protein is processed into a 26kDa and 19kDa terminal. The 19kDa is responsible 
for the signalling whereas the 26kDa carboxy terminal catalyses the addition of a cholesterol molecule 
to the amino terminus. In addition to a cholesterol molecule the amino terminal is further modified by the 
addition of a palmitic acid, this reaction is catalysed by Skinny Hedgehog. The cholesterol modification 
is also important for the secretion of Hh ligands from Hh producing cells, the cholesterol binds directly to 
the membrane transporter Dispatched which facilitates the secretion of ligands from cells. 
1.4.1.3. The pathway 
The first Hh receptor discovered was Patched (PTCH1) a 12-pass transmembrane 
protein with 2 extracellular loops which are responsible for the binding of Shh. PTCH1 
has three co-receptors GAS1, CDON and BOC which are necessary for its signalling 
(Beachy et al., 2010). When Shh binds PTCH1 it releases its repression of 
45 kDa SHH Precursor Protein 
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Smoothened (SMO) a 7-pass transmembrane protein. SMO is a G-protein coupled 
receptor (GPCR) which, once it is repression is relieved, translocates to the cell 
membrane via the primary cilia. SMO is the mediator of Hh signalling which triggers 
a downstream signalling cascade resulting in the dissociation of GLI proteins from 
kinesin-family protein, Kif7 and SUFU (Figure 1.5.). In the absence of a Shh ligand 
GLI proteins are still present in the cilia, however they are bound by SUFU and Kif7 
which results in one of two possible outcomes: the phosphorylation of GLI by PKA, 
GSK3β and CK1 which causes it to be processed into its transcriptional repressor 
form GLI3; or GLI protein is targeted for degradation which is mediated by E3 ubiquitin 
ligase (Briscoe and Therond, 2013). The binding of Shh causes a disruption of the 
equilibrium between the activator (GLI1, GLI2) or the repressor forms (GLI3) of the 
GLI proteins.  
Figure 1.5. The hedgehog signalling pathway 
Canonical Hedgehog signalling in the presence and absence of Shh ligand. Shh binding to Ptc results 
in a downstream signalling cascade which concludes in the activation of GLI1/2 and transcription of Hh 
target genes. HhN refers to Hh ligands (amino-terminal) which have undergone post translational 
modifications. Illustration reproduced courtesy of Cell Signalling Technology, Inc (www.cellsignal.com). 
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1.4.1.4. The GLI transcription factors 
There appears to be an evolutionary division between Drosophila and vertebrate Hh 
signalling as vertebrate Hh signalling activation and repression requires the primary 
cilia of a cell (Goetz et al., 2009). Genetic screening has identified a plethora of cilia-
related proteins which, when mutated are responsible for a variety of human diseases 
which have been termed ciliopathies. They have similar to symptoms to diseases 
resulting from defective Hh signalling (Bangs and Anderson, 2017). In the absence of 
Shh ligand PTCH1 is located at the base of primary cilia, but SMO and GLI proteins 
are absent they translocate through the cilia in the presence of Shh. There are three 
proteins (PKA, GSK3β and CKI) which are involved in GLI protein processing and 
they are located in the primary cilia. Upon Shh binding to PTCH1 there are changes 
which occur in the primary cilia, PTCH1 moves out of the cilia and SMO accumulates 
within it. In the absence of Hh signalling SUFU negatively regulates the pathway by 
sequestering the GLI1 proteins in the primary cilia, which begins the process by which 
they are degraded (Briscoe and Therond, 2013). Shh binding to PTCH1 results in an 
accumulation of GLI2 in the primary cilia, which overcomes Hh pathway repression 
by GLI3, GLI1/GLI2 are translocated to the nucleus and activates Hh target genes 
(Figure 1.5.) (Rimkus et al., 2016, van den Brink, 2007). Changes in the expression 
of Hh pathway components PTCH1, SMO and GLI1 are most commonly used to 
identify changes in Hh pathway activity (Lauth et al., 2007, Huang et al., 2006, Onishi 
et al., 2011). 
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1.4.1.5. The hedgehog signalling pathway in development 
In order to yield a biological response, the Hh pathway maintains a balance between 
the activator (GLI1, GLI2) and repressor forms (GLI3) of the GLI transcription factors. 
During development Shh is expressed throughout the midline tissues specifically the 
notochord and floor plate which control left-right and dorso-ventral patterning of the 
embryo (Sampath et al., 1997, Pagan-Westphal and Tabin, 1998, Schilling et al., 
1999, Watanabe and Nakamura, 2000). Shh is also expressed in the limb buds during 
development and is responsible for the patterning of the development of the distal 
limbs (Riddle et al., 1993, Johnson et al., 1994). In the later stages of development 
Shh also has a role in the development of epithelial tissues (Chuong et al., 2000). dhh 
expression is found mainly in the ovaries and testis and is involved in the maintenance 
of sertoli and granulosa cells (Bitgood et al., 1996, Wijgerde et al., 2005). ihh is 
expressed in a variety tissues including the endoderm, gut and bones (Dyer et al., 
2001, van den Brink, 2007, Vortkamp et al., 1996). One unique characteristic of Hh 
signalling is its ability to exert a biological effect over long distances; in mammals this 
is approximately 300μm (Zhu and Scott, 2004) compared to short range signalling 
which is 40μm (approximately 10 cells). The gradient of Hh signalling is tightly 
controlled and is dependent on the context of the Hh signal. This is most apparent 
during development of the neural tube in mammals; Shh is secreted from the 
notochord and floor plate and diffuses across the ventral neural tube which creates a 
concentration gradient across this region (Jessell, 2000, Patten and Placzek, 2000). 
The cells exposed to different concentrations of Shh differentiate into 5 different 
neuronal subtypes (Marti and Bovolenta, 2002). 
1.4.1.6. The hedgehog target genes 
Due to its diverse array of functions during development and homeostasis, Hh 
pathway activation can have a wide variety of consequences within the tumour 
microenvironment. The Hh pathway is critical for the developing embryo especially 
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as it has control over cell proliferation and survival. The tumour is able to hijack this 
signalling pathway to promote tumour proliferation and survival through the 
upregulation of fibroblast growth factor (FGF) (Sherman et al., 2017), insulin like 
growth factor binding protein 6 (IGFBP6) (Hao et al., 2013), histone deacteylase 
(HDAC) (Lee et al., 2013b), telomerase reverse transcriptase (TERT) cyclin D1 (Mille 
et al., 2014), B-cell lymphoma-2 (Bcl-2)(Han et al., 2009) and nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) (Hanna and Shevde, 2016). The 
upregulation of TERT also allows cells to transform to neoplastic cells with unlimited 
replicative capability (Mazumdar et al., 2013). Hh pathway activation also leads to an 
upregulation of inflammatory cytokines in the tumour microenvironment including 
nucleotide-binding oligomerisation domain-containing protein 2 (NOD2) (Ghorpade et 
al., 2013), tumour necrosis factor-alpha (TNF-α), interleukin-1-Beta (IL-1β) and 
interleukin-6 (IL-6) (Li et al., 2015) which are involved in tumour development. The 
Hh pathway has also been associated with inducing angiogenesis as this is a 
necessary requirement during the development of the embryo. This is achieved 
through the upregulation of VEGF (Pinter et al., 2013), FGF, vascular endothelial 
growth factor receptor (VEGFR) (Hong et al., 2013) and cysteine-rich angiogenic 
inducer 61 (CYR61)(Harris et al., 2012). The Hh pathway is involved in the 
differentiation of cells in development; in the tumour this facilitates metastases and 
invasion which is achieved by the upregulation of matrix metalloproteinases and 
activation of the transforming growth factor beta-1 (TGF-β) (Choe et al., 2015). 
1.4.2. The Wnt signalling pathway 
1.4.2.1. Post-translational modifications of Wnt ligands  
Wnt ligands are glycoproteins approximately 40kDa in size and contain many cysteine 
residues, which are critical in the formation of disulphide bonds which occur during 
appropriate folding of the protein. To date, 19 Wnt ligands have been identified 
(Mason et al., 1992). Immature Wnt ligands undergo post translational modification in 
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the endoplasmic reticulum (ER). Firstly, N-linked oligosaccharide chains are added 
to the peptide backbone, however the biological function of this modification is not 
clear (Reichsman et al., 1996). The next step is the addition of a palmitate group by 
the O-acetyl transferase Porcupine (PORCN) which is present in the ER (Tanaka et 
al., 2002). The addition of the palmitate group has been associated with the 
successful trafficking and secretion of Wnt ligands from the donor cell, by targeting 
the Wnt ligands to the cell membrane. The palmitate moiety has also been identified 
as playing a role in ensuring the appropriate folding of the proteins so they do not get 
retained by the ER (Mikels and Nusse, 2006). One theory also suggests that the lipid 
modification has an important role after the secretion of Wnt as it targets the ligand to 
the cell membrane arguing; that it controls the spatial distribution of Wnt ligands after 
secretion (Vincent and Dubois, 2002). 
1.4.2.2. The canonical Wnt signalling pathway 
Just as there are many Wnt ligands there are also many different Wnt receptors. 
There are 10 known human Wnt receptors known as Frizzled (Fzd) receptors which 
are 7-pass transmembrane proteins. All Fzd receptors have an extensive extracellular 
domain which has a cysteine rich site which binds Wnt ligands (Hsieh et al., 1999, 
Wu and Nusse, 2002). In addition, there are low density lipoprotein (LDL) receptor 
related proteins 5 and 6 (LRP5 and LRP6), which are required for active Wnt 
signalling. Different Wnt and Fzd receptor combinations are responsible for the 
activation of either the canonical or non-canonical Wnt signalling pathway 
(Dijksterhuis et al., 2014). 
In the absence of Wnt ligands a scaffolding protein, Axin interacts with the β-Catenin 
degradation complex which consists of glycogen synthase kinase 3 (GSK3), casein 
kinase 1-alpha (CK1α) and adenomatosis polyposis coli (APC). In a complex together 
they organise the phosphorylation of β-Catenin at serine 45 by CK1α followed by 
threonine 41, serine 37 and serine 33 by GSK3 (Kimelman and Xu, 2006). This 
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process targets the β-Catenin for ubiquitination and subsequent degradation (Figure 
1.6.) (MacDonald et al., 2009).In the presence of Wnt ligand, a Fzd-LRP5/6 receptor 
complex forms; this complex recruits Axin which disrupts the GSK3/CK1α/APC 
degradation complex (Mao et al., 2001). Wnt binding to the Fzd-LRP-5/6 receptor 
complex also results in the stabilisation of Axin. The disruption of the β-Catenin 
degradation complex leads to the stabilisation and cytoplasmic accumulation of β-
Catenin which then translocates to the nucleus (Komiya and Habas, 2008). The 
mechanism by which the nuclear translocation occurs is not well understood as β-
Catenin does not contain a nuclear localisation sequence, neither does this process 
involve Ran-mediated nuclear transport or importin proteins (Fagotto et al., 1998). 
One theory suggests β-Catenin may combine with other proteins which are in the 
process of nuclear import such as Axin (Cong and Varmus, 2004). Once in the 
nucleus β-Catenin behaves as a transcriptional co-activator in complex with LEF/TCF 
transcription factors; this complex binds to the promoter region of target genes 
(Clevers, 2006) (Figure 1.6.). Changes in the mRNA level of AXIN2 is most commonly 





Figure 1.6. Wnt/β-Catenin signalling pathway 
Canonical Wnt signalling in the presence and absence of Wnt ligands. Illustration reproduced courtesy 
of Cell Signalling Technology, Inc (www.cellsignal.com).  
 
1.4.2.3. The non-canonical Wnt signalling pathway 
Non-canonical Wnt signalling is described as Wnt pathway activation with 
downstream effectors which are not β-Catenin-TCF/LCF (Gomez-Orte et al., 2013). 
There are two main forms of non-canonical Wnt signalling, the planar cell polarity 
(PCP) and the Wnt/Ca2+ pathways. These pathways are both believed to inhibit 
canonical Wnt/β-Catenin signalling (Bernard et al., 2008). Firstly, the PCP pathway is 
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activated when a Wnt ligand (specific to this pathway) binds to a Fzd receptor which 
is in complex with a co-receptor ROR1/2, Ryk or PTK7. Upon binding, the ligand-
receptor complex is internalised and a downstream signalling cascade of Rho and 
Rac GTPases, Rho-kinase (ROCK) and c-Jun N-terminal kinase (JNK) results in the 
activation of target genes (Yang and Mlodzik, 2015), which are responsible for tissue 
polarity and cell motility (Walck-Shannon and Hardin, 2014, Sedgwick and D'Souza-
Schorey, 2016). The Wnt/Ca2+ pathway once activated triggers downstream signalling 
of a standard GPCR signalling pathway (De, 2011),  eventually resulting in the 
activation of nuclear factor associated with T-cells (NFAT) which activates genes 
associated with cell fate and migration (Gomez-Orte et al., 2013).  
1.4.2.4. Wnt signalling in development 
Wnt signalling is indispensable in the developing embryo (Holstein, 2012), the 
complexity of this signalling pathway comes from the multitude of Wnt ligands and 
Fzd receptor combinations which can result in the activation of canonical, PCP or 
Wnt/Ca2+ signalling pathways (Kikuchi et al., 2009). Wnt ligands are long range 
(120μm) signalling molecules which affect cellular fate in a concentration dependant 
manner (Serralbo and Marcelle, 2014). One theory suggests that long range Wnt 
signalling is achieved through the interaction between the membrane of cells and the 
palmitoyl group on the Wnt ligand itself (Takada et al., 2006). Extracellular heparin 
sulfate proteoglycans (HSPG) have also been suggested as one method of 
stabilisation and transport of Wnt ligands (Fuerer et al., 2010). The role of the Wnt 
signalling pathway can be divided into four specific roles: axis patterning, control of 
cell fate, cell proliferation and cell migration. In a developing embryo Wnt signalling 
has been implicated in the development of the anteroposterior and dorsal ventral axis 
(Hikasa and Sokol, 2013). Wnt signalling has an important role in the determination 
of cell fate in a variety of cell types including the differentiation of pluripotent stem 
cells into progenitor cells of the mesoderm and endoderm (Nusse, 2008). Wnt 
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signalling is involved in the development of many tissues throughout the body such 
as gut, germ cell, hair follicle, lung, nephron and ovary (Verzi and Shivdasani, 2008, 
Cantu and Laird, 2013, Choi et al., 2013, De Langhe and Reynolds, 2008, Schmidt-
Ott and Barasch, 2008, Vainio et al., 1999). During development embryonic signalling 
pathways such as the Wnt pathway control cell proliferation which is required on a 
large scale in a growing organism (Willert and Jones, 2006). Cell migration is also a 
critical part of development as it allows the movement required for the body axis 
patterning, tissue formation and limb induction, this is achieved through both 
activation of the canonical Wnt signalling pathway and the PCP pathway (Sedgwick 
and D'Souza-Schorey, 2016). 
1.4.2.5. Wnt signalling target genes 
The Wnt signalling pathway is diverse in development and has a wide variety of 
functions, especially in the activation and maintenance of stem cells which are 
present throughout the tissues of the body (Nusse, 2008). In the adult organism Wnt 
signalling maintains rapidly proliferating cell populations such as the epithelium of the 
crypt cells of the villi in the gut, the hair follicle and skin epidermis through the 
modulation of the Lgr5 gene (Haegebarth and Clevers, 2009). During normal tissue 
homeostasis the stem cell pools which are present in each of these tissues are able 
to differentiate into a variety of cell lineages, however during tumour growth this 
property leads to an increased cell proliferation and differentiation. Another Wnt target 
gene is c-Myc which controls cell fate and apoptosis in normal tissues, however 
during neoplastic transformation it is involved in the switching to glycolysis only 
metabolism of glucose (Warburg Effect) (Pate et al., 2014). Cyclin D1 is also under 
transcription control of the Wnt signalling pathway; in thyroid tumour development it 
is associated with metastases (Zhang et al., 2012). It has an extensive assortment of 
target genes which includes many genes which in neoplastic cells would be able to 




PDAC represents a devastating disease with a high unmet therapeutic need. The 
combination of late diagnosis, poor response to current chemotherapy and the lack 
of a genetically defined targeted therapy results in a poor prognosis with a low median 
survival for patients. Moreover, the discrepancy between in vitro efficacy of 
chemotherapeutic agents and clinical outcomes highlights a need for better targeted 
therapies, but also the necessity for the development of in vitro assays that take into 
account the PDAC tumour microenvironment. The aim of this project was to establish 
an in vitro model for use in pre-clinical drug development which incorporates PDAC 
cells and CAFs, the most abundant non-cancerous cell type of the PDAC tumour 
microenvironment. 
1.6. Objectives 
1. Create a reproducible 3D co-culture model using CAFs isolated from the PDAC 
tumour microenvironment. 
2. Determine if active Hedgehog signalling is achieved in an in-vitro model 
Transwell model of CAFs and tumour cells 
3. Establish whether the Canonical Wnt signalling pathway is involved in the cross-
talk between CAFs and tumour cells.  





2. Materials and Methods 
2.1. Materials 
2.1.1. Consumables 
The following items were purchased from Corning Inc. (USA): All tissue culture 
flasks (catalogue numbers 430641, 430825, 43001); 96-Well Clear Flat Bottom Ultra 
Low Attachment Microplates (catalogue number 3474).  
Nunc Cryovials (catalogue number 479-1235) disposable sterile scalpels (catalogue 
number 233-5364) and Superfrost plus adhesion slides (631-0446) were all 
purchased from VWR.  
The following kits, stains and antibodies were all purchased from Abcam (UK): Human 
Sonic Hedgehog ELISA Kit (ab100639) Human Dickkopf-1 ELISA Kit (ab100501) 
Picro-Sirius Red Stain Kit (ab150681) Anti-alpha smooth muscle Actin antibody 
(ab7817) Anti-Rabbit IgG Alexa Fluor  488 (ab150077) Anti-Sonic Hedgehog antibody 
(ab73958) Rabbit Polyclonal IgG Isotype control (ab27478) Anti-wide spectrum 
Cytokeratin antibody (ab9377) Anti-Vimentin antibody (ab92547) Anti-CD68 antibody 
(ab125212) Anti-Desmin antibody (ab32362). 
Unless otherwise specified in parentheses, all materials not listed above were 
purchased from Sigma-Aldrich (UK). 
2.1.2. Primers 
The primers used in this project were purchased from Primer Design and were 
ordered to ensure they spanned intronic regions to remove the likelihood of 
contaminating genomic DNA being amplified. The efficiency of these primers was 
determined by comparing the gradient of the expression curve of the gene amplified 
(using a serial dilution of a positive control sample) and the curve produced using the 
housekeeping gene Glyceradehyde 3-phosphate dehydrogenase (GAPDH).  
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Primer Forward Primer (5’ – 3’) Reverse Primer (3’ – 5’) 
GAPDH Primer design protected sequence  
RPLP0 CCATTGAAATCCTGAGTGATGTG CGAACACCTGCTGGATGAC 
ACTB CTCTTCCAGCCTTCCTTCCT CGTACAGGTCTTTGCGGATG 
GLI1 CCAGCCAGAGAGACCAACA GCATCCGACAGAGGTGAGA 
SMO ACCACCTACCAGCCTCTCTC CCCACAAAACAAATCCCACTCA 
PTCH1 CACCATCCTCGGCGTTCT TGGGCAGGCGGTTCAAG 
Shh CCAGAAACTCCGAGCGATTTA GCCAAAGCGTTCAACTTGTC 
AXIN2 CCAAGTGTCTCTACCTCATTTCC GCGGCTCTCCAACTCCAG 
LEF1 CCGAAGAGGAAGGCGATTTAG CTGAGAGGTTTGTGCTTGTCT 
SFRP1 CATGACGCCGCCCAATG CCTCAGATTTCAACTCGTTGTC 
SFRP4 GATGATGCTTCTTGAAAATTGCTTAG GGGGGATTACTACGACTGGTG 
PORCN CTGCTGTCCCTGGCTTTTAT CGATGCTGGTGCGAACA 
Table 2.7. Forward and reverse primer sequences used throughout this project 
 
2.2. Methods 
2.2.1. Specimen collection 
Pancreatic specimens were obtained from patients undergoing surgery to remove a 
portion of the pancreas with curative intent at the Royal Liverpool University Hospital 
with local ethical approval and fully informed consent. Patients with PDAC were 
selected for this project. Histopathologists Professor Fiona Campbell or Dr. Timothy 
Andrews performed a gross analysis of the specimen and immediately selected 
“fibrous appearing” pancreatic tissue for isolation of CAFs and epithelial cancer cells, 
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and “normal appearing” tissue clearly separated from the boundary of the tumour for 
isolation of Normal Activated Fibroblasts (NAFs). The specimen provided was split in 
half with one half used for isolation of cells (Section 2.2.2.) and the other half fixed 
and prepared for staining (Section 2.2.4.). 
2.2.2. Isolation of cells from the pancreas 
2.2.2.1. Isolation of CAFs 
CAFs were isolated using the outgrowth method (Apte et al., 1998, Bachem et al., 
1998). This method involves the explantation of pieces of fibrotic tissue removed from 
the pancreas.  Once a fibrotic sample had been identified it was placed immediately 
into ice cold phosphate buffered saline (PBS). Using sterile disposable scalpels the 
tissue was divided into small pieces (1-2mm3). These pieces were then arranged in 
uncoated 6-well tissue culture plates (5-7 pieces/well) and 500μL of growth media 
(Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 20% Fetal Bovine 
serum (FBS), 2% L-Glutamine and 1% Penicillin Streptomycin) was added carefully 
to ensure that the tissue pieces were not disturbed. Plates were incubated overnight 
at 37oC in a 5% CO2 air humidified atmosphere. After 24h 500μL of fresh medium was 
added with care taken not to disturb the tissue, with further medium changes every 
three days. Cells were seen growing out of the tissue within 24h (Figure 2.1) and 
continued for approximately 7days. Once wells had reached 80-90% confluence, cells 
were sub-cultured (Section 2.1.3.2) into T75 flasks at a concentration of 200,000 




Figure 2.1.   Representative Image of cells growing out of tissue pieces 
Cells (black arrow) can be observed growing out of the tissue piece (white arrow) from 24h after 
explantation. This image was taken using Brightfield Microscopy at 20x magnification. Scale bar 100μm. 
2.2.2.2. Isolation of epithelial tumour cells 
The procedures used to isolate epithelial cancer cells from the pancreas are reviewed 
in Section 3.2.2. 
2.2.2.3. Isolation of normal activated fibroblasts 
Normal fibroblasts were isolated from normal appearing tissue adjacent to tumour 
tissue by my colleague Dr Lawrence Barrera-Briceno using the density gradient 
method described in Section 3.2.2. 
2.2.3. Cell culture 
In order to take into consideration the heterogeneity of PDAC, 5 epithelial cancer cell 
lines (ASPC1, MIAPACA2, PANC1, SUIT2, BXPC3; purchased from the American 
Type Culture Collection (ATCC)) were selected. These cell lines had varied source, 
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Table 2.1. Summary of characteristics of pancreatic epithelial cancer cell lines 
Characteristics of the pancreatic cancer cell lines used throughout this project including patient 
information and molecular characteristics such as mutational status of Kras, P53, P16 and SMAD4. Wt 
indicates a cell line is Wild-type for the gene of interest, M indicates an oncogenic mutation, HD indicates 






Figure 2.2. Representative Images of pancreatic epithelial cancer cell lines. 
Images taken of each cell line under standard growth conditions. Images taken using Brightfield 
Microscopy at 20x magnification. Scale bar 50μm. 
 
Wnt-3A producing cells (L-Wnt-3A) and Normal pancreatic fibroblasts (NPF) were 
also purchased from the ATCC.  
 
2.2.3.1. Cell culture conditions 
Pancreatic cancer cell lines were cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) supplemented with 10% FBS and the cells were maintained at 37oC in a 5% 
CO2 air humidified atmosphere. CAFs, NAFs and Normal Pancreatic Fibroblasts 
(NPF) were cultured in IMDM supplemented with 10% FBS, 2% L-Glutamine and 1% 
Penicillin Streptomycin.  
2.2.3.2. Maintenance of cells 
Once cells had reached 70-80% confluence, the media was removed from the flask. 
10mL of PBS was added to wash off any excess media, this was removed and 
another wash was completed. 2mL of Trypsin-EDTA was then added to each flask. 
EDTA is a chelating agent which binds calcium and thus prevents the cadherins 
between cells from binding and forming clumps during detachment. Trypsin is a 
proteolytic enzyme which cleaves focal adhesion proteins which allow the cells to bind 
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to each other and the surface of the culture vessel. Both agents have maximal 
function at 37oC (Freshney and Freshney, 2005) so the flask was incubated at 37oC, 
5% CO2 for approximately 5min (epithelial cancer cell lines) or 10min (CAFs and 
NAFs). Once the cells were in suspension, 10mL of culture medium was added to 
each flask and the culture surface was washed twice using this medium to ensure the 
maximal yield of cells. Cell culture medium must be added in excess in order to 
quench the trypsin as it contains FBS which inhibits the trypsin. If the trypsinization 
was allowed to continue it would eventually damage the cell membrane. A 10μL 
sample of the cells was removed and set aside for counting. The rest of the culture 
was added to a 15mL centrifuge tube and centrifuged at 400g for 5min. The medium 
was removed and the pellet re-suspended in an appropriate volume of medium 
depending on the cell count (Section 2.2.3.3.). The cells were then seeded into a new 
T75 flask at an appropriate cell density. 
2.2.3.3. Cell counting 
To quantify the yield of cells from each flask a 10μL aliquot of the cells was taken and 
10μL of 0.4% trypan blue was added. Trypan blue is a diazo dye which is commonly 
used to identify viable cells. As it is a negatively charged molecule it does not cross 
the cell membrane unless there is membrane damage, therefore it is customarily used 
to stain dead cells. When a cell suspension has been incubated with trypan blue dead 
cells appear blue and live cells appear white within a haemocytometer chamber. A 
haemocytometer was used to count total cell number followed by the live cell number. 
A haemocytometer is a counting slide used to determine the amount of cells in a liquid 
sample. The sample is covered with a coverglass which has gridlines etched onto it 
at a precise distance (250μm) apart which allows the researcher to determine the 




 Density calculation: 
𝑥
𝑛
∗ 10 000 = 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿 
Figure 2.3 Image of haemocytometer etchings and cell density formula 
Typically a haemocytometer comprises 4 large squares (example highlighted in purple) with each 
representing 1/10,000mL once the coverslip is in place. The formula for calculating the cell density 
(cells/mL) is given beneath the image of the haemocytometer where x represents cell number and n 
represents the number of large squares used to generate the cell number. The calculated density does 
not take into account the initial dilution made using trypan blue (1:2) and therefore the cell density should 
be adjusted accordingly. Cell viability was determined using (live cell number/Total cell number) x 100.  
 
2.2.3.4. Long-term storage of cells 
In order to use cells at a similar passage throughout the project, cells were frozen and 
kept in liquid nitrogen for long-term storage. In order to create cell banks for this 
project, cells were cultured in larger culture vessels (T225) and allowed to reach 80-
90% confluence. Upon reaching this level, the cells were dissociated from the culture 
vessel using the method described above (Section 2.2.3.3.). The supernatant was 
removed and the pellet re-suspended in freezing media (DMEM, 10% FBS, 10% 
DMSO). The suspension was then aliquoted by 1mL volumes into cryovials at a 
density of 2 x 106 cells/mL. The tubes were transferred to an insulated container and 
cooled to -80oC at an approximate rate of 1oC/min. After 24h the cryovials were 
transferred to a liquid nitrogen storage container until further use. 
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2.2.3.5. Recovery of cells 
In order to recover cells from long term liquid nitrogen storage a vial was collected 
and placed on dry ice. 10mL of pre-warmed culture medium was prepared in a 
centrifuge tube. The cryovial was partially submerged in a water bath at 37oC and 
agitated until the cell suspension had thawed. The cell suspension was then 
transferred to the prepared centrifuge tube. This was then placed in a centrifuge and 
spun at 400g for 5min. The freezing medium was removed and the pellet was re-
suspended in fresh medium. The cells were then transferred to a T75 and put into a 
37oC, 5% CO2 air humidified incubator overnight. The following day the cells were 
checked to determine if the cells were recovering and had adhered to the flask 
appropriately; the media was refreshed if necessary. 
2.2.4. Tissue staining 
2.2.4.1. Tissue processing 
At specimen collection a part of each sample was taken and fixed in 4% 
paraformaldehyde (PFA) solution in PBS (Affymetrix), which penetrates the tissue at 
1mm/h. The tissue was incubated at 4oC overnight to ensure it was thoroughly fixed. 
The role of tissue fixation is to preserve the morphological and physical characteristics 
of the tissue at a given point in time. PFA fixes the cells by forming crosslinks between 
proteins. These crosslinks are methylene bridges formed between nitrogen 
containing side chains of basic amino acids. The fixed tissue was placed in a cassette 
and stored in 4% PFA solution until processing. The cassettes were then loaded into 
a Leica TP1020 tissue processor and dehydrated using the following conditions: 
1. 1x wash 70% (v/v) methanol 
2. 1x wash 90% (v/v) methanol 
3. 5x wash 100% methanol 
4. 3x wash of Xylene for 1h each 
5. 2x wash in molten paraffin wax at 65oC 
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This tissue processing step is necessary as melted paraffin wax is hydrophobic; the 
water present in the tissue must be removed before embedding can occur. This 
process is carried out step-wise in increasing concentrations of ethanol until a water-
free solution is reached. It is carried out in this manner to avoid the tissue distortion 
which could occur if the tissue was immediately immersed in 100% ethanol. An 
intermediate solvent (Xylene) is then used in a process commonly referred to as 
“clearing”. This solvent is immiscible with both ethanol and paraffin wax and therefore 
displaces the ethanol before eventually being displaced by the paraffin wax. Xylene 
also has a role in removing fat from the tissue specimens which can prevent wax 
infiltration.  
2.2.4.1.1. Paraffin embedding 
Once the tissue had been processed, the cassettes were placed in a paraffin wax 
reservoir at 65oC in a Leica 61160 embedding station. Tissues were removed from 
the cassettes and positioned in a metal mould of the appropriate size, and the mould 
was filled with paraffin wax. The moulds were then placed on an ice plate to solidify. 
After approximately 2h in the ice tray the paraffin embedded samples were removed 
from the moulds and stored at room temperature for sectioning at a later date.  
2.2.4.1.2. Sectioning 
Tissue specimens were kept on ice for 1h before sectioning. Cooling the tissue blocks 
allows for thinner sections as it increases the structure of the wax. The block was then 
placed in a Leica RM2245 microtome ensuring the blade would cut straight across 
the block, and the blocks were sectioned (section thickness set at 4μm). Animal tissue 
is commonly sectioned at 4µm as it is the average diameter of a cell, and a monolayer 
of cells is desirable for clarity of images. Once a ribbon of sections was obtained, it 
was floated on the surface of a water bath (40-45oC) to flatten the sections. Tweezers 
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were used to separate the sections which were then picked up using microscope 
slides and stored at 37oC overnight in a slide rack. 
2.2.4.2. Haematoxylin and Eosin staining 
Haemotoxylin and Eosin (H&E) is the most commonly used staining system in 
medical pathology (Fischer et al., 2008). It contains two dyes, the first Haemotoxylin 
is a dye which is used to stain acidic structures purple/blue. Acidic structures in the 
cell include heterochromatin which is found in the nucleus and ribosomes which are 
found in the ER. Eosin stains basic material a pink colour; the cytoplasm of a cell 
contains proteins which are basic, therefore the cytoplasm of a cell appears pink 
(Figure 2.4).  
H&E staining was completed using a Leica Autostainer XL using the following steps:  
1. Xylene dip to remove the paraffin wax (5min) 
2. 2x wash in xylene 
3. 2x wash in 100% ethanol (30s; Shaking) 
4. 2x wash in 95% ethanol (30s; Shaking) 
5. 2x wash in 70% ethanol (30s; Shaking) 
6. Rinse with tap water (2min) 
7. Haematoxylin stain (10min) 
8. Rinse with running tap water (5min) 
9. Acid water (0.25% HCl/dH2O)- (30s) 
10.  Rinse with running tap water (2min) 
11.  Scott’s tap water (30s; Shaking) 
12.  Rinse with running tap water (2min) 
13.  1x wash in 100% ethanol (30s) 
14.  Eosin stain (2min) 
15.  100% ethanol to remove eosin (1min) 
16.  2x wash 100% ethanol (30s;Shaking) 
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17.  3x wash in xylene (30s) 
18.  Mount coverslips 
Once coverslips had been added the slides were left overnight at room 
temperature to dry.  
 
 
Figure 2.4. Example of H&E stained section 
H&E stained section of a PDAC tumour, which allows the visualisation of the cellular structures of the 
tissue. The cytoplasm of epithelial ductal cells is stained pink (black arrow). Stroma surrounding the 
ducts is identified based on the morphology of the cells; nuclei are stained purple/blue (white arrow). 
Scale bar 50µm. 
 
2.2.4.3. Picro-Sirius red staining (connective tissue stain) 
Picro-Sirius Red stain is used to visualise (using standard bright field microscopy) 
collagen I and III fibres (red) in addition to muscle fibres (yellow) and cell cytoplasm 
(yellow) (Figure 2.5.). 
Picro-Sirius Red staining was carried out manually using the following steps: 
1. Xylene dip to remove the paraffin wax (5min) 
2. 2x wash in xylene (30s) 
3. 2x wash in 100% ethanol (30s; Shaking) 
4. 2x wash in 95% ethanol (30s; Shaking) 
5. 2x wash in 70% ethanol (30s; Shaking) 
6. Rinse - running tap water (2min) 
7. Picro-Sirius Red Stain (30min) 
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8. 2x wash in acetic acid solution (1min) 
9. Rinse in 100% ethanol (30s) 
10. 2x wash in 100% ethanol to dehydrate (1min) 
11. Mount coverslips 
 
Figure 2.5. Picro-Sirius red stained section PDAC microenvironment 
An example of a Picro-Sirius Red stained section of a PDAC tumour, which allows the histological 
visualisation of connective tissue (collagen I and III). The cytoplasm of epithelial ductal cells and acinar 
cells are stained a yellow/pink colour (black arrow) with collagen fibres appearing red (white arrow). 
Scale bar 50µm. 
2.2.5. Immunohistochemistry (IHC) 
In order to visualise the expression of various proteins within the tumour 
microenvironment or normal adjacent tissue, IHC was used. Deparaffinisation and 
antigen retrieval was performed using a PT-Link (Dako) which is a module that 
combines the process of deparaffinization, rehydration and epitope (antigen) retrieval. 
Antigen retrieval is necessary due to the formation of methylene bridges during the 
fixation process which cross-links proteins and can conceal the antigens preventing 
antibody binding. The PT-Link uses heat-induced antigen retrieval with target retrieval 
solutions at pH6 and pH8 (Dako).  Once the slides had undergone antigen retrieval 
using the PT-Link, slides were placed on a staining tray and covered with Tris-
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buffered saline with 0.1% Tween (TBST) ensuring full coverage of all the slides. The 
TBST was removed and the sections were dried carefully with a paper towel. The 
slides were covered with 1% hydrogen peroxide in methanol for 10min. The slides 
were washed three times for 1min with TBST. The slides were blocked with 10% goat 
serum in PBS for 30min at room temperature. The primary antibodies were made up 
in blocking solution according to the concentrations below (Table 2.2.). 200μL of 
antibody solution was added to each slide, ensuring each section was covered 
completely. The slides were incubated in primary antibody or isotype control overnight 
at 4oC. An isotype control is a negative control used to measure the level of non-
specific background signal caused by the primary antibody binding to non-specific Fc 
receptors on the surface of cells. Isotype controls are matched to both the host 
species and working concentration of the primary antibody. The following day the 
primary/isotype antibody was removed and the slides were washed with TBST, three 
times for one minute each. The excess TBST was removed using a paper towel, and 
Horse Radish Peroxidase (HRP) conjugated secondary antibody was added to the 
slides and incubated at room temperature for 60min. The secondary antibody was 
removed and the slides were washed again with TBST. 500μL of 3, 3’-
diaminobenzidine (DAB) chromogen was added to each slide and incubated at room 
temperature for 10min. The DAB/chromogen was washed off with TBST.  The slides 
were then counterstained with haemotoxylin.  Coverslips were added using DPX 
mountant which was added using a Pasteur pipette. The slides were then left 


















αSMA 200 1:50 9 IgG2a 50 1:200 Mouse 
Cytokeratin 200 1:300 6 IgG 1000L 1:1500 Mouse 
Shh 200 1:100 6 IgG 1000 1:500 Mouse 
β-Catenin 250 1:500 9 IgG 1000 1:2000 Mouse 
Table 2.2. Summary of IHC antibody dilutions 
2.2.6. Immunocytochemistry (ICC) 
Coverslips were sterilised in ethanol, washed in PBS and placed in the wells of a 24-
well plate. 12,000 cells were seeded in each well in 1mL of complete growth media. 
These cells were monitored until they reached 80% confluency, at which point the 
media was removed and the wells washed twice with 1mL PBS at room temperature. 
The cells were fixed in 500μL of 4% PFA which was added to each well and incubated 
at room temperature for 10min. The 4% PFA was removed then replaced with 1mL 
of PBS and the plate was wrapped in parafilm and stored at 4oC.Once the plates were 
removed from 4oC they were washed 3 times with TBS at room temperature. The 
cells were permeabilised using PBS containing 0.1% Triton X-100 for 10min. Triton 
X-100 is a non-ionic detergent which can solvate cellular membranes, forming small 
pores which allows the antibodies to access the cells. The coverslips were then 
incubated with 1% hydrogen peroxide in methanol to block endogenous peroxidases. 
500μL was added to each well and this was incubated for 30min. The plates were 
washed 3 times with 1mL of TBS before the addition of 500µL blocking solution (TBS 
containing 10% goat serum and 1% bovine serum albumin (BSA)). Blocking solution 
is used to reduce the non-specific binding of secondary antibodies. This step is crucial 
to decrease the cross reactivity of endogenous immunoglobulins and the secondary 
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antibodies. The cells were blocked for 30min at room temperature after which the 
blocking solution was removed and primary antibodies, diluted in blocking solution, 




















1:1000 IgG1 Mouse 1000 1:1000 
Desmin 200 1:500 Normal 
Rabbit IgG 
200 1:500 
Cytokeratin 200 1:300 IgG 
Mouse 
1000 1:1500 
CD68 200 1:500 Normal 
Rabbit IgG 
200 1:500 
Table 2.3.  Primary Antibodies with dilution factors and the appropriate isotype controls 
 
The plate was incubated with primary antibodies at 4oC overnight after which it was 
removed and the wells washed with 1mL TBS 3 times. Both rabbit and mouse HRP-
conjugated secondary antibodies were diluted 1:100 in blocking solution and 
incubated for 30mins at room temperature. The secondary antibody was removed 
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from all wells and washed 3 times with TBS. 500μL of DAB chromogen (Dako) was 
added to each well and the plate was incubated for 10min. DAB is oxidised in the 
presence of peroxidase and hydrogen peroxide which produces a brown stain, 
therefore in the presence of HRP-conjugated secondary antibodies a brown colour is 
observed. The plate was rinsed with water for approximately 5min, at which point no 
excess stain was evident in the run-off. The plates were counterstained with 500μL 
per well Haematoxylin for 2min. The plate was then rinsed with tap water for 
approximately 2min at which point no excess stain was evident in the run-off. The 
coverslips were carefully removed from the wells using forceps and dried off by gentle 
tapping on absorbent tissue paper. The coverslips were then mounted onto slides 
using 1 drop of mounting glue per coverslip. The slides were then left to dry at room 
temperature until they were imaged. 
2.2.7. Immunofluorescence (IF) 
Immunofluorescence (IF) staining was used to stain 3D cell cultures and 2D co-
cultures of CAFs and epithelial cancer cell lines. 3D cell cultures which had been fixed 
embedded and mounted on slides were deparaffinised before the staining procedure 
was carried out (described in section 2.2.4.2.). For 2D co-cultures CAFs and PANC1 
cells were seeded in 96-well, black, clear bottom, Cell Carrier plates (PerkinElmer, 
UK) at different ratios and left for 24h to adhere; monocultures were also seeded for 
comparison. The cells were dosed with gemcitabine using a D300 digital liquid 
dispenser (Tecan). After 48, 72 and 96h the media was removed from the plates and 
the cells were washed twice with PBS ensuring the complete removal of liquid from 
the wells each time. The cells were fixed with 100μL of 4% PFA per well, for 10min at 
room temperature. If the cells were being stained immediately the protocol was 
continued but it was possible to remove the PFA and add 100μL of PBS to each well 
and the plates could be stored at 4oC until the staining could be continued. In these 
experiments cells were fixed when their time points dictated but all plates were 
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stained at the same time to avoid variation in the staining. Once the plates were 
removed from 4oC they were washed once with PBS (100μL per well) before 
progressing onto the staining protocol. 
The samples were permeabilised with 0.1% (v/v) Triton X-100 in PBS and incubated 
for 30min at room temperature. The plates/slides were then washed twice for 5min in 
PBS. The plates were then washed with 5% (v/v) goat serum in PBS for 1h at room 
temperature before the addition of primary antibodies diluted in blocking solution 
(dilutions summarised in Table 2.4).  
Table 2.4 Summary of IF Antibody Conditions 
 
The cells were incubated with both primary antibodies or isotype controls overnight 
at 4oC. The following day the antibodies were removed and the plates were washed 
three times with PBS for 5min each. Secondary antibodies were diluted 1:500 and 
incubated for 1h at room temperature. The secondary antibodies were removed and 
the nuclei were stained with 4’, 6-diamidino-2-phenylindole (DAPI) at a 1:10,000 
dilution for 10min at room temperature. DAPI is a fluorescent stain which binds to 
Adenosine-Thymidine regions of DNA, and is excited by ultraviolet light (358nm) with 
an emission maximum of 461nm.  The plates were then washed 3 times for 5min in 
PBS. The staining was visualised using an Operetta High-Content Imaging system 
(PerkinElmer). 
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actin 
1:400 Alexa-488 Excitation 490 
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Using dual staining within the direct co-cultures (section 2.2.4.6.) it was 
possible to differentiate cancer cells (CTK stained) from CAFs (αSMA stained). 
Using the isotype controls to remove background fluorescence, it was possible 
to distinguish αSMA positive cells from CTK positive cells. αSMA staining was 
used to determine CAFs which were then subtracted from the total nuclei 
count. 5 regions were imaged in each well at 10x magnification, with each 
condition run in duplicate. The data was presented as a percentage of the 
DMSO control. 
2.2.8. Molecular biology 
2.2.8.1. RNA extraction from cells 
To extract RNA from each sample of cells an Aurum total RNA mini kit was used. 
When each sample was ready for RNA isolation the sample was washed twice with 
PBS ensuring that all excess was carefully removed. In a T75 flask 350µL of lysis 
buffer was used, in the experiments which used 6-well plates 150µL per well was 
used. The lysis buffer contained within the kit is a composition of guanidine 
thiocyanate (GTC) and β-mercaptoethanol which rapidly lyses the cells and 
inactivates RNases.  GTC is typically used to lyse cells for RNA extraction as it is a 
chaotropic compound which is very effective at denaturing proteins including cellular 
membranes. It is used in conjunction with a reducing agent such as β-
mercaptoethanol which denatures the RNases by breaking disulphide bonds. If β-
mercaptoethanol was not used the RNases would degrade the RNA present in the 
sample and prevent RNA extraction. Once the lysis buffer had been added to the 
vessel it was aspirated and dispensed over the cells to help with the lysis. After 5min 
incubation at room temperature the lysate was collected and stored at -80oC until 
required. If RNA was being isolated immediately an equal volume of 70% (v/v) ethanol 
was added to the culture vessel to reduce the viscosity of the lysis buffer. The lysis 
solution was then added to the silica membrane column contained within the kit. The 
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spin column was mounted within a cap-less wash tube, and centrifuged for 30s at 
21,000g and the filtrate was discarded. 700µL of low stringency wash solution was 
added to the spin column and it was centrifuged for 30s at 21,000g and the filtrate was 
discarded. DNase was then added to the column and incubated for 30min at room 
temperature to remove any contaminating genomic DNA. Two additional wash steps 
using 700µL of high stringency and low stringency wash solution were performed 
before the total RNA was eluted from the column and collected in a sample collection 
tube.  When eluting total RNA extracted from primary fibroblasts, 30µL of elution 
solution was used and 80µL was used for all cell lines. RNA was stored at -80oC until 
required. 
2.2.8.2. RNA quantification 
The concentration of total RNA was measured using a NanoDrop 2000 UV-Vis 
Spectrophotometer (Thermo Scientific) at 260nm. The NanoDrop was blanked using 
the RNA elution buffer and then 1µL of sample was loaded onto the NanoDrop and 
the reader closed such that the sample was in direct contact with the optical surfaces. 
The concentration of the RNA was determined and the 260:280 and 260:230 ratios 
were used to indicate the quality of the total RNA sample. The 260:280 ratio is used 
to assess the purity of the RNA; if the ratio is ~2.0 the sample is considered pure, 
however if the ratio is much lower it indicates the presence of protein, phenol or 
contaminants which absorb light at ~280nm. The 260:230 ratio is used as a secondary 
measure of contamination with a 260:230 ratio of 2.0-2.2nm deemed pure. If the ratio 
is lower it indicates the presence of contaminants that absorb at 230nm such as EDTA 
or carbohydrates.  
2.2.8.3. cDNA synthesis 
RNA samples were reverse transcribed into cDNA using the QuantiTect Reverse 
Transcription Kit. In addition to the total RNA samples, a cDNA-free negative control 
and a reverse transcriptase free control was prepared.  All kit components were 
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thawed at room temperature and the template RNA was thawed on ice. All kit 
components were centrifuged before use and then left on ice once thawed. Up to 1µg 
of RNA was added to a 0.2mL tube and the sample made up to a total volume of 12µL 
with DNase free water. 2µL of genomic DNA wipeout buffer was added and this 
reaction was incubated for 2min at 42oC and then placed on ice. The reverse-
transcription master mix contains 4µL of Quantiscript RT Buffer, 1µL of reverse 
transcriptase and 1µL of RT primer mix. The master mix was made up in batches, 
added to all sample tubes, and the reaction was incubated at 42oC for 15min followed 
by 95oC for 3min. cDNA was immediately stored at -20oC. 
2.2.8.4. Quantitative real time polymerase chain reaction (qRT-PCR) 
One of the most robust research tools available to study relative gene expression is 
qRT-PCR. It is used in a variety of areas of scientific research including forensic, 
clinical and diagnostic. In 1986 Kary Mullis described his invention of the polymerase 
chain reaction (PCR) method (Mullis et al., 1986) and Michael Smith and colleagues 
described the establishment of oligonucleotide-based, site-directed mutagenesis and 
its development for protein studies (Smith, 1982).  In 1993 Higuchi et al. (Higuchi et 
al., 1993) discovered that a fluorescent label could be incorporated into the 
















Figure 2.6. Example of qRT-PCR amplification plot 
Fluorescence levels are not detected until the amplified PCR product overcomes the threshold, PCR 
product accumulates exponentially. The cycle number at which the threshold is overcome is known as 
the quantification cycle (Cq). Cq values are measured during the exponential phase of amplification when 
the PCR reagents are in excess. This image was reproduced (without permission) from the Biorad qPCR 
Manual.  
 
As the quantity of the PCR product increases this correlates with an increase in the 
intensity of the fluorescent signal. In order to investigate changes in gene expression 
using qPCR, RNA was extracted from cell cultures and cDNA was synthesised using 
the methods outlined above. To amplify a specific genetic target it is necessary to 
choose forward and reverse primers with sequences that correspond to matching 
sequences at the 3’ to 5’ and 5’ to 3’ ends of the sequence to be amplified. The 
amplification process involves an exponential phase during which the number of 
molecules doubles with each amplification cycle. This plateaus at the point the 
reaction reagents are consumed. The amount of PCR-end product is used to 
calculate the amount of genetic starting material using a known standard. The amount 
of DNA is measured within the exponential phase in real-time (Shipley, 2006). There 
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are two methods of quantification currently in use: one uses a sequence specific DNA 
probe the other involves the incorporation of a non-specific fluorescent dye.  
The sequence specific probe method uses an oligonucleotide with a specific 
sequence which hybridises with the target gene and the activity of Taq DNA 
polymerase (an enzyme isolated from Thermus aquaticus DNA polymerase; (Holland 
et al., 1991)). The oligonucleotide sequence labelled with a fluorescent reporter and 
a quencher which inhibits the fluorescent signal. When the amplification process is 
underway the Taq polymerase removes the oligonucleotide sequence which removes 
the quencher from the probe allowing the fluorescent reporter to emit light (520nm) 
This model requires the specificity of both the forward and reverse primers and the 
oligonucleotide probe.  
The non-specific probe method involves the use of a fluorescent dye (SYBR Green) 
which binds to all double stranded DNA present in the sample. The amplification 
process depends on the specificity of the forward and reverse primers to the cDNA 
template, the SYBR Green dye will bind to all double stranded DNA. The pitfall of this 
method is the potential to produce false positive signals which are a result of the dye 
binding to non-specific double stranded DNA sequences.  The dissociation curve can 
give the user insight into the purity of the amplification, the dissociation curve shows 
the correlation between SYBR Green labelling and the dissociation temperature 
which is shown as ΔFluorescence/ΔTemperature against temperature. The 
dissociation (melting) point (Tm) is the time point at which all of the double stranded 
DNA has dissociated and corresponds to the peak of the dissociation curve. If there 
are multiple peaks present on the dissociation curve this can indicate non-specific 
double stranded PCR products. 
During this project both methods outlined above were utilised, the Taqman probe 
based design was used for the genetic profile arrays, and the SYBR Green method 
was used for all other genetic analyses. For every rt-PCR reaction there is a baseline 
signal which generally falls between 3-15 cycles during which the fluorescent signal 
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is too low to be detected and is therefore considered background. The threshold cycle 
is the level which indicates a statistically significant increase in signal, and is set 
carefully to ensure pertinent signals are differentiated from background signals. The 
Ct value is the cycle number at which the reaction is higher than the threshold cycle 
(Figure 2.6.) The Ct value allows the calculation of the starting DNA copy number 
present in the initial sample. As the starting template amount increases the Ct value 
will decrease. To remove variability related to the amount of target DNA added to the 
reaction mixture, the efficiency of the RNA extraction and cDNA synthesis the 
expression of the target gene is normalised to an endogenous control (this is a gene 
which is expressed in all samples and is referred to as a housekeeping or reference 
gene). All qPCR reactions were performed in green shell 96-well plates (Biorad 
Laboratories), each reaction mixture contained 1µL of primers (forward and reverse), 
10µL of 2x SYBR Green Master mix and 9µL of cDNA template (10ng per reaction 
with the remaining volume made up with DNase free water). All reactions were run in 
triplicate. The PCR reactions were performed using a CFX96 real time PCR detection 
system (Bio-rad laboratories) using the PCR conditions outlined in Table 2.5. 
Hold PCR (39 cycles) 
Melt Anneal/Extend 
95oC 95oC 60oC 
10min 0.15min 1min 
 
Table 2.5. PCR conditions  
Summary of the conditions used to amplify cDNA in the PCR reaction 
 
Data Analysis 
The Ct values measured for the genetic target were normalised using the Ct value 
obtained from the reference gene in the same cDNA sample. In addition to this, the 
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target gene was analysed in the experimental sample and compared with a 
comparator sample. For example: Treated versus Untreated  
Gene expression is expressed as 2-ΔΔCt  
ΔCt = Ct Target Gene - Ct Reference Gene (GAPDH) 
ΔΔCt = ΔCt - Ct Comparator Sample 
2.2.9. Enzyme-linked immunosorbent assay (ELISA) 
2.2.9.1. Quantification of Shh Secretion 
To investigate the level of Shh produced by cells exposed to different serum 
concentrations, a quantitative human Shh ELISA was used. To collect samples for 
this assay 10,000 cells per well were seeded in a 96-well plate in triplicate per serum 
concentration. The serum concentrations used were 1%, 5% and 10%. Supernatants 
were harvested at 24, 48 and 72h. To harvest the supernatant the plate was 
centrifuged at 400g for 5min and the supernatant was transferred immediately to a 
fresh 96-well plate and stored at -20oC. This method of analysis was developed in 
order to replace radioimmunosorbent techniques which involved the use of 
radiolabelled antibodies and was first described in 1960 (Yalow and Berson, 1960). 
An alternative was sought due to the inherent risk involved in the use of radioactive 
particles. In 1971 a substitute was discovered which utilised enzymes conjugated to 
antibodies rather than isotopes (Engvall and Perlmann, 1971)(Figure 2.7.).  The 
assay kit comprised a 96-well plate which had been pre-coated with an antibody 
specific for Human Shh, thus any Shh present in the samples will become bound by 
the immobilised antibody. 100µL of sample or standard (standard curve 
concentrations: 2000, 800, 320, 128, 51.2, 20.5, 8.2 and 0pg/mL) was added to each 
well in duplicate. The wells were washed to remove anything which remained 
unbound and a biotinylated anti-Human Shh antibody was added. The plate was then 
washed again before the addition of HRP-conjugated streptavidin. Streptavidin 
tetramers have a high affinity for Biotin and together they form an exceptionally strong 
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non-covalent bond. This interaction is therefore frequently utilised  in research as it 
can withstand extremes of temperature and pH (Green, 1975). The wells were 
washed for a final time and a 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate solution 
was added and incubated for 30min at room temperature. The HRP present catalyses 
the conversion of TMB into a coloured product depending on the amount of secondary 
antibody present which is directly proportional to the amount of bound Shh in the well.  
A stop solution was added to the plate which changes the colour from blue to yellow 
and the absorbance was measured using an Envision multilabel plate reader (Perkin 
Elmer) at 450nm.   
 
Figure 2.7.  Summary of ELISA Technique 
  
2.2.9.2. ELISA for DKK1 
To investigate the levels of DKK1 produced by epithelial cancer cells and CAFs a 
quantitative human DKK1 ELISA kit was used. 10,000 cells per well were seeded in 
a 96-well plate in triplicate per serum concentration. Supernatants were harvested at 
72h. To harvest the supernatant the plate was centrifuged at 400g for 5min and the 
supernatant transferred immediately to a fresh 96-well plate and stored at -20oC (For 
full methodology of ELISA see section 2.2.5.2.).  
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2.2.10. BCA assay to determine protein concentration 
In order to determine that the level of secretion of various molecules (Shh, Dkk1 and 
Collagen1a1) by cells was related to factors other than cell number, the protein 
concentration for each sample was determined. This was achieved by comparing the 
samples against a set of known standards which, for the purpose of this experiment 
was BSA.  Protein concentration was determined by the bicinchoninic acid (BCA) 
protein assay using the manufacturer’s protocol. This assay utilises a reaction 
whereby Cu2+ is reduced by proteins to form Cu1+ in alkaline conditions.  This 
reduction can be mediated by cysteine, tryptophan and tyrosine residues, and the 
peptide bond.  The greater the reduction of Cu2+ ions, the higher the protein 
concentration.  The BCA forms a blue/purple coloured complex with the reduced Cu1+ 
in alkaline conditions, which has an absorption maxima of 562nm.  Therefore with 
higher protein concentrations the solution will be less blue / purple and more green in 
colour.  Eight parts of each of the protein standards (0-2000 g/ml in duplicate) were 
mixed with 1 part of the BCA working reagent (containing 0.08% copper sulphate 
pentahydrate) in a 96-well plate.  In addition to the standards, the cell homogenate 
(neat and diluted 10-fold) was also mixed in the same proportions with the BCA 
working solution.  The plate was then incubated for 30min at 37C.  The absorbance 
of each sample was then measured at 562nm and a standard curve constructed using 
Graphpad Prism analysis software using the results obtained from the protein 
standards.  Using this standard curve, the protein concentration of the homogenate 




3. Characterisation of cells isolated from the 
pancreas and their use in a 3D model of 
PDAC 
3.1. Introduction 
PDAC is characterised by a desmoplastic stroma which can encompass greater than 
70% of the tumour volume and is believed to be involved in the poor clinical outcome 
of this disease (Farrow et al., 2008, Waghray et al., 2013, Ghaneh et al., 2007). More 
sophisticated models of this disease are required to understand the complex 
interactions between the cancer cells and the cells which make up the stroma such 
as CAFs. The initial aim of this project was to isolate and characterise pancreatic cells 
and develop a model which incorporates the most prominent aspect of the tumour 
microenvironment, namely CAFs. The stroma consists of CAFs, ECM proteins, 
inflammatory cells and enlarged nerves. The amount of stroma present in a tumour 
varies greatly between patients, however a greater stromal compartment has been 
linked to a significantly poorer outcome for the patient (Erkan et al., 2008). Despite 
the presence of a large stromal component of PDAC being known for 20 years, its 
contribution to tumorigenesis, resistance to therapy and metastasis remains poorly 
understood. In 1982, Watari and colleagues reported the presence of star shaped, 
vitamin-A storing cells in the mouse pancreas (Watari et al., 1982). However it was 
not until approximately 20 years later that these cells were first isolated, 
characterised, and their importance in the mechanism of pancreatic fibrosis began to 
be elucidated (Apte et al., 1998, Bachem et al., 1998). Fibrosis is a critical feature of 
both chronic pancreatitis and pancreatic cancer; it is understood to be the deposition 
of excessive amounts of extracellular matrix in response to a disruption in the balance 
between deposition and degradation of ECM. CAFs were discovered to play an 
important role in pancreatic fibrogenesis with activated CAFs found to be the source 
of collagen deposition in response to pancreatic injury (Haber et al., 1999). In this 
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chapter the method used to isolate primary CAFs is described. Their characterisation 
using the expression of a panel of markers and their ability to secrete ECM, 
specifically Collagen1a1 is also described. 
In recent years controversy has arisen in the field regarding the role of CAFs in the 
PDAC tumour microenvironment, initially CAFs were believed to be involved in 
maintaining a tumour supportive microenvironment and contributing to resistance to 
chemotherapies has been identified (Sherman et al., 2017, Olive et al., 2009). 
However, it has also been discovered that pharmacological and genetic removal of 
the tumour results in more aggressive and reduced survival in mice suggesting that 
the stroma also as a role in restraining the tumour (Rhim et al., 2014, Lee et al., 2014). 
To determine the effect of including CAFs in drug screening models it was necessary 
to develop a model which allowed the cells to interact with a similar level of complexity 
as they do in the tumour microenvironment. In this chapter the characterisation of a 
3D co-culture model of PDAC is described. 
3.2. Methods 
3.2.1. Isolation of cancer-associated fibroblasts (CAFs) 
This method is described in section 2.2.2.1. 
3.2.3. Generation of a 3D co-culture model 
A methylcellulose stock solution was created by dissolving 6g of methylcellulose 
powder in 250mL of IMDM which was pre-warmed to 60oC. Fresh media 
supplemented with 20% FBS was used to dilute the stock solution 1:1, and this 
solution was then mixed overnight at 4oC. The solution was aliquoted and centrifuged 
for 2h at 5000rpm. The clear viscous supernatant was used for the spheroid formation 
assay. For the spheroid formation assay the stock solution was diluted 1:5. 20µL 
drops of methylcellulose supplemented media containing 20,000 cells were pipetted 
onto the lid of 6-well plates with approximately 9 drops per well. The wells were filled 
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with 2mL of PBS solution. Hanging drops were suspended over the wells containing 
PBS and cultured under normal culture conditions (5% CO2, at 37oC) for 7d which 
allowed the formation of spheroids. In order to harvest the spheroids 10µL of cell 
media was carefully pipetted under the spheroids which allowed each spheroid to be 
collected using a sterile spatula. Spheroids were placed into one well of a 96-well 
round bottom plate and washed twice with PBS. The cells were then fixed overnight 
at 4oC using 4% PFA and the following morning the spheroids were embedded in 
Histogel (Thermo Scientific Richard-Allan Scientific) processed and sectioned 
(Section 2.2.4.1.2 and 2.2.4.1.3). 
3.3. Results 
3.3.1. Sample collection and isolation of CAFs 
Isolation of cells from “fibrous” appearing tissue was completed in collaboration with 
Dr Lawrence Barrera. Isolation of cells from “normal” appearing tissue was completed 
by Dr Lawrence Barrera. Pathologists (Professor Fiona Campbell and Dr Tim 
Andrews) performed gross analysis of the specimen to identify “normal” appearing 
tissue, which is yellow in colour and “fibrous” appearing tissue which typically appears 
white and is hard when touched. In order to isolate cells from the PDAC 
microenvironment it was necessary to collect tissue samples from patients 
undergoing pancreatic resection at Royal Liverpool University Hospital. Figure 3.1A 
shows representative images from two of the specimens collected highlighting the 
difference in morphology between normal pancreatic tissue and tissue taken from an 
area of fibrosis. In the tumour section it is possible to visualise tumour cells embedded 
in the desmoplastic stroma (Figure 3.1A, black arrow). IHC analysis of αSMA and 
pan-cytokeratin stained tumour cores (Figure 3.1B & C) displayed strong αSMA 
positive staining in the stroma consistent with its expression in activated fibroblasts. 
Pan-cytokeratin staining was found in the cytoplasm of epithelial cells which was 
consistent with previous reports (Erkan et al., 2012a, Erkan et al., 2008). Tumour 
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sections were taken from each specimen collected and stained for αSMA and pan-






Figure 3.1. Representative Images of staining of normal tissue compared with tumour tissue 
A: Haematoxylin and Eosin staining of normal appearing tissue and tumour tissue sections taken from 
specimens used to obtain CAFs. Normal histology section showing a standard arrangement of 
pancreatic acinar cells. Tumour section shows a prominent desmoplastic stroma surrounding tumour 
cells (black arrow). B: Tumour cores stained for αSMA and Pan-cytokereratin. Representative pairs of 
serial tumour cores clearly show stromal elements stained positively for αSMA (left image) and tumour 
cells stained positively for Pan-cytokeratin (right image). Positive αSMA staining indicates the presence 
of activated CAFs in the pancreatic tumour microenvironment. Epithelial cancer cells are stained positive 
for Pan-cytokeratin. Scale bar 200µm. C: Higher magnification images of tumour cores stained for αSMA 
and Pan-cytokereratin. Higher magnification (20x magnification) images show strong αSMA positive 
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staining of stromal elements (black arrows). Pan-cytokeratin staining shows the morphology of the 
tumour cells (black arrows).Scale bar 50µm. 
3.3.2. Characterisation of CAFs using fibroblast markers 
Isolation of cells using the outgrowth method can yield a mixed population of cells as 
the tumour microenvironment contains a variety of cells types. Therefore it was 
necessary to determine the purity of the cell populations using a selection of markers 
to characterise CAFs or contaminating cells such as macrophages or epithelial cells. 
It was important to investigate the purity and heterogeneity of all cells isolated from 
the pancreas at the earliest possible passage using a panel of markers; αSMA stains 
positively smooth muscle cells and pericytes of blood vessels, therefore it was 
combined with staining for the intermediate filament protein vimentin which is 
expressed in stromal cell lineages. Desmin is also an intermediate filament protein 
which positively stains up to 20% of CAFs (Apte et al., 1998). CAFs are identified by 
their myofibroblast-like phenotype and expression of αSMA, Vimentin and desmin.  All 
of the fibroblasts isolated (both from normal and tumour tissue) showed 80% or above 
expression of αSMA and Vimentin. There was minimal expression of Desmin. All 
isolated fibroblast cultures were negative for CTK and CD68 which indicated that they 




















Normal 80% 100% 0% 0% 0% 
R3030 PDAC Fibrous 100% 80% 1% 0% 0% 
R3072 PDAC Fibrous 90% 100% 0% 0% 0% 
R3088 PDAC Fibrous 80% 85%% 2% 0% 0% 
R3104 PDAC Fibrous 100% 100% 1% 0% 0% 
R2875 PDAC Fibrous 90% 90% 0% 0% 0% 
Table 3.1 Samples used in this study and their expression of CAF markers 
The characteristics of samples collected by myself and Dr L. Barrera which were used in this study. The 
percentage of marker expression was estimated by myself and Dr L. Barrera independently and then 
compared and the average calculated. This estimation was achieved by approximation of the percentage 





Figure 3.2. Characterisation of CAFs using expression of various markers 
Expression of CAF (R3088) marker proteins demonstrated by ICC in CAFs. Alpha smooth muscle actin 
(α-SMA), Vimentin and Desmin are commonly expressed in CAFs (Apte et al., 1998). Pan-cytokeratin 
and CD68 were used to identify if contaminating cells were present in these primary cultures. As a 
negative control, cells were incubated with an isotype matched control antibody, at the same 
concentration as the primary antibody. Scale bar 50µm.  
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3.3.3. Characterisation of CAFs using collagen production 
Having established that the isolated CAFs express the appropriate markers it was 
also necessary to determine the functionality of the CAFs isolated which was 
established using the ability of the CAFs to secrete collagen 1a1. A major component 
of the pancreatic tumour microenvironment is collagen; it has been established that 
CAFs are the source of the deposition of the excessive amount of extracellular matrix 
(Bachem et al., 2005). Figure 3.3.A shows the co-localisation of αSMA positive cells 
and the deposition of collagen using Picro Sirius Red staining which was consistent 
with previous reports (Apte et al., 2004). In order to determine that the isolated CAFs 
exhibited a similar phenotype in culture, the level of secreted collagen1a1 was 
quantified using an ELISA. All 3 CAF lines secreted significantly more collagen than 
pancreatic cancer cell lines (Figure 3.3B). This clearly demonstrates that the isolated 
CAF cells not only express the protein markers associated with CAFs, but also 





Figure 3.3. Collagen production in CAFs compared to a panel of pancreatic cancer cell lines 
A: A representative image of serial sections of pancreatic cancer showing co-localisation of Picro Sirius 
Red and αSMA. B: CAFs secrete significantly more collagen than pancreatic cancer cell lines. 
Quantification of Col1a1 was determined using a standard curve for comparative analysis. ** indicates 
significance with p<0.0014 (N=3) in collagen secretion between CAFs and MIAPACA2, the level of 
collagen secreted by the other cell lines was below the limit of detection (shown as a dotted line) of the 
ELISA therefore statistics could not be performed. 
3.3.4. Isolation of epithelial tumour cells 
In order to best model the PDAC tumour microenvironment I sought to combine 
isolated tumour cells with CAFs. However, despite using a variety of techniques I was 
unable to isolate epithelial cells. The methods used and the results obtained are 
detailed below. The first method used was the outgrowth method (Erkan et al., 
2012a), unfortunately within 7 days CAFs outgrew the cultures and the epithelial 
cancer cells did not survive (Figure 3.4.).  
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Figure 3.4. Morphologically different cell types isolated using the outgrowth method 
Representative images of cells growing out of tissue explants after 7 days. It is possible to distinguish 
between two morphologically different cell types. Black arrows indicating CAFs and red arrows indicating 
what is believed to be epithelial tumour cells. Scale bar 50µm. 
 
There are two methods generally used for the removal of contaminating fibrolasts 
from primary epithelial cell cultures. The first is the use of a sterile canula to 
mechanically remove fibroblasts from cultures. This method was trialled and was 
found to be ineffective due to the rapid recovery of the CAFs from this treatment. The 
second method for removal of contaminating fibroblasts is selective trypsinization, 
which is possible due to the fact that CAFs do not adhere to the culture vessel as 
strongly as epithelial tumour cell lines (Felix Rückert, 2012). However, over time the 
selective trypsinization process appeared to damage the epithelial cells as fewer cells 
survived each round. The next method attempted was the use of selective media to 
attempt to reduce the growth of CAFs within the mixed cultures. The following media 
formulations were used: 
 Dulbecco’s Modified Eagle’s Medium (Supplemented with 10% FBS) 
 Dulbecco’s Modified Eagle’s Medium (Supplemented with 20% FBS) 
 Keratinocyte-Serum Free Medium 
 Dulbecco’s Modified Eagle’s Medium/HAMS F-12 Nutrient Mixture 
(Supplemented with 10% FBS) 
 Dulbecco’s Modified Eagle’s Medium/HAMS F-12 Nutrient Mixture 
(Supplemented with 20% FBS) 
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 “Dresden” modified DME medium - Dulbecco’s Modified Eagle’s 
Medium(Supplemented with 20% FBS) with Keratinocyte-Serum Free 
Medium in a 2:1 ratio (Ruckert et al., 2012) 
In all cases the CAFs maintained their growth rate and appeared to be resistant to 
changing the culture conditions, therefore it was necessary to develop an alternative 
method to separate the cell populations. 
Epithelial cancer cells were removed from the well surface using cloning rings, 
however once they had been removed they did not reattach to the new culture vessel. 
In order to determine why the epithelial cells would not reattach, trypsin was 
substituted for other, milder dissociation solutions such as Accutase. However, 
substitution of trypsin with Dispase and Accutase also resulted in a lack of epithelial 
cell reattachment. The mechanical dissociation of the cells using a sterile spatula was 
also unsuccessful. To ensure that the epithelial cells were in sufficient contact with 
the culture vessel surface, the volume of media was reduced to encourage cellular 
attachment. The epithelial cancer cells were seeded into a 96-well plate to reduce the 
size of the culture vessel, therefore reducing the area available for the cells to re-
attach encouraging cell-cell communication.  
The second most commonly used method for the isolation of primary epithelial cells 
is the use of digestive enzymes to break down connective tissue and produce a 
suspension of cells (Owens et al., 1976, Chifenti et al., 2009, Kalinina et al., 2010). 
The only cells which survived this treatment were CAFs, most likely because 
approximately 80% of the PDAC tumour microenvironment is made up of stromal 
cells, and therefore CAFs are the more abundant cell type. After two separate 
experiments this method was deemed unsuitable. The next method utilised was the 
use of density gradients in an attempt to capture fractions which contained epithelial 
cells. Unfortunately this method was unsuccessful after three attempts, with the only 
cells proliferating from these cultures being CAFs. The presence of CAFs and cancer 
cells in mixed cultures isolated from tumour specimens was investigated using ICC 
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staining for αSMA and Pan-cytokeratin. It was found that mixed cultures contained 
both α-SMA positive cells and Pan-cytokeratin positive cells, which indicates the 







Figure 3.5. Expression of αSMA and pan-cytokeratin in mixed cultures of CAFs and cancer cells 
isolated from PDAC specimens 
A: Representative images of mixed cultures showing CAFs positively stained for αSMA and cancer cells 
positively stained for pan-cytokeratin. B: Representative image of a mixed culture of CAFs and cancer 




It was possible to visualise colonies of cancer cells growing out of tumour pieces in 
addition to CAFs (Figure 3.4.). However upon attempting to dissociate them using 
various techniques (see section 3.1.2) the epithelial cells would not successfully re 
attach resulting in a loss of the sample. Given the difficulties with maintaining freshly 
isolated epithelial cells from pancreatic cancer patient samples an alternative was 
required in order to model the interaction between epithelial and fibroblast cells. A 
panel of 5 well-characterised pancreatic cancer cell lines was selected (PANC1, 
SUIT2, MIAPACA2, ASPC1 and BXPC3) (Lieber et al., 1975, Iwamura et al., 1987, 
Yunis et al., 1977, Chen et al., 1982, Tan et al., 1986) to best match patient variation 
due to their diverse origins (Table 2.1.). The expression of pan-CTK and αSMA in the 
5 cell lines chosen and a CAF line was determined using IF (Figure 3.6.). As expected 
the 5 PDAC cell lines expressed pan-CTK and the CAF line was negative and only 





Figure 3.6. Immunofluorescence images of cancer cell lines and CAF stained for αSMA and pan-
cytokeratin 
Cancer cell lines are negative for αSMA expression and positive for pan-cytokeratin, CAFs are positive 
for αSMA expression and negative for pan-cytokeratin.  
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3.3.5. 3D model of pancreatic cancer 
The importance of the tumour microenvironment in PDAC has become increasingly 
clear in recent years, specifically the role of CAFs in the production of a desmoplastic 
stroma which has been implicated in resistance to chemotherapy, metastasis and 
maintenance of a tumour supportive microenvironment (Erkan et al., 2012b, Farrow 
et al., 2008). However, despite such knowledge there has been little progress in the 
development of drug discovery models which include CAFs. In order to identify the 
complex interactions between CAFs and cancer cells, the effect of CAFs on tumour 
cell growth and the role of CAFs in reducing the efficacy of chemotherapy, more 
sophisticated models of the tumour microenvironment are required. 3D models have 
been shown to more accurately represent the behaviour of tumour cells in vivo (Wu 
and Swartz, 2014, Nyga et al., 2011), however these models have been lacking in 
pancreatic cancer due to the inability to recreate the stroma. Recently methods have 
been developed to create 3D co-culture models which include CAFs (Ware et al., 
2016b). In order to create a reproducible 3D co-culture model for use in drug 
screening assays it was necessary to characterise how these cells interact in 3D and 
to elucidate the effect of introducing CAFs into a 3D model of PDAC. There were clear 
morphological differences between the spheroids formed from mono-cultures of 
different pancreatic cancer cell lines: BXPC3, PANC1 and ASPC1 formed spheroid 
structures in the absence of CAFs, whereas SUIT2 and MIAPACA2 formed 











Figure 3.7. Histological analysis of PDAC spheroids after 1 week in culture 
Representative H&E images of cancer cell lines in 3D culture alone and in the presence of CAFs in a 
1:2 ratio of CAFs:cancer cells. Brightfield microscopy indicates differences in morphology between cells 
cultured alone and in the presence of CAFs. Overall the addition of CAFs visibly increases the density 
of the spheroids. Scalebar 50µm.  
 
In order to quantify the effects of including CAFs on the morphological phenotype of 
spheroids, the parameters of diameter and circularity were measured (Figure 3.8, 
Figure 3.9.). PANC1, SUIT2 and MIAPACA2 spheroids showed an increase in 
circularity upon addition of CAFs (Figure 3.9). In the case of SUIT2 and MIAPACA2 
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it was not possible to measure circularity in the absence of CAFs as they did not 
maintain a spheroid structure and therefore statistical analysis was not performed. 
PANC1 spheroids had an increase in circularity in the presence of CAFs with a mean 
circularity of 0.82±0.02 alone compared to 0.96±0.02 in the presence of CAFs 
(p=0.0023, N=3). 
Upon co-culturing BXPC3 cells with CAFs, the resulting spheroids appeared to have 
a similar shape which is verified by a statistically similar circularity score (0.988, 0.985 
and 1.000 for mono-BXPC3, mono-CAF and co-culture respectively; Figure 3.9). 
However, despite having the same number of cells the co-culture was significantly 
smaller in diameter than BXPC3 alone (241.2µm and 377.3µm; Figure 3.8) 
suggesting the addition of CAFs causes the spheroids to be more structurally 
compact. Similarly PANC1, MIAPACA2, and SUIT2 cell lines also appeared to be 
more dense in the presence of CAFs compared to when they were cultured alone 
(Figure 3.7.). 
Staining of spheroids created using PANC1, MIAPACA2 and CAFs was carried out 
in order to investigate the orientation and spatial distribution of the cells within the co-
culture models.  
In both MIAPACA-CAF and PANC1-CAF spheroids it appears that αSMA positive 
cells (CAFs) are found throughout the spheroid rather than confined to a specific area 
(such as the centre) (Figure 3.10.). This is consistent with the model of the PDAC 
tumour microenvironment created by Ware and colleagues, who describe a stroma 
rich spheroid model with collagen deposition throughout their spheroids (Ware et al., 
2016b). Together this suggests this model replicates the distribution of αSMA positive 
cells throughout the PDAC tumour microenvironment and resembles the pathology of 





Figure 3.8. Diameter of spheroids in the presence and absence of CAFs 
Brightfield microscopy allowed the measurement of the diameter of the spheroids. All spheroids except 





Figure 3.9. Circularity of spheroids in the presence and absence of CAFs  
As an indicator of the morphological differences between the spheroids. The circularity of the spheroids 








   
Circularity =  4π Area of spheroid 






Figure 3.10. Characterisation of the 3D co-culture model 
A: 3D cultures of cancer cell lines (PANC1, MIAPACA2) alone or in co-culture with CAFs stained for 
αSMA. Co-cultures show the presence of αSMA positive cells dispersed throughout the spheroid. B: 3D 




CAFs have been found to be the main cell type involved in the maintanence of the 
stroma and deposition of abundant extracellular matrix proteins (Apte et al., 2004, 
Wilson et al., 2014). It has been established that a high activated stroma index 
(αSMA/collagen) results in a poorer prognosis for patients (Erkan et al., 2008). Given 
such a crucial role for CAFs within PDAC, it is necessary to develop models which 
include elements of the stroma. The initial aim of my project was to isolate and 
characterise cells from the PDAC microenvironment. CAFs were successfully isolated 
from human PDAC tissue samples and characterised using a panel of CAF specific 
markers. The presence of positve αSMA and vimentin and an absence of CTK and 
CD68 (Figure 3.2) is consistent with previous reports (Apte et al., 1998, Apte et al., 
2004) and therefore show that the isolated and cultured CAFs exhibit a morphology 
consistent with those observed in tissue. The fact that CAFs secrete Col1a1 in culture 
demonstrates that the isolated CAFs were phenotypically functional. Taken together 
these data suggest that the CAFs used throughout this project represent a suitable 
model of CAFs found within the PDAC tumour microenvironment.  
In order to recapitulate the tumour microenvironment it would have been preferable 
to isolate primary epithelial tumour cells from patients, however this was not possible. 
In lieu of isolated primary epithelial cells a panel of 5 pancreatic cancer cell lines was 
chosen. These cells have previously been shown to offer a suitable model of PDAC 
(McConkey et al., 2010) and therefore were considered to be a good alternative to 
primary epithelial cells. 3D cell culture has been shown to provide cellular genetic 
profiles which more closely resemble the clinical genetic profiles than 2D cell cultures 
(Kenny et al., 2007). In vivo cells are ellipsoidal, have complex 3D interactions and 
form elaborate cellular structures. It is impossible to recreate this in vitro but 3D 
models are closer than unsophisticated 2D models (Nelson and Bissell, 2005, Shield 
et al., 2009). Consistent with these findings, the data presented above describes an 
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appropriate 3D model of PDAC, which mimics tumour morphology and the presence 
of stromal cells (CAFs). The addition of CAFs changed the morphology of the 
spheroids; they visibly appeared to be more densely packed. In all cell lines except 
MIAPACA2 the addition of CAFs to the model caused a decrease in diameter. This 
could be due to the fact that MIAPACA2 did not form structurally robust spheroids 
when they were cultured alone. These findings indicate that the CAFs may be 
providing structural support for the growth of cancer cells. This is consistent with the 
findings above showing that the 3 CAF cell lines tested secreted significantly more 
collagen than the epithelial cells. Collagen maintains tissue structure in a healthy 
pancreas. In the PDAC tumour microenvironment homeostatic control of collagen 
deposition is lost and CAFs secrete over 3-fold what benign fibroblasts would secrete 
in healthy tissue (Ryschich et al., 2009). During tumour progression the role of 
collagen fibres also changes dramatically and they become aligned (Egeblad et al., 
2010). This can lead to an increase in interstitial pressures due to compactness of 
the microenvironment (McConnell et al., 2016)  and create migratory corridors which 
makes collagen fibres complicit in tumour invasion (Provenzano et al., 2008, Riching 
et al., 2014). Preliminary staining showed the location of αSMA positive cells 
dispersed throughout the co-culture model which was consistent with the findings of 
Ware and colleagues who found collagen deposited throughout the spheroids they 
had created indicating the distribution of CAFs (Ware et al., 2016a, Ware et al., 
2016b). This is similar to tumour architecture and the presence of collagen deposits 
suggests this model with functionally active CAFs is a model which closely resembles 
the PDAC tumour microenvironment. The importance of CAFs within the pancreatic 
tumour microenvironment is clear; these cells have a complex and intricate 
relationship with cancer cells resulting in tumour progression. Understanding the key 
mechanisms that underpin the pro-oncogenic relationship between cancer cells and 
CAFs is therefore key to devloping treatment for PDAC. One such mechanism 
thought to contribute toward PDAC progression are the embryonic signalling 
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pathways (Morris et al., 2010, Bai et al., 2016, Zhang et al., 2013). The cross-talk 
between CAFs and cancer cells of these signalling pathways must therefore be 
characterised in vitro in order to determine how these cells communicate in vivo. The 
co-culture model presented herein provides an ideal platform by which this 




4. Hedgehog signalling in the PDAC tumour 
microenvironment 
4.1. Introduction 
In 2003 Thayer and colleagues observed aberrant Shh ligand expression in early 
pancreatic cancer precursor lesions (Thayer et al., 2003).  This finding has since been 
corroborated in KRAS driven mouse models of PDAC (Hingorani et al., 2005) 
suggesting that Shh has an important role in the initiation and progression of PDAC. 
Indeed, abnormal expression of Hh ligands has been observed in other solid tumours 
including prostate, colon and breast (O'Toole et al., 2011, Sheng et al., 2004, Wang 
et al., 2013). Perhaps more surprisingly however, in PDAC there appeared to be no 
activated Hh signalling within the tumour epithelial cells (Yauch et al., 2008) 
suggesting that aberrant Shh signalling may be a product of cross talk between CAFs 
and epithelial cancer cells.  Hh signalling has been implicated in the formation of the 
stroma through the activation of CAFs (Bailey et al., 2008). The development of PDAC 
with its associated desmoplastic stroma alters the architecture of the pancreas. This 
can, in part be due to excessive proliferation of activated CAFs (αSMA positive) that 
secrete large amounts of ECM preventing blood perfusion, oxygen diffusion and 
effects the distribution of nerves throughout the parenchyma (Erkan et al., 2012b) . 
The presence of the desmoplastic stroma presents a physical barrier to drug delivery 
due to its effect on the blood perfusion of the PDAC microenvironment (Provenzano 
and Hingorani, 2013). Therefore, antifibrotic agents such as  Vitamin E and Hh 
pathway inhibitors, aimed at depleting the stroma offered a promising therapeutic 
approach. In a KPC model of PDAC (mouse model produced from a mixed genetic 
background which develops and has similar pathological features of the human 
disease (Lee et al., 2016)), treatment of tumour bearing mice with IPI-926 (a small 
molecule SMO inhibitor created by Infinity Pharmaceuticals) resulted in collapse of 
the stroma which allowed for increased perfusion and, when combined with 
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Gemcitabine resulted in an increased survival rate (Olive et al., 2009) . However, 
despite the hopeful results in these pre-clinical studies, the Phase 2 clinical trial of 
IPI-926 in combination with Gemcitabine (IPI-926-03 trial; NCT01130142) showed 
reduced survival in patients compared to the placebo arm. Further studies into Hh 
signalling in the pancreatic tumour microenvironment showed that genetic deletion of 
Shh or inhibition of SMO during tumour formation resulted in a reduced tumour mass 
which corresponded to a decreased desmoplastic stroma. However, unexpectedly 
these tumours showed a much more lethal phenotype (Rhim et al., 2014, Lee et al., 
2014). Such a surprising finding demonstrates that, despite a clear role for the Hh 
signalling pathway in PDAC, the precise manner by which it functions within the 
mircroenvironment has yet to be elucidated. 
I therefore sought to determine whether the Hh pathway was active in an in vitro 
model of PDAC, and whether Redx SMO inhibitors could be used to block this 
activation. 
4.2. Methods 
4.2.1. ELISA for Shh 
To investigate the level of Shh produced by cultured cells, a quantitative human Shh 
ELISA Kit was used. Samples were prepared using the following method: cells were 
seeded in triplicate at 10,000 cells per well in a 96-well plate and grown in the 
presence of differing FBS concentrations (1%, 5% or 10% FBS). After 24, 48 and 72h, 
the plate was spun at 400g for 5min and the supernatant transferred immediately to 
a fresh 96-well plate and stored at -20oC. For a full description of the technique see 
Section 2.1.6.1. 
4.2.2. Recombinant Shh treatment optimisation 
To determine the optimal concentration of recombinant Shh (rShh) able to cause the 
greatest upregulation of the Hh pathway in CAFs, a titration of rShh was performed 
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at 3 different time points (24, 48 and 72h) using one example of CAFs (R3104). 
50,000 CAFs per well were seeded onto 6-well plates and left to adhere under 
standard culture conditions overnight. The following day the growth media was 
changed to serum free IMDM. The serum starvation step is necessary in order to 
measure changes in Hh pathway activation as serum is rich in growth factors and 
proteins and may therefore negate the cells’ dependency on embryonic cell signalling 
pathways. After 24h of serum starvation the cells were treated with either IMDM 
containing 1% FBS or serum-free IMDM with either 0.25, 0.5, 1, 2 or 3 µg/mL of rShh 
in duplicate per condition. This concentration range was chosen to confirm literature 
reports showing that treatment with rShh could induce an upregulation in GLI1 mRNA 
(Hwang et al., 2012). RNA was isolated after 24, 48 and 72h and Hh pathway 
activation was analysed using changes in the mRNA level of GLI1.  
4.2.3. Inhibition of Hh pathway in a 2D model 
Once the optimal rShh concentration and time point required for the largest detectable 
activation of the Hh pathway had been selected, the effect of Redx SMO inhibitors on 
Hh pathway activation in CAFs was investigated. 50,000 CAFs were seeded per well 
of a 6-well plate, the cells were left overnight in an incubator (37oC, 5% CO2 air 
humidified atmosphere). The following day the media was replaced with IMDM (2% 
L-Glutamine, 1% Penicillin Streptomycin) supplemented with either 1% FBS or 
2μg/mL of rShh and containing Redx SMO inhibitors. The plate was then incubated 
for a further 24h (37oC in a 5% CO2 air humidified atmosphere; for plate map see 
Table 4.1). At 24h RNA was isolated and changes in GLI1 mRNA were analysed 
using q-PCR (Section 2.1.5.4.). 2 technical replicates were included on each plate 





1% FBS IMDM 
0.1% DMSO 
2μg/mL rShh in IMDM 
0.1% DMSO 
2μg/mL rShh in IMDM 
0.1% DMSO 
2μg/mL rShh in IMDM 
1000nM Redx Inhibitor 
2μg/mL rShh in IMDM 
100nM Redx Inhibitor 
2μg/mL rShh in IMDM 
10nM Redx Inhibitor 
Table 4.1. 6-Well plate map summarising the conditions used to investigate the inhibition of Hh 
pathway in CAFs. 
4.2.4. Transwell co-culture for Hh pathway activation 
Transwell co-culture allows for the analysis of changes in Hh pathway genes in CAFs 
when PANC1 cells and CAFs are cultured in the same well. The Transwell co-culture 
model used in this project involved the separation of epithelial cancer cells from CAFs 
using a permeable membrane to allow paracrine signalling to occur with a physical 
barrier between the two cell populations. 6-well Transwell polycarbonate membranes 
(Corning Life-sciences) were used with a pore size of 0.4µm, which does not permit 
the migration of cells through the membrane but does allow the passage of proteins 
and signalling molecules such as Shh and Wnt. During the optimisation of this 
experiment various epithelial cell:CAF ratios and time points were explored until the 
optimal conditions to give the highest activation of Hh pathway was determined. 
Optimisation experiments were carried out in duplicate using one exemplar CAF cell 
line (R3215) with the final conditions repeated in duplicate with 3 CAF lines (R3030, 
R3072 and R3088). 1 week before the Transwell experiment was carried out, cells 
were transferred from DMEM (supplemented with 10% FBS) to IMDM (supplemented 
with 10% FBS, 2% L-Glutamine and 1% Penicillin Streptomycin). This was done to 
ensure that changes in mRNA expression could not be attributed to a change of 
growth medium. An empty 6-well plate was filled with 2mL per well of growth medium, 
the Transwell inserts were added and 50,000 PANC1 cells or CAFs were loaded onto 
the insert in 2mL of media. In the empty Transwell plate 50,000 PANC1 cells or CAFs 
were seeded in 2mL of growth medium and the cells were allowed to adhere 
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overnight.  Cells in the Transwell plate were serum starved for 24h and cells on the 
Transwell inserts were placed in IMDM (5% FBS, 2% L-Glutamine and 1% Penicillin 
Streptomycin) for 24h. Following this, all media was removed from both Transwell 
chambers and the inserts were placed in their corresponding wells following the plate 
map below (Table 4.2.). This was repeated in 3 individual CAF lines. To investigate 
tumour cell paracrine signalling to CAFs in this Transwell  model, it was decided that 
CAFs should be seeded on the bottom chamber. This is because the yield of RNA 
from the plate was greatly decreased when CAFs were seeded on the inserts despite 
cell adherence and growth being unaffected (Figure 4.1.). This could be due to the 
difference in the growth area on the Transwell insert compared to the bottom 
chamber. 2mL of fresh IMDM (5% FBS, 2% L-Glutamine and 1% Penicillin 










Table 4.2: Platemap of conditions used in a Transwell model 
RNA was isolated from both chambers after 48h and the difference in Hh pathway 
activation between CAFs cultured with either CAFs or PANC1 cells was measured by 



























mRNA level of GLI1, SMO and PTCH1 as these are the main effectors of the Hh 
pathway (Choudhry et al., 2014). 
4.2.5. Hh pathway inhibition in a Transwell co-culture model 
Using the Transwell co-culture model developed above, it was possible to investigate 
how effective Redx SMO inhibitors would be in a model which allowed paracrine 
signalling between epithelial cancer cells and CAFs. The method used is identical to 
section 4.2.4 with the addition of either Redx SMO inhibitor (10mM stock in DMSO, 
final DMSO concentration 0.1%) or vehicle control (0.1% DMSO) to all wells (see 












Table 4.3 Platemap of condition used in a Transwell model to investigate if Redx SMO inhibitors 
could reduce activation of Hh pathway in CAFs 
RNA was isolated from cells in both chambers after 48h and the difference in Hh 
pathway activation between CAFs cultured with CAFs/PANC1 cells in the absence or 
presence of Redx SMO inhibitors was investigated by RT-PCR (section 2.2.5.4.). Hh 























































4.2.6. Taqman Array for Hh pathway 
A human Hh pathway TaqMan Array (Thermo Fisher Scientific)  was used to compare 
the differential expression of Hh pathway associated genes in CAFs and NAFs 
compared with a normal pancreatic fibroblast cell line (NPF; purchased from ATCC). 
The array plate contained 44 Hh associated genes (BCL2, BNC1, BTRC, CREBBP, 
CSNK1A1, CSNK1D, CSNK1E, CSNK1G1, CSNK1G2, CSNK1G3, dhh, DISP1, 
DISP2, E2F1, FBXW11, FOXA2, GAS1, GLI1, GLI2, GLI3, GSK3B, HHIP, IFT52, 
IFT88, ihh, LRP2, MTSS1, MYF5, PRKACA, PRKACB, PRKACG, PRKX, PRKY, 
PTCH1, PTCH2, RAB23, Shh, SMO, STIL, STK36, SUFU, ZIC1, ZIC2, ZIC3) and 4 
control genes (18S, GAPDH, GUSB and HPRT1) in duplicate. The genes included in 
this array are from the vertebrate Hh family of associated genes. CAFs, NAFs and 
NPFs were cultured in IMDM (10% FBS, 2% L-Glutamine, 1% Penicillin Streptomycin) 
and were allowed to reach 80% confluence at which point their RNA was isolated. 
The cDNA was diluted with a volume of DNase free water to a concentration of 1ng/µL 
which corresponds to 10ng/reaction. The array plate was centrifuged at 1000rpm for 
2min, each well was loaded with 10µL of cDNA and 10µL of mastermix. The 
mastermix used was TaqMan Fast Universal PCR Master Mix (2X), no AmpErase 
UNG (AppliedBiosystems). The plate was centrifuged for a second time at 1000rpm 
for 2min and then loaded into a T100 Thermal Cycler (Biorad) and the plate was run 
according to the cycle detailed in Table 2.5. The fluorophore used with TaqMan was 
carboxyfluorescein (FAM).  
4.3. Results 
4.3.1. Shh expression and secretion 
In order to confirm the presence of aberrant Shh expression in the pancreatic tumour 
microenvironment, IHC analysis was performed (See section 2.2.4.4.).  Figure 4.2 
shows that Shh was expressed in epithelial cells lining ducts in the pancreatic tumour 
microenvironment compared to an absence of strong positive staining in the acini and 
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ducts of normal tissue (Figure 4.2A-B). When strong positive Shh staining was 
compared using a positive pixel count algorithm the difference between tumour and 
normal tissue was shown to be statistically significant (p=0.0008) (Figure 4.2C). It is 
interesting to note that the Shh staining in the epithelial cells surrounding ducts shows 
strong positive staining in a perinuclear compartment in a pattern reminiscent of that 
observed in staining for the golgi/ER (Figure 4.2.B). This spatial staining is consistent 
with the presence of Shh precursors which are targeted to the golgi/ER for post-























Figure 4.2.Shh staining in the pancreatic tumour microenvironment 
A: IHC analysis of Shh staining in tissue isolated from normal appearing tissue compared with fibrous 
appearing tissue from PDAC specimens. There is no specific positive staining in normal pancreatic acini 
compared to strong positive staining in pancreatic tumour cells in PDAC samples. Scale bar: 100µm. B: 
Higher magnification image of a pancreatic tumour showing strong perinuclear staining in tumour cells. 
Scale bar: 50µm. C: Quantification of staining in Normal compared with Tumour specimens using Aperio 
Imagescope to isolate and count strong positive pixels. To quantify staining three areas were chosen 
per sample. This data shows the comparison of 3 normal vs 3 tumour specimens. P value = 0.0008. 
 
As discussed in Section 3.3.4. it was not possible to isolate primary pancreatic tumour 
cells from tumour specimens, therefore it was necessary to establish the expression 
of Shh in a panel of established pancreatic cancer cell lines. To this end, PANC1, 
MIAPACA2, SUIT2, ASPC1 and BXPC3 cell lines were fluorescently labelled using 





Figure 4.3. Shh expression in pancreatic cancer cell lines 
Representative images of pancreatic cell lines and a CAF isolate (R3104).  All cells were stained for Shh 
expression (green) and counterstained with the nuclei dye DAPI (blue). An isotype control was used to 





Figure 4.3. shows that PANC1, MIAPACA2 and SUIT2 express Shh in a homogenous 
manner. Moreover, the positive Shh staining in these cell lines is also in a perinuclear 
compartment in a pattern reminiscent of that observed in staining for the golgi/ER 
which is similar to that observed in tumour cells in the PDAC tumour 
microenvironment (Figure 4.3, Figure 4.1A & B). However, Shh staining was 
minimal/absent in BXPC3, ASPC1 and CAF despite similar cell numbers present. The 
absence of staining in the CAF cells was similar to the lack of Shh present in the 
stromal cells of the pancreatic tumour microenvironment (Figure 4.2A & B). The 
presence of Shh within the cells may not necessarily translate into secreted Shh 
which is crucial for effective modelling of paracrine Hh signalling between CAFs and 
epithelial cells. I therefore sought to quantify the level of Shh secreted by each cell 



























Figure 4.4. Secretion of Shh by pancreatic cancer cell lines and CAFs at varying serum 
concentrations 
A: Shows the levels of Shh secretion from PDAC cancer cell lines compared to CAFs under standard 
culture conditions (10% Serum). CAFs secrete below the limit of detection for this ELISA therefore 
statistical analysis was not appropriate. B: Shows the effect of different serum (FBS) concentrations on 
the secretion of Shh secretion in PDAC cancer cell lines and CAFs. Dotted line indicates the limit of 






































































It was necessary to investigate not only the Shh expression level in the various cancer 
cell lines but also their ability to produce Shh ligand in low serum conditions. In 
standard culture conditions (10% FBS) Shh was detected in the supernatants of all 5 
PDAC cell lines (Figure 4.4A). However only PANC1 cells secrete significantly more 
Shh than CAFs when compared using a one-way ANOVA (p<0.0001; Figure 4.4A). 
PANC1 and MIAPACA2 cells secrete significantly more Shh when they are cultured 
in 10% and 5% serum compared to 1% serum condition. No Shh was detected in 
CAF supernatants (Figure 4.4.) which is consistent with the absence of Shh 
expression in the cells (Figure 4.3). In stark contrast, all 5 PDAC lines secreted 
detectable levels of Shh in each of the 3 serum conditions with PANC1 cells exhibiting 
the most secreted Shh in all 3 conditions with a mean of 3451.4±415.9, 3175±314.5 
and 329.1±156.2 pg.mg protein-1 in 10, 5 and 1% serum respectively (Figure 4.3 B). 
The lack of detectable Shh in CAF supernatant at 1% and 5% serum makes direct 
statistical comparison unfeasible for these conditions. 
4.3.2. Hh pathway in CAFs 
Having established that the PDAC cell lines used in this project secrete Shh the next 
step was to investigate whether differences in the expression of Hh pathway genes 
exist between activated fibroblasts isolated from the tumour microenvironment 




















































Figure 4.5.  Differentially expressed genes in CAFs and NAFs 
Differentially expressed genes in CAFs and NAFs using a normal pancreatic fibroblast line (Purchased 
from ATCC) as a control fibroblast line, gene expression profiles were obtained by Taqman mini array. 
Upregulation of genes of interest is indicated by red colour, downregulation is shown using green. The 
discovery analysis (Benjamini, Krieger and Yekutieli, with Q = 1%. Computations assume that all rows 
are sample from populations with the same scatter (SD)) identified three statistically significant gene 
differences CSNK1E1 (p<1x10-14), RAB23 (p=0.000004) and GSK3β (p=0.0001). 
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Analysis of both CAFs (N=3) and NAFs (N=3) show three significantly upregulated 
genes in CAFs which are associated with the Hh pathway CSNK1E1, RAB23 and 
GSK3β (Figure 4.5). Casein Kinase1E1 and GSK3β are involved in the proteolytic 
processing of the GLI transcription factors in response to the released repression of 
SMO upon binding of a Shh ligand to its receptor PTCH11 (Aikin et al., 2008). RAB23 
is a regulator of the Hh pathway as it is involved in the control of intracellular vesicles; 
PTCH11 and SMO are continually trafficked between the cytoplasm and cell 
membrane through vesicles, therefore this protein is essential for effective Hh 
signalling (Eggenschwiler et al., 2001). Another finding from this gene expression 
panel was a lack of gene expression relating to the Hh ligands, Shh, ihh and dhh in 
both CAFs and NAFs. Interestingly, there appeared to be no significant changes in 
the downstream Hh pathway components such as PTCH1, SMO and GLI1 (Figure 
4.5). Together these data demonstrate that Hh signalling is not active in CAFs and 
NAFs when they are cultured alone suggesting that Hh signalling does not occur in 
an autocrine manner. However, they are capable of responding to Hh ligand in a 
paracrine fashion as they have downstream Hh signalling components. This is also 
consistent with the lack of mRNA for Hh ligands in CAFs and NAFs. 
4.3.3. Hh pathway activation in CAFs in response to Hh stimulus 
Having established that pancreatic cancer cells secrete Shh whereas CAFs do not, it 
was necessary to determine if it was possible to activate the Hh signalling pathway in 
the CAFs. This is because the CAFs, despite lacking Hh ligand, clearly express the 
components necessary for responding to external Hh ligand (Figure 4.5). Should the 
CAFs respond then it was also important to determine the most appropriate time point 


























Figure 4.6. Time-course of GLI1 induction in pancreatic CAFs.  
Graphs showing GLI1 expression (RT-PCR) in CAFs exposed to different concentrations of recombinant 
Shh (0.25, 0.5, 1 ,2 and 3 μg/mL) for 24, 48 and 72h. Gene expression was normalised to GAPDH and 
compared to expression of GLI1 in CAFs cultured in IMDM (1% FBS, 2% L-Glu, 2% PenStrep). Each 

















At 24h post stimulation of CAFs, a significant upregulation in GLI1 mRNA expression 
could be observed across all rShh concentrations (Figure 4.6.). At 48h concentrations 
>0.25μg/mL showed a significant upregulation of GLI1 mRNA (Figure 4.5). At 72h 
only 1, 2 and 3 μg/mL were able to elicit a significant upregulation in GLI1 (Figure 
4.6). This could be due to the mechanism of Hh pathway activation. For example, 
during development of the neural progenitor regions of the brain in mammals, Shh 
produces a rapid response in GLI1 expression which is lost over time (Cohen et al., 
2015). This is important in as neural development requires varying duration and level 
of Shh signal (Cohen et al., 2015) . Similar temporal signalling is also present in the 
JAK/STAT and Wnt pathway and is referred to as ligand pulsing (Bachmann et al., 
2011, Hernandez et al., 2012). This could explain why only the higher concentrations 
of rShh elicit a response at 72h. Once it was established that there was a significant 
upregulation of Hh pathway activity in CAFs from as early as 24h and using the lowest 
concentration (0.25µg/mL) of rShh, it was then necessary to investigate if exposing 
CAFs to conditioned media from PDAC cell lines induced a change in GLI1 
expression. This was to determine if the cross talk between these cell types could be 
recapitulated in an in vitro model. 
Media was collected 
from PDAC cell lines at 
48h 
CM was added to 
CAFs neat or diluted 
with fresh medium 
(FM) at different 
ratios. 
A 










Figure 4.7. Induction of GLI1 mRNA in response to conditioned medium from pancreatic cancer 
cell lines 
A: Schematic illustrating conditioned medium assay setup. 
B: Graphs showing GLI1 expression (RT-PCR) in CAFs exposed to conditioned media (IMDM 
supplemented with 5% FBS, 1% L-Glutamine, 2% Penicillin streptomycin) from pancreatic cancer cell 
lines either undiluted, or diluted with fresh media. Gene expression was normalised to GAPDH and 
compared to expression of GLI1 in CAFs cultured in IMDM (1% FBS, L-Glutamine, 2% Penicillin 
streptomycin). Each bar represents the ΔΔCt gene expression of 3 different CAF lines (R3088, R3072 
and R3030) with 2 technical replicates per cell line. Statistical significance was determined using an 




Figure 4.7. shows that it was possible to detect significant changes in GLI1 expression 
in CAFs in response to conditioned media from PANC1, SUIT2 and MIAPACA2 cells. 
Interestingly, this response corresponded well to the levels of Shh produced by the 
pancreatic cancer cell lines (Fig 4.4A) with the same rank order of PANC1, SUIT2 
and MIAPACA2 for both Shh secretion and conditioned media response. PANC1 cells 
were found to secrete the most Shh (3451.0± 415.9pg.mg protein-1) and they 
stimulated the largest upregulation of GLI1 mRNA in CAFs (9.04-fold), followed by 
SUIT2 (472.2±153.4 pg.mg protein-1) which produced the next largest upregulation of 
GLI1 mRNA (3.89-fold). The only other cell line to produce a change in GLI1 mRNA 
was MIAPACA2 (3.89-fold) which was also found to produce relatively high levels of 
Shh (192.7±2.647 pg.mg protein-1). The only anomaly was in the case of ASPC1 
which did not produce a significant GLI1 mRNA induction despite secreting a higher 
level of Shh than SUIT2 and MIAPACA2 cells (748.5± 220.7 pg.mg protein-1). Despite 
the detection of Shh secretion by ASPC1 using ELISA (Figure 4.4.A) which is 
consistent with the findings of Li and colleagues who found that ASPC1 cells secreted 
Shh (Li et al., 2014) there did not appear to be any expression of Shh detected using 
IF in ASPC1 cells (Figure 4.3). Together this data suggests that the Shh secreted 
from ASPC1 is not functionally active (Figure 4.7.). 
Once it had been established that CAFs were responsive to both rShh and Shh 
produced by pancreatic cancer cell lines it was possible to determine if changes in 
GLI1 induction could be inhibited using small molecule SMO inhibitors developed by 
Redx Pharma.  
Redx compounds A-E significantly reduced the response to rShh ligand as 
demonstrated by a reduced induction of GLI1 mRNA. For example 1000nM Redx 
compound A reduced the induction of GLI1 mRNA from 6.2±1.3 to 1.8±0.3 fold  
(Figure 4.8).  The ability of SMO inhibitors to reduce GLI1 induction in response to 
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rShh stimulation demonstrates that Redx SMO inhbitors are effective at reducing the 






Figure 4.8. rShh-mediated GLI1 induction in the presence of Redx SMO inhibitors 
Graphs showing GLI1 expression (RT-PCR) in CAFs exposed to media (IMDM 1% FBS, 1% L-
Glutamine, 2% Penicillin streptomycin) supplemented with 2μg/mL of rShh in the presence of either a 
vehicle control (0.1% DMSO) or Redx SMO Inhibitors (0, 10nM, 100nM and 1000nM). Gene expression 
was normalised to GAPDH and compared to the expression of GLI1 in CAFs cultured in (1% Serum 
Media). Each bar represents the ΔΔCt gene expression of 3 experiments using 3 individual CAF lines (3 
replicates/cell line). Statistical significance was determined using an ordinary one way ANOVA.  
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Once the efficacy of Redx SMO inhibitors had been established using GLI1 mRNA 
expression, it was important to determine if this resulted in any change in GLI1 protein 
expression. Therefore, Redx compounds A and B were selected to determine whether 
the reduction in GLI1 mRNA would translate into a reduction of GLI1 protein, 
measured using IF.   
IF labelling of GLI1 revealed that exposure of CAFs to 2μg/mL rShh resulted in 
increased GLI1 protein expression (Figure 4.9A). However, when cells were treated 
with 1000nM of Redx compound (A or B) this staining was almost completely ablated 
(Figure 4.9A). This reduction was highly significant when compared using an ordinary 
ANOVA with a p value of p<0.0001 (Figure 4.9B). These data are consistent with the 
mRNA expression data (Figure 4.8.) thus demonstrating that the reduction in GLI1 






















Figure 4.9. Loss of GLI1 stimulation in response to Redx SMO Inhbitors 
GLI1 expression was measured in CAFs in 1% media, Vehicle (rShh + 0.1% DMSO) and Stimulation + 
Compound treatment (rShh + SMO inhibitors 1000nM). A: Representative Images of experimental 
conditions. Nuclei stained with DAPI (blue), Actin stress fibres stained with Phalloidin (Red) and GLI1 
is labelled with an anti-GLI1 antibody followed by an ALEXA-488 conjugated secondary antibody (green). 
Isotype control, was used to exclude background fluorescence is also shown. B: Quantitative analysis 
of GLI1 staining intensity .GLI1 staining intensity per cell was measured using an Operetta HTS 
imaging system (PerkinElmer). Each bar represents mean ± SEM GLI1 staining intensity. 3 wells per 
condition with 3 regions of interest (ROI) per well. Cells touching or crossing a ROI border were 
automatically excluded to reduce variation. Statistical significance was determined using an ordinary one 






4.3.6. Transwell co-culture model of CAFs and PANC1 cells 
Having established that CAFs not only express the proteins capable of responding to 
Shh stimulation, but also exhibit Shh pathway activation (GLI1 induction) in response 
to rShh, it was important to determine whether CAFs responded to endogenous levels 
of Hh activation. This was necessary in order to determine if co-culture models of 
CAFs and cancer cells exhibit similar Hh pathway activation when cultured in the 
same well. This was achieved using a Transwell system. Firstly, it was critical to 
establish appropriate experimental conditions which resulted in an upregulation of the 
Hh pathway. PANC1 cells were chosen for use in this model as they produce the 
most Shh relative to the other pancreatic cancer cell lines used in this project (Figure 
4.4 A) and their conditioned media induced the largest GLI1 mRNA upregulation in 
CAFs (Figure 4.7).  
A Transwell co-culture model of CAFs and PANC1 cells showed that after 24h neither 
a 1:1 or 1:2 ratio of CAF:PANC1 elicited an increase in GLI1, SMO and PTCH1 mRNA 
which suggests that 24h is not sufficient time for Shh concentrations to overcome the 
threshold required to activate Hh signalling in CAFs (Figure 4.10.). At 48h a 1:1 ratio 
gave the largest combined induction of GLI1 and SMO mRNA with a fold induction of 
5.63±1.37 and 8.57±1.25 respectively (Figure 4.10.). This was consistent with the 
induction of GLI1 mRNA which was achieved using recombinant ligand (~6-fold; 
Figure 4.8.). Consequently, these conditions were chosen for future experiments. 
Increasing the ratio to 1:2 (CAF:PANC1) did not result in a further increase of GLI1 
induction, however there was an upregulation of SMO 9.23±0.62 fold and PTCH1 
7.55±1.27 fold mRNA (Figure 4.10.). At 72h using a 1:1 ratio of CAF:PANC1 there 
was a 3.88±2.09 fold upregulation of GLI1 mRNA, 1.50±0.61 fold upregulation of 
SMO and 3.78±1.05 upregulation of PTCH1 (Figure 4.10.). This could suggest that 
the maximal activation of Hh signalling is achieved at 48h whereas at 72h Hh pathway 
activation level is reduced. This could be a consequence of a decrease in Shh 
115 
 
secretion by PANC1 cells as the nutrients present in the Transwell become depleted. 
The reduced activation of Hh pathway activation at 72h was consistent with the data 
achieved using rShh ligand (Figure 4.6.) suggesting response to Shh ligand is rapid 



























Figure 4.10. Upregulation of Hh signalling pathway in CAFs in a Transwell co-culture model 
Graphs showing GLI1, PTCH1 and SMO expression (RT-PCR) in CAFs cultured in the same well as 
PANC1 cells at either 1:1 ratio or 1:2 (CAF:PANC1) ratio for 24, 48 and 72h. Each bar represents the 
ΔΔCt gene expression of 1 experiments using 2 replicates. Statistical analysis was not performed as this 








Having established the 1:1 ratio of CAF:PANC1 cells at 48h induced the greatest 
upregulation of GLI1 mRNA expression in CAF R3104, it was necessary to confirm 
upregulation of the Hh pathway using multiple primary CAF lines to ensure that 
changes in GLI1 expression were a consistent finding and not specific to CAFs 
isolated from one specific patient. The Hh pathway was activated in CAF cell lines 
R3088, R3072 and R3030 when they were cultured in the same well as PANC1 cells 
as demonstrated by the significant (p=0.0007) upregulation of GLI1 mRNA 






Figure 4.11. Upregulation of GLI1 in a Transwell co-culture model 
Graph showing GLI1 expression (RT-PCR) in CAFs cultures in the same well as PANC1 cells at a 1:1 
ratio for 48h. Each bar represents the ΔΔCt gene expression of 3 CAF lines (R3088, R3072, R3030) (3 
replicates per cell line). Statistical significance was determined using an ordinary one way ANOVA. *** 
represents p= 0.0007 taking into consideration the standard deviation of the calibrator sample 
(CAF+CAF) 
 
Having established that a Transwell model of CAFs and PANC1 cells results in Hh 
pathway activation in CAFs, I sought to determine if this was an appropriate model to 
test the efficacy of Redx SMO inhibitors. In the presence of 1000nM Redx compound 
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A and Redx compound B, the induction of GLI1 mRNA was reduced from 6.05±0.68 
fold to 2.22±0.41 fold, and to 1.20±0.31 fold respectively (Figure 4.12.). This 
demonstrates that it was possible to inhibit Hh pathway activation in a paracrine 





















Figure 4.12. Inhibition of Hh pathway in a Transwell co-culture model 
Graph showing GLI1 expression (RT-PCR) in CAFs cultured in the same well as PANC1 cells at a 1:1 
ratio for 48h in the presence of  Redx SMO inhibitors (1000nM) or a vehicle control (0.1% DMSO). RNA 
was isolated from CAFs at 48h. Gene expression was normalised to GAPDH and compared to the 
expression of GLI1 in CAFs cultured alone. Each bar represents the ΔΔCt gene expression of 3 CAF 
lines R3088, R3072 and R3030 (3 replicates per cell line). Statistical significance was determined using 
an ordinary one way ANOVA. *** represents p<0.0006 taking into consideration the standard deviation 































The importance of the tumour microenvironment in facilitating tumour progression 
and metastases has been well studied (Carr and Fernandez-Zapico, 2016, Feig et 
al., 2012, Apte and Wilson, 2012, Apte et al., 2013). However conflicting evidence 
has implicated the tumour stroma in both a tumour supportive and a tumour 
restraining role (Rhim et al., 2014, Rucki and Zheng, 2014). One critical pathway 
involved in the formation of the desmoplastic stroma in PDAC is the Hh signalling 
pathway (Thayer et al., 2003). The results in this chapter demonstrate the presence 
of aberrant Shh expression present in the pancreatic tumour microenvironment 
(Figure 4.1) specifically in the pancreatic tumour cells, which is consistent with 
previous reports (Bailey et al., 2008, Thayer et al., 2003). To create an in vitro model 
which incorporates aspects of the tumour microenvironment and which has 
appropriate signalling between the cell types it was necessary to discover which 
pancreatic cancer cell lines expressed Shh in a similar pattern to tumour cells 
observed in the PDAC tumour microenvironment (Figure 4.3). Using IF to visualise 
Shh expression, PANC1, SUIT2 and MIAPACA2 cells expressed Shh in a perinuclear 
pattern (Figure 4.3.) which indicates localisation to the golgi/ER which was in the 
same location as Shh expression observed in pancreatic ductal epithelial cells (Figure 
4.2). This confirms that with regards to Hh signalling, these cell lines were appropriate 
to represent PDAC tumour cells. Once it had been established that the pancreatic 
cancer cell lines chosen to represent PDAC mirrored the spatial expression of Shh in 
epithelial cancer cells, the next step was to determine if the expression of Shh 
correlated to secretion of the ligand.  PANC1 cells secreted the greatest amount of 
Shh ligand (3.4ng.mg protein-1) with the other cell lines secreting detectable amounts 
of Shh (0.5, 0.19, 0.75 and 0.02 ng.mg protein-1 for SUIT2, MIAPACA2, ASPC1 and 
BXPC3 respectively; Figure 4.4A). The secretion of Shh was impacted by nutrient 
deprivation in the cases of PANC1 and MIAPACA2 (Figure 4.4 B). This observation 
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was significant as it was critical to isolate which cell lines could activate Hh signalling 
in vitro, and to determine under what condition it would be possible to maintain active 
Hh signalling. It was established that Shh secreting cell lines could maintain secretion 
under conditions of 5% serum-containing media, however there was a significant loss 
when exposed to 1% serum-containing media. The finding that Shh secretion is 
detected in nutrient deprived conditions indicated that Shh secretion levels could vary 
as the tumour develops and conditions within the tumour microenvironment decline. 
The expression of Shh is detected throughout PDAC progression even in precursor 
lesions as early as PanIN1a (Thayer et al., 2003), however as the desmoplastic 
stroma develops it alters the architecture of the pancreas; capillaries are compressed 
which creates a nutrient deprived, hypoxic microenvironment (Rasheed et al., 2012) 
. Therefore the finding that nutrient deprived conditions (1% serum) has a significant 
impact of Shh secretion in PANC1 and MIAPACA2 cells suggests that the conditions 
within the tumour could have an impact on Shh secretion.  
My finding of little difference in expression of Hh pathway-associated genes in NAFs 
and CAFs is intriguing. Only three genes (CSNK1E1, GSK3β and RAB23) were 
significantly differentially expressed between the two cell types with each found to be 
differentially upregulated in CAFs compared to NAFs. All three genes are involved in 
active Hh signalling. CSNK1E1 and GSK3β are part of the degradation complex for 
GLI2 and GLI3 which is necessary for GLI1 activation, GLI2 specifically is targeted 
for phosphorylation by CSNK1E1 (Riobo and Manning, 2007). RAB23 acts 
downstream of SMO and upstream of the GLI proteins and is involved in the 
subcellular localisation of downstream Hh pathway effectors; it is involved in 
preventing the activation of GLI proteins in the absence of Hh ligand stimuli 
(Eggenschwiler et al., 2006). These genes are not the main effectors of the Hh 
signalling pathway (PTCH1, SMO and GLI1)(Briscoe and Therond, 2013). This 
suggests that the presence of active Hh signalling in the PDAC tumour 
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microenvironment is not due to the general upregulation of Hh pathway machinery in 
CAFs, but rather increased stimulation from PDAC cancer cells in the tumour 
microenvironment. This is supported by the lack of expression of Shh, ihh and dhh in 
CAFs and NAFs (Figure 4.5) which is consistent with previous reports that Hh 
signalling in the PDAC tumour microenvironment occurs in a paracrine fashion with 
Shh being secreted from epithelial cells and acting upon cells of the stroma (Yauch 
et al., 2008). 
Consistent with CAFs expressing components of the pathway allowing them to 
respond to active Hh signalling, treatment with rShh induced GLI1 expression. 
Moreover, Shh secreted from a physiological source (pancreatic cancer cell lines) 
was also able to elicit the induction in GLI1 expression, as demonstrated by 
incubation of CAFs with conditioned media from Shh secreting PANC1, SUIT2 and 
MIAPACA2 cells. The only cell line which secreted Shh and did not cause an 
upregulation in GLI1 was ASPC1 cells. One of the obstacles of using conditioned 
media from cell lines is the inability to determine the exact composition of the media 
as cells secrete a variety of signalling molecules. Therefore it is possible that ASPC1 
cells are secreting factors which result in the antagonism of the Hh pathway for 
example through the activation of Hedgehog Inactivating Protein or Suppressor of 
Fused (SuFu) which both result in the inhibition of Hh pathway activation (Merchant 
and Matsui, 2010, Velcheti and Govindan, 2007). The maximal GLI1 upregulation 
using recombinant ligand was 6.31-fold when CAFs were treated with 2μg/mL rShh 
for 24h (Figure 4.6.). The maximal upregulation measured in response to Shh present 
in conditioned media was a 9.04-fold upregulation of GLI1 mRNA using 100% PANC1 
conditioned medium (Figure 4.7.). A drawback of conditioned media experiments is 
the possibility that the cancer cells have diminished the nutrient supply in the media 
and this could have a negative impact on the growth or response of CAFs. To 
overcome this, a dilution of the conditioned media was made using fresh growth 
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media to ensure that the maximal GLI1 induction was observed (Figure 4.7). 
Interestingly, the cell lines with the fastest growth rates, SUIT2 and MIAPACA2 (Table 
2.1.) showed a maximal GLI1 induction in CAFs when the conditioned media from 
these cell lines was diluted with fresh media to replace nutrients. This indicates that 
the nutrient content of the conditioned media could have an effect on Hh signalling in 
CAFs.  
Once it had been established that CAFs were responsive to external Hh stimuli using 
both rShh and conditioned media from CAFs, it was possible to determine if SMO 
inhibitors could inhibit the induction of GLI1 in CAFs. The stimulation of Hh pathway 
using rShh was diminished in the presence of Redx SMO inhibitors at the lowest 
concentration tested (10nM; Figure 4.8), and corresponded to reduced expression of 
GLI1 in CAFs (Figure 4.9). Modulating the Hh signalling pathway which is involved in 
the maintenance of the pancreatic tumour microenvironment as a treatment option 
for PDAC has been trialled with IPI-926, however the positive results obtained in mice 
did not translate to positive clinical outcomes for human patients (Olive et al., 2009). 
The ability to model the tumour microenvironment in vitro to provide more information 
surrounding the mechanism of action of the complex signalling pathways involved in 
the PDAC tumour microenvironment would be beneficial in drug screening models in 
order to predict the efficacy of treatments before they reach the clinic. Using a 
Transwell co-culture model which contained PANC1 cells, it was possible to 
investigate the function of Redx SMO inhibitors in a model that incorporates two cell 
types (Figure 4.10). Redx SMO inhibitors tested in this model showed a reduction in 
GLI1 induction compared with the Transwell co-culture alone (Figure 4.11). Together 
these results suggest that Hh signalling occurs in a paracrine manner via the 
activation of downstream Hh signalling in CAFs in response to secretion of Shh ligand 
from epithelial cells lining ducts in the PDAC tumour microenvironment. Treatment of 
CAFs with rShh or conditioned media from Shh producing cells result in the 
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upregulation of GLI1 mRNA which was blocked using Redx SMO inhibitors at 
concentrations as low as 10nM. These data are consistent with reports that found that 
Hh pathway inhibitors were much more potent against mesenchymal cells than 
cancer cell lines (Yauch et al., 2008). These results corroborate studies indicating 
that the Hh pathway facilitates cross talk between cancer cells and CAFs (Yauch et 
al., 2008, Bailey et al., 2009) thus providing a tumour supportive environment. Using 
Transwell co-culture models allows the cross talk between CAFs and cancer cells 
which provides an effective research tool in the investigation of signalling pathways 
involved in PDAC. The data presented in this chapter would suggest that preclinical 
models that do not include stromal elements such as CAFs may not bet adequate for 
testing PDAC therapies as the stroma plays an important role in supporting tumour 
progression, metastasis and chemotherapy resistance (Apte and Wilson, 2012, Apte 










5. Wnt/ β-Catenin signalling in the PDAC 
tumour microenvironment 
5.1. Introduction 
In various cancers such as colorectal and cutaneous melanoma, mutations of Wnt 
pathway signalling components (APC, LRG5, LRP6, AXIN, CTNNB1) are common 
(Zhan et al., 2017) However these mutations are rare in PDAC and the role of Wnt 
signalling in PDAC development and progression is not well understood (Zhan et al., 
2017). Despite the lack of mutations, aberrant localisation (cytoplasmic and nuclear) 
of β-Catenin is found in approximately 65% of PDAC cases (Zeng et al., 2006). In a 
healthy human pancreas, β-Catenin is found at the cell membrane; nuclear and 
cellular localisation is associated with canonical pathway activity (Zeng et al., 2006). 
Surprisingly, studies have revealed that Wnt/ β-Catenin signalling seemingly 
antagonises KRAS driven acini-ductal-metaplasia (ADM) and subsequent PanIN 
formation, until the cells have been directed into a metaplastic lineage at which point 
the cells develop a reliance on Wnt/ β-Catenin signalling and other developmental 
signalling pathways (Morris et al., 2010). Wnt/ β-Catenin signalling has also been 
implicated in the PDAC tumour microenvironment, wherein nuclear localisation of β-
Catenin is observed in PDAC cancer cell lines in response to being cultured on 
collagen type 1 This results in increased expression of Wnt target genes c-myc and 
cyclin D1 and an increased growth rate of the cells (Koenig et al., 2006). Given the 
presence of aberrant Wnt signalling in the PDAC tumour microenvironment, the aim 
of this chapter was to determine if the Wnt/ β-Catenin signalling pathway is involved 
in the crosstalk between PDAC cancer cells and CAFs.  
5.2. Methods 
5.2.1. Taqman array for Wnt pathway 
In order to investigate the Wnt pathway gene expression profile for PDAC cancer cells 
compared with normal pancreas ductal (HPDE) cells a human Wnt pathway TaqMan  
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Array plate (Applied Biosystems) was used. The array plate contained 92 Wnt 
associated genes (APC, AXIN1, AXIN2, BTRC, CSNK1A1, CSNK1D, CSNK1G1, 
CSNK1G2, CSNK1G3, CSNK2A1, CSNK2A2, CSNK2B, CTNNB1, CTNNBIP1, 
CXXC4, DACT1, DKK1, DKK2, DKK3, DKK4, DVL1, DVL2, DVL3, EP300, FBXW11, 
FGF4, FOXN1, FRAT1, FRAT2, FRZB, FZD1, FZD10, FZD2, FZD3, FZD4, FZD6, 
FZD7, FZD8, FZD9, GSK3A, GSK3B, KREMEN1, KREMEN2, LEF1, LRP5, LRP6, 
MYC, NKD1, NLK, CBY1, PITX2, PORCN, PPP2CA, PPP2R1A, PYGO1, PYGO2, 
RHOU, SENP2, SFRP1, SFRP2, SFRP4, SFRP5, SLC9A3R1, TCF7, TCF7L1, 
TCF7L2, TLE1, TLE2, TLE3, TLE4, TLE6, WIF1, WISP1, WNT1, WNT10A, WNT10B, 
WNT11, WNT16, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, 
WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B ) and 4 control genes (18S, 
GAPDH, GUSB and HPRT1) in duplicate. The genes included in this array are mainly 
from the vertebrate Wnt family of associated genes including inhibitors of the Wnt 
pathway including secreted frizzled related proteins and the Disheveled family. RNA 
was isolated from flasks once the cells reached 80% confluence which had been 
cultured in complete growth medium, the RNA was quantified and reverse 
transcription performed on the total RNA samples. The cDNA was diluted with a 
volume of DNase free water to a concentration of 1ng/µL which corresponds to 
10ng/reaction. The array plate was centrifuged at 1000rpm for 2min, each well was 
loaded with 10µL of cDNA and 10µL of mastermix. The mastermix used was TaqMan 
Fast Universal PCR Master Mix (2X), no AmpErase UNG (AppliedBiosystems). The 
fluorophore used with TaqMan was carboxyfluorescein (FAM). The expression 
profiles of the pancreatic cancer cell lines (PANC1, MIAPACA2 and BXPC3) were 
compared with the ductal cell line HPDE as a control. The expression profiles of 3 
CAF lines were compared with 3 NAF lines using normal pancreatic fibroblasts (NPF) 
as a control. 
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5.2.2. L-Wnt-3A conditioned medium 
L-Wnt-3A is a mouse fibroblast cell line which constitutively produces Wnt-3A (Willert 
et al., 2003). The cells were produced by the transfection of L-M(TK-) cells with the 
Wnt-3A expression vector. The secretion of Wnt ligands depends on their 
palmitoylation, a post translation modification which is required for Wnt ligand to be 
effectively trafficked out of the cell (Mikels and Nusse, 2006). This palmitoylation step 
is catalysed by the o-acetyl-transferase Porcupine (PORCN) (Voloshanenko et al., 
2013). Wnt secretion can be inhibited in the donor cells by inhibition of PORCN using 
Redx small molecule inhibitors. In order to generate L-Wnt-3A conditioned medium 
(CM) 1 million cells per T75 flask were seeded. Two flasks were seeded: one was 
seeded in L-Wnt-3A culture medium (DMEM, 4.5g/mL glucose, 10% FBS, 1% 
Geneticin) with 0.1% DMSO, and the other was seeded in L-Wnt-3A culture medium 
with 100nM Redx compound F.  An empty flask was also filled with culture medium 
and incubated with the other flasks for 72h to generate control media, at which point 
the L-Wnt-3A cells had reached 80% confluency.  The CM was removed from the 
cells and centrifuged at 400g for 5min, and then sterile filtered using a 2μm filter. This 
CM was then added to PDAC cancer cell lines, CAFs and NAFs which had been 
seeded at 50,000 cells per well in 6-well plates 24h previously. The RNA was isolated 
after the cells had been incubated with CM for 24h. Changes in AXIN2 level were 
measured using qRT-PCR. To determine if the effect of the CM was concentration-
dependent the stock amount was diluted with fresh growth media to the following 
concentrations: 25%, 50%, 75% and 100% CM. 
5.2.3. Transwell co-culture for Wnt pathway activation 
The optimal ratio of PDAC cells to CAFs found to cause an activation of Wnt pathway 
was a 1:2 ratio for 72h. An empty 6-well plate was filled with 2mL per well of growth 
medium, the Transwell inserts were added and 100,000 PANC1 cells or 50,000 CAFs 
were loaded onto the insert in 2 mL of media. In the empty Transwell plate 100,000 
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PANC1 cells or 50,000 CAFs were seeded in 2mL of growth medium, and the cells 
were allowed to adhere overnight.  Cells in the Transwell plate were serum starved 
for 24h. At this point all the media was removed from both Transwell plate and inserts 
and the inserts were placed in their corresponding wells (Table 5.1.) and the wells 
were filled with 3mL of medium (5% Serum IMDM) . To investigate the effect of a 
Transwell co-culture model on Wnt pathway activation in CAFs and PANC1s in this 













Table 5.1. Platemap of Transwell co-culture model 
5.2.3. Wnt pathway inhibition in a Transwell co-culture model 
Using the Transwell co-culture model developed above, it was possible to 
investigate how effective a Redx PORCN inhibitor would be at inhibiting 
canonical Wnt signalling in a model which allowed paracrine signalling 
between PDAC cells and CAFs. The method used is described above with the 





















5.3.1. β-Catenin Expression in the PDAC tumour microenvironment 
To investigate the presence of active canonical Wnt signalling in the PDAC tumour 
microenvironment IHC analysis was performed (method described in Section 
2.2.4.4.) to determine the location of β-Catenin in the PDAC tumour 
microenvironment compared to normal pancreatic tissue. In the normal pancreas β-
Catenin forms part of the E-cadherin-catenin complex which maintains the 
intracellular adhesion which is believed to be disrupted during pancreatic 
tumorigenesis (Li and Ji, 2003). Consistent with previous reports β-Catenin is 
localised to the cell membrane of normal pancreatic acini (Figure 5.1.B) which 
undergoes redistribution to cytoplasmic and nuclear location in epithelial cancer cells 















Figure 5.1. β-Catenin staining in the PDAC tumour microenvironment 
A: IHC of tumour cores stained for β-Catenin showing that positive staining is restricted to tumour cells. 
(black arrows). Scale bar 200µm B: Representative image of tissue isolated from normal appearing 
tissue stained using IHC for β-Catenin. The staining appears to be found restricted to the cell membrane 
of the normal pancreatic acini (black arrow).Scale bar 100µm C: Higher magnification image of tumour 
core (40x) showing the localisation of β-Catenin in the cell membrane and cytoplasm of tumour cells 
(black arrow).Scale bar 50µm. 
 
 
5.3.2. Expression of Wnt Signalling associated genes in pancreatic 
cancer cell lines 
Unlike the Hh pathway the role of the Wnt pathway in PDAC tumorigenesis is not well 
understood. I sought to determine if any pattern of gene expression was common to 
pancreatic cancer cell lines to elucidate the role of PDAC tumour cells in canonical 
Wnt signalling. 3 pancreatic cancer cell lines were chosen for this study: PANC1, 
MIAPACA2 and BXPC3. Their expression of genes associated with Wnt signalling 
was compared with a normal pancreatic ductal cell line HPDE.  There did not appear 
to be a clear pattern of Wnt associated genes commonly expressed in all three cancer 
cell lines investigated (Figure 5.2.).  These well characterised cell lines were chosen 
to represent patient variation as they have diverse genetic origins (Table 2.1.) 
however this could also be responsible for the differences in expression of Wnt 
associated genes. Wnt ligands associated with both canonical and non-canonical Wnt 
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pathways were found to be upregulated in the PDAC cell lines (Figure 5.2.). Wnt5B 
was upregulated in PANC1 (38.2-fold) and unchanged in MIAPACA2 (1.2-fold) and 
BXPC3 (0.56-fold) when compared to the HPDE control. A threshold of ±4-fold was 
recommended in the manufacturers guide to identify biologically significant changes 
using this array format. Wnt10A was found to be upregulated in BXPC3 (22.9-fold) 
and PANC1 cells (7.5-fold) and unchanged in MIAPACA2 cells (0.4-fold). Wnt11 was 
found to be upregulated in BXPC3 (17.7-fold) and PANC1 cells (5.6-fold) and 
downregulated in MIAPACA2 cells (0.02-fold) (Figure 5.2.). Wnt4 was upregulated in 
BXPC3 (40.9-fold) and PANC1 cells (4.7-fold) and was unchanged in MIAPACA2 
cells (0.83-fold). LRP5 was upregulated in PANC1 (8.3-fold) and BXPC3 cells (5.9 
fold) and unchanged in MIAPACA2 cells (0.4-fold).  
A larger sample size including of representative PDAC cells would be required to 
determine if any Wnt signalling pathway component expression is common to PDAC. 
Nevertheless, unlike the findings in Hh pathway components (Section 4.3.2) the data 
presented in Figure 5.2. suggests that there is no universal PDAC expression profile 





Figure 5.2. Differentially expressed WNT signalling genes in pancreatic cancer cell lines 
Differentially expressed genes involved in WNT Signalling in 3 pancreatic cancer cell lines (PANC1, 
BXPC3 and MIAPACA2) using a normal ductal cell line as a control (HPDE). Gene expression profiles 
were obtained by Taqman mini array. Upregulation of genes of interest is indicated by red colour, 
downregulation is shown using green.   
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5.3.3. Expression of Wnt Signalling associated genes in pancreatic 
CAFs and NAFs 
Having established that there was no consensus secretion of Wnt ligand or 
expression of Fzd receptors in pancreatic cancer cell lines the next step was to 
determine if there were any differentially expressed Wnt associated genes between 
CAFs isolated from the PDAC tumour microenvironment and NAFs isolated from 
normal appearing tissue. 
22 genes were found to be differentially regulated in CAFs compared with NAFs (N=3) 
(Figure 5.3.), including Wnt signalling pathway components such as AXIN2, LEF1 
and LRP5. FZD3 and FZD9 were also found to be upregulated which indicates the 
ability of CAFs to respond to Wnt ligands. SFRP4 and FRZB were also found to be 
upregulated in CAFs 249-fold and 8-fold respectively (Table 5.1.). DKK1, an 
antagonist of the Wnt pathway was also found to be downregulated in CAFs 0.1-fold 
compared to 0.4-fold in NAFs. DKK1 has two mechanisms of action depending on 
whether it is antagonising canonical or non-canonical Wnt signalling. Canonical Wnt 
signalling was the focus of this project due to the presence of cytoplasmic and nuclear 
accumulation in early PDAC lesions (PanIN) right through disease progression (Al-
Aynati et al., 2004, Zeng et al., 2006, Pasca di Magliano et al., 2007) . It has also 
been suggested that levels of β-Catenin accumulation also correlates with PanIN 
grade (Al-Aynati et al., 2004) .  A more functional role for canonical Wnt signalling in 
PDAC tumour maintenance and progression has been suggested whereby increased 
Wnt signalling is associated with increased tumour cell survival (Pasca di Magliano 
et al., 2007). However, the presence of non-canonical Wnt ligand such as Wnt5a, 
commonly abberant in PDAC, indicates non-canonical Wnt signalling may also have 








Figure 5.3.  Differentially expressed Wnt/ β-Catenin genes in CAFs vs NAFs 
Differentially expressed genes in CAFs and NAFs using a normal pancreatic fibroblast line as a control 
fibroblast line, gene expression profiles were obtained by Taqman mini array. Upregulation of genes of 
interest is indicated by red colour, downregulation is shown using green.  CAF lines used (R3030, R3088, 










Mean Difference q value 
SFRP4 4.2E-11 249.7 -340.1 589.9 4.6E-10 
RHOU 1.6E-10 3.9 -464.7 468.6 1.4E-09 
FZD3 3.3E-09 48.2 -88.0 136.2 2.4E-08 
FZD9 4.4E-09 3.3 -154.3 157.6 2.7E-08 
WISP1 2.2E-08 194.5 -7.5 202.0 1.2E-07 
PYGO1 3.4E-08 1.6 -24.1 25.7 1.6E-07 
WNT11 1.2E-07 -0.1 -54.6 54.5 5.1E-07 
FRZB 1.4E-07 7.9 -73.0 80.9 5.1E-07 
LEF1 1.4E-07 12.7 -32.5 45.2 5.1E-07 
PPP2R1A 1.6E-06 -2.2 9.2 -11.4 5.3E-06 
DKK1 8.9E-06 -8.6 -2.3 -6.3 2.8E-05 
KREMEN1 5.0E-05 2.8 -22.1 25.0 1.5E-04 
AXIN2 5.8E-05 3.3 -6.3 9.6 1.6E-04 
PYGO2 6.5E-05 -28.3 -1.2 -27.0 1.7E-04 
NLK 9.7E-04 0.1 -4.0 4.1 2.3E-03 
DVL1 1.0E-03 -1.9 2.1 -4.1 2.3E-03 
DKK3 2.0E-03 1.1 5.4 -4.3 4.4E-03 
FZD7 2.4E-03 4.9 1.7 3.3 4.6E-03 
CSNK1G1 2.4E-03 -0.1 -2.6 2.5 4.6E-03 
CSNK2B 3.3E-03 -1.5 4.8 -6.3 6.2E-03 
LRP5 3.7E-03 3.4 1.4 1.9 6.7E-03 
TCF7 3.9E-03 -13.7 -6.7 -6.8 6.7E-03 
 
Table 5.1. Summary of differentially expressed genes in CAFs vs NAFs 
Differentially expressed genes in CAFs and NAFs using a normal pancreatic fibroblast line as a control 
fibroblast line, gene expression profiles were obtained by Taqman mini array. The discovery analysis 
Benjamini, Krieger and Yekutieli (with Q = 1%) was used to identify differentially expressed genes 
 
These data suggest that, unlike the Hh pathway, no clear donor/acceptor role for 
paracrine signalling exists between CAFs and PDAC cancer cells. Therefore I sought 
to determine if CAFs and PDAC cancer cells were susceptible to exogenous Wnt 




5.3.4.  Wnt pathway activation in pancreatic cells in response to Wnt 
stimulus 
Wnt pathway stimulation was achieved using an L-Wnt-3A cell line (Willert et al., 
2003). This method was chosen over the use of recombinant Wnt ligands due to 
inconsistencies which have been reported in the use of commercially available Wnt-
3A due to misfolded or proteolytically cleaved protein products (Cajanek et al., 2010).   
Changes in AXIN2 mRNA induction were used to investigate Wnt/ β-Catenin 
signalling activity; AXIN2 is commonly used to determine Wnt pathway activity as it 
has been found to be induced by Wnt ligands (Jho et al., 2002). It was possible to 
detect significant changes in response to CM from L-Wnt-3A cells in CAF, NPF and 
PANC1 cells (Figure 5.4.). Different concentrations of L-Wnt-3A CM was used to 
investigate whether the AXIN2 response in cells was concentration-dependant and if 
there was any detrimental effect on AXIN2 induction by using undiluted CM which 
was potentially nutrient depleted after 72h in culture with L-Wnt cells. The response 
observed in CAFs was concentration-dependant with the maximal induction of AXIN2 
when CAFs were exposed to 100% CM from L-Wnt-3A cells (fold change: 73.0±12.8, 
p=0.0003). NPF cells had a maximal AXIN2 induction with 75% CM (fold change: 
17.3±1.7, p<0.0001). PANC1 cells had a maximal AXIN2 induction with 50% CM (fold 
change: 28.3±3.0, p=0.0001). The effect of nutrient deprivation on Wnt signalling was 
most apparent in PANC1 cells.  These cells had the greatest induction of AXIN2 
mRNA in CM which was diluted with 50% fresh growth medium. This is most likely 
related to the fact that the population doubling time of PANC1 cells is much quicker 
than the CAFs and NPFs (approximately 40, 72 and 72-96h respectively) which 


































Figure 5.4. Induction of AXIN2 mRNA in PANC1, CAF and NPF in response to conditioned medium 
from L-Wnt-3A cells 
A: Schematic of assay setup 
B:Graphs showing AXIN2 expression (RT-PCR) in CAF, NPF and PANC1 cells exposed to conditioned 
media (DMEM supplemented with 10% FBS) from L-Wnt-3A cells either undiluted, or diluted with fresh 
media. Gene expression was normalised to GAPDH and compared to expression of AXIN2 in CAF, NPF 
and PANC1 cells cultured in DMEM (10% FBS incubated in an empty flask). Each bar represents the 
ΔΔCt gene expression of 3 experiments using the 3 different CAF lines (R3088, R3072 and R3030) or 3 













Given that it was possible to activate Wnt signalling in CAFs, NPFs and PANC1 cells, 
I sought to determine whether it was possible to reduce this activation using a Redx 
PORCN inhibitor (Redx Compound F) in PDAC cancer cell lines. PORCN is a protein 
involved in the post translational modification of Wnt ligands which is required for their 
successful secretion from Wnt producing cells (Takada et al., 2006). Inhibition of 
PORCN has resulted in effective inhibition of Wnt signalling which has highlighted 
PORCN as an important target in oncology (Liu et al., 2013) . The induction of AXIN2 
mRNA in PANC1 cells when they were exposed to CM from L-Wnt-3A cells and the 
vehicle (0.1% DMSO) was 8.3±0.9-fold (p=0.0002) upregulation which decreased to 
1.1±0.5-fold in the presence of a Redx PORCN inhibitor. This loss of AXIN2 induction 
was also observed in MIAPACA2 (fold change: 5.5±0.5 decreased to 1.4± 0.2, 




















Figure 5.5. AXIN2 mRNA induction in pancreatic cancer cell lines in the presence of conditioned 
medium from L-Wnt-3A cells and a Redx PORCN inhbitor 
A: Schematic representation of assay setup 
B: Graphs showing AXIN2 expression (RT-PCR) in PANC1, MIAPACA2 and BXPC3 cells exposed to 
100% CM (DMEM 10% FBS) from L-Wnt-3A cells in the presence or absence (Vehicle 0.1% DMSO) or 
Redx PORCN inhibitor. Gene expression was normalised to GAPDH and compared to the expression 
of AXIN2 in PANC1, MIAPACA2 and BXPC3 cultured in (DMEM 10% FBS, conditioned in an empty 
flask). Each bar represents the ΔΔCt gene expression of 3 experiments. Statistical significance was 
determined using an ordinary one way ANOVA.  
 
It was established that the PDAC cell lines tested had different levels of AXIN2 
induction in response to CM from L-Wnt-3A cells and regardless of the level of AXIN2 
induction, it was reduced in the presence of Redx PORCN inhibitors. I therefore 
sought to determine whether CAFs and NAFs had a similar response to exogenous 
Wnt ligand provided by the L-Wnt-3a cells and whether this could be reduced by the 
presence of Redx PORCN inhibitors. There was a marked difference between the 

































































activation of Wnt pathway in CAFs compared to NAFs. In CAFs induction of AXIN2 in 
the presence of CM from L-Wnt-3A cells (vehicle 0.1% DMSO) was 73.0±12.8-fold 
which was reduced to 13.9±8.2-fold (p=0.0073) in the presence of a Redx PORCN 
inhibitor. In NAFs induction of AXIN2 in the presence of CM from L-Wnt-3A cells 
(vehicle 0.1% DMSO) was 16.9±5.2-fold which was reduced to 2.8±1.1-fold in the 








Figure 5.6. Differing Induction of AXIN2  mRNA  CAF and NAF in response to conditioned medium 
from L-Wnt-3A cells 
Graphs showing AXIN2 expression (RT-PCR) in CAFs and NAFs exposed to 100% CM (DMEM 10% 
FBS) from L-Wnt-3A cells in the presence or absence (Vehicle 0.1% DMSO) or Redx PORCN inhibitor. 
Gene expression was normalised to GAPDH and compared to the expression of AXIN2 in CAFs and 
NAFs cultured in (DMEM 10% FBS, conditioned in an empty flask). Each bar represents the ΔΔCt gene 
expression of 3 cell lines (CAF: R3088, R3030, R3072) (NAF; R2797, R2796, R2951). Statistical 
significance was determined using an ordinary one way ANOVA. 
 
 
It was determined that there was a significant difference in response to Wnt stimulus 
depending on whether the cells had been isolated from either the PDAC 
microenvironment (CAFs) or normal appearing tissue (NAFs). NAFs had a similar 
induction of AXIN2 (16.9-fold, Figure 5.6.) to NPF cells (17.3-fold, Figure 5.4) which 
indicated that NAFs more closely resemble the NPF cell line. In order to investigate 
the response of other Wnt associated genes the induction of LEF1 was examined. 
Lymphoid enhancing binding factor 1 (LEF1) is a transcriptional promoter which forms 








































a complex with β-Catenin in the nucleus, which stimulates the transcriptional 
activation of Wnt target genes (Komiya and Habas, 2008). LEF1 expression has been 
found to be increased in the presence of active Wnt signalling (Planutiene et al., 2011, 
Filali et al., 2002) . There was found to be a significant induction of LEF1 mRNA in 
NPF cells in response to L-Wnt-3A when exposed to 100% CM. There was a 4.2±0.4 
(p=0.0016)-fold upregulation of LEF1 mRNA (Figure 5.7.). Treatment with a Redx 
PORCN inhibitor also reduced the induction of LEF1 in NPF’s from 4.9±0.3-fold to 

















Figure 5.7. Induction of  LEF1 mRNA in NPF in response to conditioned medium from L-Wnt-3A 
cells and the effect of PORCN inhibition on LEF induction 
Graphs showing LEF1 expression (RT-PCR) in NPF cells exposed to CM (DMEM 10% FBS) from L-
Wnt-3A cells either diluted with fresh growth media (DMEM 10% FBS)(left panel). Graphs showing LEF1 
expression (RT-PCR) in NPF cells exposed to CM (DMEM 10% FBS) from L-Wnt-3A in the presence or 
absence (Vehicle 0.1% DMSO) or Redx PORCN inhibitor (right panel). Gene expression was normalised 
to GAPDH and compared to the expression of LEF1 in NPFs cultured in (DMEM 10% FBS, conditioned 
in an empty flask). Each bar represents the ΔΔCt gene expression of 3 experiments. Statistical 
















































5.3.5. Transwell co-culture model of CAFs and PANC1 cells 
 
Having established that both pancreatic fibroblasts and pancreatic cancer cell lines 
responded to exogenous Wnt signal provided by L-Wnt-3A cells, I sought to 
investigate whether culturing CAFs and pancreatic cancer cell lines in the same well 
resulted in an induction in Wnt signalling. At 24h and 48h a 1:1 or 1:2 ratio of 
PANC1:CAF cells did not result in an induction of either AXIN2 or LEF1 (Figure 5.8.). 
At 72h using a 1:1 ratio there was an induction of AXIN2 (4.8±2.2-fold) and LEF1 
(3.3±2.1-fold)(Figure 5.8.). Using a 1:2 ratio of PANC1:CAF there was a greater 

















































Figure 5.8. Upregulation of Wnt signalling pathway in PANC1 cells in a Transwell co-culture 
model 
Graphs showing AXIN2 and LEF expression (RT-PCR) in PANC1 cells cultured in the same well as 
CAFs cells at either 1:1 ratio or 1:2 (PANC1:CAF) ratio for 24, 48 and 72h. Each bar represents the ΔΔCt 
gene expression of 1 experiments using 2 replicates. Statistical analysis was not performed as this was 
a preliminary optimisation experiment and was not replicated in multiple CAF lines. 
 
This model was used to investigate whether induction of AXIN2 mRNA in PANC1 
cells in response to being cultured with CAFs could be reduced using a Redx PORCN 
24h 






















































































































inhibitor. It was found that addition of the Redx PORCN inhibitor to a Transwell co-
culture model of PANC1 cells and CAFs reduced the induction of AXIN2 mRNA from 




Figure 5.9. Loss of AXIN2 induction in PANC1 cells in a Transwell co-culture model when treated 
with Redx PORCN inhibitor (Compound F) 
Graphs showing AXIN2 expression (RT-PCR) in PANC1 cells cultured in a Transwell with CAFs 
presence or absence (Vehicle 0.1% DMSO) or Redx PORCN inhibitor. Gene expression was normalised 
to GAPDH and compared to the expression of AXIN2 in PANC1. Each bar represents the ΔΔCt gene 
expression in PANC1 cells of 3 experiments carried out with three independent CAF lines (CAF: R3088, 
R3030, R3072)). Statistical significance was determined using an ordinary one way ANOVA. 
 
There was a marked upregulation of AXIN2 mRNA in response to being cultured in 
the same well as CAFs, I therefore sought to investigate whether there was any 
impact on Wnt signalling in CAFs when they were cultured with MIAPACA2 and 
PANC1 cells. As it had been previously established that both PDAC cancer cell lines 
and CAFs were responsive to exogenous Wnt ligand (Figure 5.4, Figure 5.5 and 
Figure 5.6.). There was found to be no upregulation of AXIN2 in CAFs in response to 
being co-cultured in a Transwell with PANC1 or MIAPACA2 cells (Figure 5.10). 
However, PORCN mRNA was significantly upregulated in CAFs in a Transwell co-
culture with PANC1 cell lines which indicates an upregulation of Wnt secretion 
(3.9±0.6-fold, p=0.0018, Figure 5.10.). This suggests that Wnt signalling is occurring 
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in a paracrine fashion in this model with Wnt ligand being secreted from CAFs and 





















Figure 5.10.  Induction of PORCN in CAFs when co-cultured with PANC1 cells in a Transwell 
model 
Graphs showing AXIN2 and PORCN expression (RT-PCR) in CAFs cultured in a Transwell with PANC1 
or MIAPACA2 cells. Gene expression was normalised to GAPDH and compared to the expression of 
AXIN2 in CAFs cultured alone. Each bar represents the ΔΔCt gene expression in CAFs (3 independent 
CAF lines: R3088, R3030, R3072)). Statistical significance was determined using an ordinary one way 
ANOVA 
 
Using the Taqman mini array for Wnt/ β-Catenin signalling it had been established 
that there was a significant upregulation of SFRP4 mRNA in CAFs compared with 
NAFs (Figure 5.3, Table 5.1), therefore the effect of a Transwell co-culture model on 
the mRNA of these genes was investigated. SFRP1 and SFRP4 mRNA was 
upregulated (3.55±1.11-fold) and (15.4±0.4-fold) in CAFs when they were cultured 
with PANC1 cells (Figure 5.11.). There was no induction of SFRP1 and SFRP4 when 
CAFs were cultured with MIAPACA2 cells (Figure 5.11.). 
































































































Figure 5.11. Induction of SFRP1 and SFRP4 in CAFs when cultured with PANC1 cells in a 
Transwell co-culture model 
Graphs showing SFRP1 and SFRP4 expression (RT-PCR) in CAFs cultured in a Transwell with PANC1 
or MIAPACA2 cells. Gene expression was normalised to GAPDH and compared to the expression of 
AXIN2 in CAFs cultured alone. Each bar represents the ΔΔCt gene expression in CAFs (3 independent 
CAF lines: R3088, R3030, R3072)). Statistical significance was determined using an ordinary one way 
ANOVA 
5.3.6. DKK1 secretion by CAFs and pancreatic cancer cell lines 
DKK1, an antagonist of Wnt pathway, was found to be downregulated in CAFs (Figure 
5.3, Table 5.1), I therefore considered whether this was consistent with the secretion 
of DKK1 in CAFs compared to PDAC cell lines. This was investigated using an ELISA. 
All of the pancreatic cancer cell lines with the exception of MIAPACA2, secreted 











Figure 5.12. Secretion of DKK1 by pancreatic cancer cell lines and CAFs 
PANC1, BXPC3, SUIT2 and ASPC1 cells secrete significantly more DKK1 than CAFs under standard 
culture conditions (10% Serum), **** indicates significance with p<0.0001 indicates significance (N=3). 
Supernatants were collected and tested for the presence of DKK1 using a quantitative sandwich ELISA 
(abcam). Bars represent supernatants collected from 3 experiments compared to the protein 
concentration of each experiment collected at the same time as the supernatants were harvested.  
 
5.4. Discussion 
Like the Hh pathway, the Wnt signalling pathway is an embryonic signalling pathway 
that has been implicated in the development of the pancreas (Wells et al., 2007). 
Mutations in genes associated with the Wnt pathway are uncommon in PDAC unlike 
other cancers such as colorectal, esophageal and gastric (Zhan et al., 2017, 
Novellasdemunt et al., 2015, Boynton et al., 1992, Chiurillo, 2015). However, despite 
the lack of mutations there is an accumulation of cytoplasmic/nuclear β-Catenin in 
approximately 65% of PDAC patients beginning in precursor lesions (Zeng et al., 
2006). This suggests a role for canonical Wnt signalling in the tumorigenesis of 
PDAC. It was demonstrated that PDAC tumour cores showed cytoplasmic localisation 
of β-Catenin (Figure 5.1 A&C) compared with normal tissue which showed β-Catenin 
expression restricted to the cell membranes in acinar cells (Figure 5.1 B). The 
presence of cytoplasmic localisation of β-Catenin in PDAC suggests this marker could 
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be used to predict the prognosis of patients. In non-small cell lung cancer and 
colorectal cancer cytoplasmic accumulation of β-Catenin correlates with a poorer 
outcome for patients (Li et al., 2013, Brabletz et al., 2001). In order to investigate the 
mechanism of Wnt signalling in the PDAC microenvironment, the expression of Wnt 
pathway associated genes in CAFs, NAFs and PDAC cell lines was measured using 
a Taqman mini array.  PANC1 cells showed an upregulation of Wnt5B which was 
consistent by the findings of Saitoh and Katoh (Saitoh and Katoh, 2002). Wnt5B is 
associated with non-canonical Wnt pathway; Wnt5B secretion from PANC1 cells has 
been found to be secreted in exosomes in a paracrine fashion (Harada et al., 2017). 
Wnt5B has been found to be highly expressed in breast cancer and head and neck 
squamous cell carcinoma (Klemm et al., 2011, Deraz et al., 2011); its expression is 
associated with a more invasive phenotype in both tumours. Wnt10A was found to be 
upregulated in both PANC1 and BXPC3 cells (Figure 5.2.); Wnt10A is associated with 
canonical Wnt pathway activation and has been found to be deregulated in leukaemia 
(Memarian et al., 2009). LRP5, a Fzd co-receptor associated with the canonical Wnt 
pathway, was also found to be upregulated in PANC1 and BXPC3 cells (Figure 5.2.) 
which suggests the potential for active canonical Wnt signalling in these cell types. 
However, there was not a clear pattern of Wnt expression genes which clarified a 
mechanism for Wnt signalling in the PDAC tumour microenvironment. 22 Wnt 
pathway associated genes were found to be differentially expressed in CAFs 
compared to NAFs. Among these genes were SFRP and Frzb. These molecules have 
traditionally been referred to as antagonists of the Wnt pathway as they bind Wnt 
ligands and prevent binding to Frizzled receptors (Lavergne et al., 2011). Evidence 
has emerged that restoring pancreatic CAFs to their quiescent phenotype using 
retinoic acid results in secretion of SFRP4 and eventually leads to a reduction of β-
Catenin translocation to the nucleus which results in increased apoptosis of cancer 
cells (Froeling et al., 2011). However, there are conflicting reports that during 
development SFRP molecules act to increase the signalling range of Wnt ligands by 
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behaving as extracellular transporters (Mii and Taira, 2009, Esteve et al., 2011). 
DKK1 was found to be down regulated in CAFs. During canonical Wnt signalling 
DKK1 binds receptor Kremen1 and 2 which form a complex with DKK1 and the LRP 
co-receptors and eventually lead to endocytosis of LRP’s removing them from the 
plasma membrane preventing the binding of Wnt ligands (Mao et al., 2002). 
Additionally, DKK1 has been found to be a target gene of β-Catenin/TCF pathway 
which suggests a negative feedback loop exists between β-Catenin nuclear 
accumulation and Wnt pathway inhibition (Niida et al., 2004). Additionally, AXIN2 and 
LEF1 were found to be upregulated in CAFs compared to NAFs (Figure 5.3.). Both 
genes are main effector of the canonical Wnt pathway (MacDonald et al., 2009), 
suggesting that CAFs are responsive to canonical Wnt ligands. Taken together there 
is no clear evidence which cell type is the donor/acceptor in the PDAC tumour 
microenvironment or if both are responsive to Wnt signalling.  
Using conditioned media from L-Wnt-3A cells it was possible to elicit an upregulation 
in AXIN2 mRNA in both fibroblasts and pancreatic cancer cell lines (Figure 5.4, Figure 
5.5). This response was reduced if the L-Wnt-3A cells were cultured in the presence 
of a PORCN inhibitor developed by Redx Pharma. This suggests that both epithelial 
and CAF cells in the pancreatic tumour microenvironment are responsive to paracrine 
Wnt signalling. This is in stark contrast to the expression of Hh signalling pathway 
components (Figure. 4.4) whereby an absence of Shh, dhh and ihh suggests that 
clear donor/acceptor roles exist between Shh-producing epithelial cells and 
responsive CAFs. Such a lack of defined roles for CAFs and PDAC cancer cells with 
respect to Wnt signalling in PDAC is reflective of the many diverse roles for Wnt 
signalling during disease and development. For example, in colon cancer Wnt ligand 
secretion has been found to be elevated in cancer stem cells and has been implicated 
in the maintenance of the tumour supportive microenvironment (Malanchi et al., 
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2011),whereas, in lung fibrosis Wnt ligands have been found to be upregulated in 
fibroblasts (Baarsma et al., 2011). 
Interrogation of the Wnt pathway-associated genes from Transwell co-cultures of both 
PDAC cancer cell lines and CAFs revealed AXIN2 mRNA induction in PANC1 cells 
in the presence of CAFs, an effect that was inhibited by a Redx PORCN inhibitor 
(Figure 5.9). Two possible mechanisms could explain this: either paracrine signalling 
exists between CAFs and PANC1 cells in this model, with CAFs secreting Wnt ligands 
which are activating downstream signalling in the PANC1 cells; or the CAFs are 
possibly stimulating an autocrine signalling loop in the PANC1 cells. There is 
evidence for autocrine activation of Wnt/ β-Catenin signalling pathway in cancer cells 
in mammary tumours (Bafico et al., 2004), however an autocrine signalling 
mechanism has not been identified in PDAC.  Further investigation revealed that 
PORCN mRNA was upregulated in CAFs when they were cultured with PANC1 cells, 
which suggests that CAFs are responsible for Wnt secretion as PORCN is involved 
in the post translational modification of Wnt ligands which is required for their 
successful secretion from Wnt producing cells (Takada et al., 2006). When CAFs 
were cultured with MIAPACA2 cells no PORCN mRNA upregulation was observed, 
however MIAPACA2 cells showed a Wnt pathway expression profile which had very 
few similarities to PANC1 and BXPC3 cells (Figure 5.2.). This suggests that the Wnt 
signalling pathway is behaving in a mechanistically different way in MIAPACA2 cells. 
DKK1 was found to be downregulated in CAFs, therefore the secretion of DKK1 in 
pancreatic cancer cell lines and CAFs was investigated using an ELISA (Figure 5.12). 
It was found that pancreatic cancer cell lines secrete significantly more DKK1 than 
CAFs. DKK1 has been found to be a target gene of β-Catenin/TCF pathway which 
suggests a negative feedback loop exists between β-Catenin nuclear accumulation 
and Wnt pathway inhibition (Niida et al., 2004). DKK1 has been found to be present 
in the PDAC tumour microenvironment, and is associated with a more aggressive 
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phenotype in pancreatic cancer cells (Takahashi et al., 2010). The presence of an 
auto-inhibitory feedback mechanism in the PDAC tumour microenvironment could be 
a result of the deregulation of Wnt signalling pathway in the tumour cells.  
The data presented within this chapter show that the Wnt pathway is clearly active 
within PDAC cell lines and suggests paracrine signalling between CAFs and PDAC 
cancer cells. However, the increased presence of endogenous Wnt pathway 
inhibitors together with the lack of a clear Wnt pathway expression profile for epithelial 
and CAFs means the role of non-canonical Wnt signalling and how this relates to 
canonical signalling must first be defined specifically within the context of PDAC in 




6. Incorporating aspects of the PDAC tumour 
microenvironment in drug screening models 
6.1. Introduction 
In vitro 2D monolayer cell based assays have been used as a critical part of the drug 
discovery process for decades (Lovitt et al., 2014, Fang and Eglen, 2017, Horvath et 
al., 2016). The limitations of these assays have been more widely exposed as the 
importance of the tumour microenvironment in drug delivery has become clearer. 2D 
monolayer assays do not accurately represent the 3D cellular environment within a 
tumour which also includes the untransformed cells and the tumour 
microenvironment. Unlike other tumours murine models for PDAC there remains a 
limited amount of models which actually represent human disease (Herreros-
Villanueva et al., 2012). This could be a contributing factor to the low success rate of 
compounds reaching clinical development; currently approximately 10% of 
compounds pass phase III clinical trials with many compounds failing because there 
is a lack of clinical efficacy or toxicities (Ledford, 2011). The in vitro profile for 
Gemcitabine, the current standard of care for PDAC shows cytotoxic activity against 
cancer cells in vitro, however this does not translate to clinical efficacy (Lee et al., 
2013a). Paclitaxel was suggested as a potential alternative treatment for PDAC as it 
also shows cytotoxic activity against cancer cells in vitro (Liebmann et al., 1993).  Due 
to reduced drug delivery it did not show any improvement on Gemcitabine (Liebmann 
et al., 1993). This was somewhat overcome by using albumin bound Paclitaxel which 
increased drug delivery, however it was also associated with increased toxicities and 
can therefore only be used in high performing patients (Adamska et al., 2017). In the 
case of pancreatic cancer the discrepancy between clinical efficacy and in vitro 
models could be due to simplistic 2D monolayer assays not allowing for the complex 
interactions between tumour cells and the stroma. A variety of signalling pathways 
including Hh and Wnt/ β-Catenin allow a dynamic cross-talk between CAFs and 
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tumour cells which results in increased ECM deposition, cancer cell proliferation, and 
migration (von Ahrens et al., 2017, Weekes and Winn, 2011). My own research 
(Chapters 3 and 4) on the Hh and Wnt/ β-Catenin signalling pathways provides 
evidence for significant crosstalk between CAFs and pancreatic cancer cells. Given 
the low success rates of standard chemotherapy regimens, targeting these signalling 
pathways in PDAC has gained more attention in recent years (Gore and Korc, 2014). 
However, research has implicated the tumour microenvironment not only in 
upregulating signalling pathways which support tumour growth but in modulating the 
efficacy of the chemotherapy itself (Hessmann et al., 2017, Richards et al., 2017). In 
order to investigate the efficacy of compounds to treat malignancies which have an 
active tumour microenvironment more sophisticated screening models must be 
produced which incorporate the microenvironment. Attempts have been made to 
include aspects of the tumour microenvironment in vitro, however the majority of 
these models involve 2D co-cultures (Haqq et al., 2014). 3D cultures have an 
advantage over 2D culture systems as the cells are able to organise into tissue like 
structures allowing the cells to establish cell-cell contacts and ECM deposition which 
have been established as playing a role in a tumour’s response to chemotherapeutic 
agents (Estrada et al., 2016). 3D cultures have been found to be more resistant to 
both chemo and radio therapeutic targeting (Longati et al., 2013), however despite 
this knowledge validated 3D culture systems are not commonly used in vitro to screen 
compounds. In this chapter, the effect of including CAFs in both 2D and 3D co-culture 
models on the efficacy of chemotherapeutic agents used to treat PDAC were 
investigated. 
6.2. Methods 
6.2.1. 2D Cell proliferation assay 
The appropriate seeding density for each cell line was determined using cell growth 
over time to ensure that the cells were in the exponential growth phase when they 
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were treated. Cells were seeded at their pre-determined seeding density (Table 6.1) 
in 100µL of medium and left for 24h to adhere in 96-well flat, white, clear bottom plates 
(Greiner Bio-One). The following day cells were treated with either Gemcitabine or 
Paclitaxel using a D300 digital liquid dispenser (Tecan). The plates were placed in an 
incubator (37oC, 5% CO2) for 72 and 96h. CellTitre-Glo  was prepared using the 
manufacturer’s instructions. At the appropriate time point, plates were removed from 
the incubator and allowed to equilibrate to room temperature for 30min. 10µL of 
CellTitre-Glo® reagent was added to each well and the plates were sealed with a 
black plate seal and placed on an orbital shaker for 10min. Luminescence was read 
using an EnVision plate reader (PerkinElmer). The luminescent signal generated is in 
direct proportion to the amount of ATP in the well, which is required for the conversion 
of luciferin to oxyluciferin in the presence of assay reagents. Cell viability was 











Table 6.1. Cell Seeding Densities for 2D Proliferation Assays 
6.2.2. Chemotherapy pulsing 
Chemotherapy pulsing was used to determine the effect of mimicking clinical dosing 
of chemotherapeutic agents in an in vitro assay on the viability of pancreatic cancer 
cell lines. The cMAX (maximum serum concentration of drug in humans) of 
Gemcitabine (74.4± 11.3 (μM)) and Paclitaxel (4.5 ± 0.4 (μM)) (Fogli et al., 2002) 
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was used to calculate an approximate exposure time such that it matched the total 
















Figure 6.1.  Example of the plasma concentration-time curve  
A typical example of a plasma-concentration over time curve showing pharmacokinetic and 
pharmacodynamic parameters after a single   drug treatment. The Area Under the Curve (AUC) value 
for Gemcitabine (9.3 ± 1.8 (h × µg/ml)) and Paclitaxel (15.8 ± 1.1 (h × µmol/l)) were used to determine 
the length of time the cells were exposed to drug at 0.5 cMAX and 0.1 cMAX, using the formula above. 
 
This assay was set up using the design outlined is Section 6.2.1. Once cells had been 
incubated overnight in order to adhere, Gemcitabine and Paclitaxel were pulsed onto 
the cells for length of time each drug is present in serum at a given concentration 
(Table 6.2.). Once the pulse was completed, media was replaced with fresh vehicle 
(DMSO) containing media. For comparison cells were also treated with the mean IC50 
(96h), which had been previously established for each cell line (Section 6.3.1.).  
 
Time (h) = Area Under Curve (μg/mL) 
cMAX (μg/mL) 
 0.83h =  9.3 (AUC h x μg/mL) 
11.15 (0.5cMAX μg/mL) 












Gemcitabine 37.21 50 7.44 250 
Paclitaxel 2.25 420 0.45 2100 
Table 6.2 Experimental conditions of chemotherapy pulsing experiment 
6.2.3. Transwell co-culture model 
To determine if the addition of CAFs could have an effect on the sensitivity of epithelial 
cells to Gemcitabine in a Transwell co-culture model, CAFs and PANC1 cells (1:1 
ratio) were seeded onto a 96-well Transwell plate with CAFs and PANC1 on the 
bottom and top chambers respectively. To control for cell number, Transwell plates 
were also seeded with CAFs alone or PANC1 alone. The cells were left for 24h to 
adhere. The following day they were treated with Gemcitabine using a digital liquid 
dispenser D300 (Tecan). After 72h cell viability was measured using the CellTitre-Glo 
procedure described in section 6.2.1. 
6.2.4. 3D Co-culture model 
Using the Promega 3D CellTiter-Glo cell viability assay it was possible to determine 
the amount of viable cells in 3D multicellular spheroids of pancreatic cancer cell lines 
and CAFs. It was first necessary to determine the appropriate seeding density, which 
was achieved by dosing 3D mono-cultures of PANC1 cells which had been seeded 
at different densities. The cells were seeded in Ultra-Low Attachment (ULA) plates at 
different seeding densities and incubated for 24h to form spheroids. The cells were 
then treated with Gemcitabine and incubated for 48, 72, and 96h. The CellTiter-Glo 
3D reagent was thawed at 4oC overnight and then placed in a 22oC water bath for 
30min before use. The plate containing the spheroids was equilibrated for 30min at 
room temperature. 50μL of CellTiter-Glo 3D was added to each well and placed on 
an orbital plate shaker for 5min. The cell lysate and CellTiter-Glo reagent was moved 
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to a flat, clear bottom 96-well plate, incubated for a further 25min (room temperature) 
and then the luminescent signal was measured using an EnVision multilabel plate 
reader (Perkin Elmer). To determine the effect of co-culturing CAFs and epithelial 
cells in a 3D culture model had on the sensitivity to Gemcitabine, the above method 
was repeated with a 1:1 ratio of CAFs and PANC1 cells. 
6.3. Results 
6.3.1. Proliferation of pancreatic cell lines cultured in 2D is inhibited by 
Gemcitabine and Paclitaxel 
In order to determine the effect of the addition of CAFs to drug screening models, it 
was first necessary to establish the effect of Gemcitabine and Paclitaxel on pancreatic 
cancer cell lines and CAFs in a traditional 2D screening model. All 5 pancreatic cell 
lines tested (PANC1, SUIT2, MIAPACA2, BXPC3 and ASPC1) were sensitive to both 
Gemcitabine and Paclitaxel at 72 and 96h (Figure 6.2, Figure 6.3, Figure 6.4. and 
Figure 6.5.) with an IC50 for Gemcitabine  338nM (SUIT2) and Paclitaxel 5.73nM 
(PANC1) in the least sensitive cell lines  at 72h. In contrast to this nM and in some 
cases, pM potency, CAF proliferation at 72 and 96h remained >50% of the DMSO 
control even in the presence of the highest concentration of either Gemcitabine or 
Paclitaxel (10μM). As 50% inhibition of growth was not achieved an IC50 value was 
not calculated and the CAFs were deemed resistant to Gemcitabine and Paclitaxel. 
These data are consistent with previous findings that CAFs are resistant to 





















Figure 6.2. Pancreatic cancer cell lines are sensitive to Gemcitabine at 72h 
A: Representative graphs of a 2D cell proliferation assay. Cells were exposed to increasing 
concentrations of Gemcitabine, at 72h cell viability was measured using Cell-Titre Glo. Data were fitted 
to a sigmoidal dose-response curve and the pIC50 was determined using GraphPad Prism 5.0. The data 
are shown as mean ±S.D. of one assay performed in triplicate, normalised to a DMSO control which was 
set at 100%. B: Shows the mean pIC50 with S.E.M for the multiple screening runs (three or greater) for 
each cell line. Summary table of average pIC50 for each cell line. C. Summary table of average pIC50 






Cell line Average pIC50 (M) 
PANC1 7.81±0.21 
MIAPACA2  7.46± 0.25 
SUIT2  6.47 ±0.38 
ASPC1 7.2±0.33 
BXPC3   6.77±0.14 
CAF  ≤5.00 

































































Figure 6.3.  Pancreatic cancer cell lines are sensitive to Paclitaxel at 72h 
A: Representative graphs of a 2D cell proliferation assay. Cells were exposed to increasing 
concentrations of Paclitaxel, at 72h cell viability was measured using Cell-Titre Glo. Data were fitted to 
a sigmoidal dose-response curve and the pIC50 was determined using GraphPad Prism 5.0. The data 
are shown as mean ±S.D. of one assay performed in triplicate, normalised to a DMSO control which was 
set at 100%. B: Shows the mean pIC50 with S.E.M for the multiple screening runs (three or greater) for 
each cell line. C. Summary table of average pIC50 for each cell line.  
 
  
Cell line Average pIC50 (M) 
PANC1 8.27 ±0.17 
MIAPACA2 8.55 ±0.09 
SUIT2 8.71 ±0.12 
ASPC1  9.15 ±0.05 
BXPC3  8.70 ±0.22 
CAF  ≤5.00 































































Figure 6.4.  Pancreatic cancer cell lines are sensitive to Gemcitabine at 96h 
A: Representative graphs of a 2D cell proliferation assay. Cells were exposed to increasing 
concentrations of Gemcitabine, at 96h cell viability was measured using Cell-Titre Glo. Data were fitted 
to a sigmoidal dose-response curve and the pIC50 was determined using GraphPad Prism 5.0. The data 
are shown as mean ±S.D. of one assay performed in triplicate, normalised to a DMSO control which was 
set at 100%. B: Shows the mean pIC50 with S.E.M for the multiple screening runs (three or greater) for 

















Cell line Average pIC50 (M) 
PANC1 7.45 ±0.13 
MIAPACA2  7.65 ±0.24 
SUIT2 7.05 ±0.20 
ASPC1  7.99 ±0.22 
BXPC3   7.65 ±0.36 









































Figure 6.5. Pancreatic cancer cell lines are sensitive to Paclitaxel at 96h 
A: Representative graphs of a 2D cell proliferation assay. Cells were exposed to increasing 
concentrations of Paclitaxel, at 96h cell viability was measured using Cell-Titre Glo. Data were fitted to 
a sigmoidal dose-response curve and the pIC50 was determined using GraphPad Prism 5.0. The data 
are shown as mean ±S.D. of one assay performed in triplicate, normalised to a DMSO control which was 
set at 100%. B: Shows the mean pIC50 with S.E.M for the multiple screening runs (three or greater) for 
each cell line. C. Summary table of average pIC50 for each cell line.  
  
Cell line Average pIC50 (M) 
PANC1 8.88 ±0.12 
MIAPACA2  8.70 ±0.09 
SUIT2 8.56 ±0.06 
ASPC1 8.58 ±0.15 
BXPC3  8.90 ±0.16 




6.3.2. Chemotherapy pulsing as an alternate method for dosing cells 
during in vitro drug screening assays 
Drug screening assays in the pharmaceutical industry are designed with a variety of 
factors in consideration such as pharmacological relevance, reproducibility, quality 
and importantly cost (Hughes et al., 2011). In PDAC research the standard, mono-2D 
cell based assay is still the most widely used to compare the anti-proliferative effect 
of drugs on pancreatic cancer cells (Awasthi et al., 2013). However, the findings 
presented in chapters 3-5 strongly suggest that CAFs contribute to a dynamic tumour 
supportive microenvironment exhibiting active signalling pathways which support 
tumour growth and metastases, as found by others (Farrow et al., 2008, Waghray et 
al., 2013). A mono-2D cell based assay does not take into consideration factors within 
the tumour microenvironment which can affect chemotherapeutic agents. Neither 
does it take into account length of time and concentration of drug that the cancer cells 
within the tumour are exposed to. In a 2D mono culture based assay, compounds are 
ranked based on their potency whereby cells are continuously exposed to a 
compound. However, this does not replicate the in vivo situation as compounds are 
rapidly cleared by the host. One method of investigating the effect of 
chemotherapeutic agents on cancer cells is using a dosing schedule which mimics 
the clinical exposure of cells to drug as closely as possible within the limits of in vitro 
testing. Once it had been established that pancreatic cancer cell lines were sensitive 
to treatment with chemotherapeutic agents (Gemcitabine and Paclitaxel) at both 72 
and 96h, the effect of a clinical dosing regimen was investigated. 
Using a clinical dosing regimen PANC1 cells did not show any increase in cell viability 
when treated with 37.21μM for 50min (0.5 cMAX)(Figure 6.6.). However when treated 
with 7.44μM for 250min (0.1 cMAX) they appeared to have a normal cell growth until 
72h after which point there was a reduction in cell viability (Figure 6.6.). SUIT2 and 
MIAPACA2 showed a reduction in cell viability which fell below 0h in all 3 conditions 
(0.5 cMAX, 0.1 cMAX and IC50) which suggests cell death (Figure 6.6.). ASPC1 cells 
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were sensitive to 0.5 and 0.1 cMAX as there was no increase in cell viability after 
dosing with these concentrations (Figure 6.6.). There was no effect on BXPC3 cell 
viability when treated with the (previously determined) IC50 of Gemcitabine (22.4nM) 
at 96h (Figure 6.4.). CAFs retained their resistance to Gemcitabine and there was 

























Figure 6.6.  Cell Viability of pancreatic cancer cell and CAFs after pulsing with Gemcitabine 
Representative graphs of a 2D cell proliferation assay. Cells were exposed to Gemcitabine 
concentrations which corresponded to 0.5 cMAX, 0.1 cMAX, IC50 and a DMSO control. At 24, 48, 72 and 
96h cell viability was measured using Cell-Titre Glo. Data was analysed using GraphPad Prism 5.0. The 
data are shown as mean ±S.D. of one assay performed in triplicate. 
  



























































Using a clinical dosing regimen to dose cells with Paclitaxel SUIT2 and MIAPACA2 
showed a decrease in cell viability in all 3 conditions (IC50, 2.25μM for 420min (0.5 
cMAX) and 0.45μM for 2100min (0.1 cMAX)) which was below that detected at the 
0h time-point and indicates that there was cell death in response to treatment (Figure 
6.7). PANC1 cells did not proliferate after dosing with 0.5 cMAX, though there was a 
slight increase in viable cells when  treated with 0.1 cMAX (Figure 6.7.). However, 
dosing with the previously determined  IC50 (96h time point; 1.3nM) appeared to 
prevent proliferation up to 72h after dosing before the cells appeared to recover such 
that there was no difference in cell proliferation between the IC50 and vehicle (DMSO) 
control (Figure 6.7). ASPC1 cells were sensitive to dosing with both 0.5 cMAX and 
0.1 cMAX as there was no increase in viable cells up to 96h after dosing (Figure 6.7.). 
BXPC3 cells showed a decrease in proliferation when treated with 0.5 cMAX and 0.1 
cMAX and there was a slight decrease in viable cells when BXPC3 were treated with 
the pre-determined IC50 (1.3nM Figure 6.5.). CAFs were sensitive to Paclitaxel using 
this model and did not recover from dosing with 0.5 and 0.1 cMAX as there was no 
increase in cell proliferation (Figure 6.7.). As it was not possible to determine an IC50 
for CAFs the highest IC50 determined for the pancreatic cancer cell lines was used 
which was SUIT2 (2.8nM, Figure 6.5.). This did not have any effect on the proliferation 



























Figure 6.7.  Cell Viability of pancreatic cancer cell and CAFs after pulsing with Paclitaxel 
Representative graphs of a 2D cell proliferation assay. Cells were exposed to Gemcitabine 
concentrations which corresponded to 0.5 cMAX, 0.1 cMAX, IC50 and a DMSO control. At 24, 48, 72 and 
96h cell viability was measured using Cell-Titre Glo. Data was analysed using GraphPad Prism 5.0. The 
data are shown as mean ±S.D. of one assay performed in triplicate. 
  






















































Figures 6.6 and 6.7 show that, rather than better modelling the efficacy drop-off 
between in vitro testing and clinical observation, mimicking the clinical AUC by pulsing 
with either 0.5 or 0.1 cMAX had a more marked anti-proliferative effect at 96h than 
dosing with the pre-determined IC50. It is therefore clear that the dosing regimen is 
not responsible for the discrepancy between clinical and in vitro efficacy and that an 
alternative model should be sought. 
6.3.3. CAFs reduce the anti-proliferative effect of Gemcitabine in 2D co-
culture models 
To investigate the effect of including CAFs in drug screening assays, a direct 2D co-
culture model was used. The addition of CAFs to a 2D model to create a direct co-
culture showed a reduction in the anti-proliferative effect of Gemcitabine (Figure 6.8.). 
Gemcitabine exposure to PANC1 cells alone gave an IC50 of 63.1nM whereas the 
addition of CAFs caused a decrease in sensitivity (Gemcitabine IC50: 9 PANC1:1 



















Figure 6.8.  Addition of CAFs to a 2D screening model reduces the anti-proliferative effect of 
Gemcitabine on PANC1 cells 
A: Representative graph of a 2D cell proliferation assay. Cells were exposed to Gemcitabine and a 
DMSO control. At 72h cell viability was determined using a nuclei count which was achieved by staining 
the cells with DAPI, anti-α-SMA-488 and anti-CTK-594. Nuclei which were associated with areas of 
positive α-SMA-488 staining were considered to be CAFs and excluded from nuclei count. Data were 
analysed using GraphPad Prism 5.0. The data are shown as mean ±S.D. of one assay performed in 
triplicate. B: Example image from this assay showing anti-α-SMA-488 (Green) and anti-CTK-594 
(Yellow) and nuclei (Blue). Average nuclei count was measured using an Operetta (Perkin Elmer), using 





In order to confirm that co-culture with CAFs with PANC1 cells were responsible for 
the reduction in the anti-proliferative effect of Gemcitabine in PANC1 cells, the effect 
of CAFs on the Gemcitabine IC50 in PANC1 cells was investigated using a Transwell 
co-culture model.  A ratio of 1:1 of each cell type was chosen as it was clear from the 
co-culture model described above (Figure 6.8.) that the ratio of CAFs to epithelial 
cells did not significantly impact the Gemcitabine IC50.  
 
Figure 6.9.  CAFs reduce the anti-proliferative effect of Gemcitabine in a Transwell model 
PANC1 cells were cultured on Transwell (Top) inserts alone or in the presence of CAFs (Bottom) 1;1 
ratio. Cells were cultured for 72h in the presence of gemcitabine. Proliferation of PANC1 cells was 
measured using Cell Titre Glo. 
 
The co-culture of CAFs with PANC1 cells in a Transwell system dramatically reduced 
the anti-proliferative effect of Gemcitabine (Figure 6.9.). This reduction resulted in a 
10-fold decrease in Gemcitabine potency (pIC50 from 7.7±0.16 to 6.3±0.13M, N=3). 
Such a significant reduction in potency (P value = 0.0036) is consistent with the direct 
co-culture model (Figure 6.8.) and suggests that CAFs are able to reduce the anti-




6.3.4. CAFs reduce the anti-proliferative effect of Gemcitabine in a 3D 
co-culture model 
To develop a model which more closely mimics the PDAC tumour microenvironment 
allowing a physical interaction between the tumour cells and CAFs, a 3D co-culture 
model was used. Initially, it was necessary to determine an optimal cell density for 
this model. Due to the limitations of the assay it was found that in order to measure 
any response to Gemcitabine the spheroids had to be reduced in size to 1,000 
















Figure 6.10.  Optimisation of pancreatic cancer cell number in a 3D drug screening model 
PANC1 cells were plated at varying cell densities in ULA plates and left overnight in order to form 
spheroids.  At 24h the spheroids were treated with Gemcitabine or a DMSO control. At 24, 48 and 72h 
after dosing cell viability was determined using 3D Cell Titre Glo. Spheroids were resistant to 
Gemcitabine treatment when they were cultured at 20,000, 15,000, 10,000, 5,000 cells/ spheroid. At 
1,000 cells/ spheroid at 72 and 96h there was an anti-proliferative effect dependant on Gemcitabine 
concentration. 
 
CAFs were found to be resistant to Gemcitabine in 3D culture regardless of the cell 
density (Figure 6.11.). It was not possible to calculate an IC50 as there was not a 50% 
decrease in ATP concentration using up to 50μM Gemcitabine. There was a slight 
decrease in cell proliferation in the 10,000 and 1,000 cell conditions; however this 






Figure 6.11.  CAFs are resistant to gemcitabine in a 3D cell culture model 
CAFs were plated at varying cell densities in ULA plates and left overnight in order to form spheroids.  
At 24h the spheroids were treated with Gemcitabine or a DMSO control. At 72h after dosing cell viability 
was determined using 3D Cell Titre Glo. Spheroids were resistant to Gemcitabine treatment when they 
were cultured at 20,000, 15,000, 10,000, 5,000 and 1,000 cells/ spheroid.  
 
Once an appropriate cell number had been established a 3D co-culture was tested 
using this model. A 1:1 ratio of pancreatic cancer cell to CAFs was used as this ratio 
had been shown to effect drug potency in both co-culture and Transwell 2D models 
(Figure 6.8, Figure 6.9.). The anti-proliferative effect of Gemcitabine was reduced in 
all cases in which pancreatic cancer cells were cultured with CAFs: PANC1 cells 
cultured in 3D alone gave a pIC50 6.1 ±0.13M which was reduced to a pIC50 ≤4.30M 
(Figure 6.12, Table 6.1.). The pIC50 of SUIT2 cells was reduced from 6.6 ±0.22M to 
≤4.30, though in this case the cell proliferation was reduced to approximately 58%. 
MIAPACA2 cells when cultured alone in 3D gave a pIC50 of 7.5 ±0.19 which was 
reduced to ≤5.50 (Figure 6.12, Table 6.1.). BXPC3 had a pIC50 of 7.3 ±0.24 which 
was reduced to ≤5.00, in this case there also appeared to be an effect on cell 
proliferation, however this was not marked enough to be able to determine a pIC50 
(Figure 6.12, Table 6.1.). Together these data suggest that CAFs have a significant 







Figure 6.12. CAFs are resistant to Gemcitabine in a 3D co-culture model 
Representative graphs of 2D and 3D Cultures generated using normal tissue culture (2D) or ultra-low 
attachment plates (3D), whereby cells were seeded and left overnight to form spheroids at which point 
they were treated with Gemcitabine. At 72h spheroids were lysed and ATP concentration was 
determined using 3D Cell Titre Glo. When cells were cultured in 3D with CAFs the anti-proliferative effect 






Table 6.1.  Comparison of average pIC50’s of Gemcitabine of pancreatic cancer cells in 2D, 3D 
and in 3D co-culture models with CAFs (N=3) 
 
6.4. Discussion 
Only 20% of patients are diagnosed with resectable tumours; the vast majority of 
patients have locally advanced or metastatic disease by the time of diagnosis  
(Heestand et al., 2015). In the more common event that a tumour is not resectable, 
the current standard of care is Gemcitabine treatment. This however, has limited 
efficacy with a median survival of less than 6 months (Hidalgo, 2010). During in vitro 
testing of Gemcitabine and Paclitaxel (Figure 6.3, 6.4, 6.5. and 6.6.), pancreatic 
cancer cells appear to be sensitive to both chemotherapies, which would suggest they 
would be effective therapies for PDAC. Conversely, both drugs appeared ineffective 
with regards to the proliferation of CAFs. Both of these drugs target the rapidly 
proliferating epithelial cancer cells. Gemcitabine is a nucleoside analogue which 
inhibits DNA synthesis when dFdCTP is incorporated into DNA which prevents DNA 
polymerases from functioning past the incorporation (Huang et al., 1991). This traps 
cells within the S phase of the cell cycle preventing further cell proliferation. In 
addition, Gemcitabine also targets the enzyme ribonucleotide reductase (RNR). The 
diphosphate analogue binds to the RNR active site and inactivates the enzyme 
irreversibly. Once RNR is inhibited, the cell cannot produce the deoxyribonucleotides 
required for DNA replication and repair this leads to cell cycle arrest and apoptosis 
(Cerqueira et al., 2007).  






3D Co-Culture Mean  pIC
50   
(M) 
PANC1 6.9 ±0.17 6.1 ±0.13 ≤4.30 
BXPC3 7.3 ±0.34 7.3 ±0.24 ≤5.00 
MIAPACA2 8.2 ±0.09 7.5 ±0.19 ≤5.50 
SUIT2 6.4 ±0.41 6.6 ±0.22 ≤4.30 
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 Paclitaxel functions by binding to the β-subunit of tubulin, which is a protein highly 
involved in the structure of microtubules which need to be fluid in order for a cell to 
function appropriately (Horwitz, 1994). Paclitaxel binds to tubulin and locks the 
microtubules in place preventing them from undergoing the dynamic instability which 
is necessary for chromosome remodelling during mitosis, this causes mitotic arrest  
(Weaver, 2014). CAFs are untransformed cells and proliferate at a much slower rate 
than epithelial pancreatic cancer cell lines and this could, in part, explain their 
resistance to Gemcitabine and Paclitaxel.  
In many drug discovery programmes, the anti-proliferative potency of compounds are 
ranked using IC50 values obtained using 2D cell culture. One key difference between 
this method and in vivo/clinical dosing is that the concentration of the compound is 
sustained throughout the in vitro experiment albeit with the potential for cellular 
enzymatic breakdown of the compound. Due to pharmacokinetics this sustained 
concentration is not achievable within an animal with the serum concentration often 
experiencing a sharp peak (cMAX) followed by a rapid decline as the drug is cleared 
through phase I and II metabolism (Figure 6.1). Therefore one potential explanation 
of the discrepancy between in vitro and clinical efficacy could be the dosing regimen. 
In order to determine if mimicking in vivo drug exposure in an in vitro model had any 
effect on the viability of the cells, chemotherapeutic pulsing was used whereby cells 
were briefly exposed to either 0.1 or 0.5 cMAX for a time equivalent to the overall 
clinical exposure (AUC) calculated from literature (Fogli et al., 2002, Wang et al., 
2007) reports (Figure 6.1, Table 6.2.) before the media was refreshed. This was then 
compared to cells exposed continuously to a previously determined IC50 
concentration. Using this method of the anti-proliferative effect of Gemcitabine and 
Paclitaxel in pancreatic cancer cell lines was sustained with the exception of BXPC3 
which appeared to recover from chemotherapy pulsing over time (Figure 6.6, Figure 
6.7). CAFs remained resistant to Gemcitabine (Figure 6.6) however, pulsing with 
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Paclitaxel reduced the cell viability of CAFs (Figure 6.7). The data comparing dosing 
regimen would suggest that the discrepancy between in vitro and clinical potency is 
not due to the difference in compound exposure between the two disciplines. 
However one such limitation of this technique is that the AUC and cMAX calculations 
were taken from serum concentrations. As discussed before, the desmoplastic 
reaction reduces the blood perfusion in the PDAC tumour microenvironment and 
therefore the serum concentration may be far larger than the concentration that the 
tumour is exposed to. Nevertheless, in all cases, the pulsing was more effective in 
inhibiting PDAC cell growth than the IC50 concentration, suggesting that a specific 
regimen does not underpin efficacy. Given the resistance of CAFs to Gemcitabine 
and Paclitaxel, I hypothesized that the interplay between CAFs and epithelial cells 
may contribute toward the decreased sensitivity of tumour cells to Gemcitabine. 
A direct 2D co-culture model was used to investigate the effect of the addition of CAFs 
to a drug screening model. It was shown that CAFs confer Gemcitabine resistance in 
this model (Figure 6.8A). However, this model used IF to exclude nuclei which were 
associated with positive αSMA staining (Figure 6.8B) and therefore did not include 
PANC1 cells which grew in close proximity to CAFs. In order to confirm this finding a 
Transwell co-culture model was used. This model in which both cell types were 
separated by a physical barrier confirmed that culturing CAFs and PANC1 cells in the 
same well reduced the anti-proliferative effect of Gemcitabine on PANC1 cells (Figure 
6.9). 3D models have been developed as the future of pharmacological drug 
screening assays (Horvath et al., 2016). In order to model the tumour 
microenvironment in PDAC a 3D co-culture model was used. It was found that 
culturing the cells in 3D in the presence of CAFs reduced the anti-proliferative effect 
of Gemcitabine more than in a direct 2D or Transwell co-culture model (Figure 6.12). 
The presence of CAFs within a 2D co-culture model has an impact on pancreatic 
cancer cell resistance to Gemcitabine. The 3D co-culture model presented herein 
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causes a complete loss of the anti-proliferative effect of Gemcitabine and therefore is 
able to better reflect the chemotherapy resistance which is observed in the clinic and 
may therefore represent a more sophisticated and ultimately more accurate model by 
which to predict a new treatment’s in vivo and subsequently clinical efficacy. 
 It has been suggested that one method by which CAFs increase resistance to 
chemotherapy is by the secretion of exosomes which contain micro RNAs that 
upregulate pathways which are involved in chemotherapy resistance in cancer cell 
lines (Richards et al., 2017). Therefore in the 3D co-culture model described above 
the cells are in very close contact with one another and exosome signalling could 
explain the chemotherapy resistance. Additionally, it was found that pre-treating 
CAFs with Gemcitabine increased the secretion of these exosomes (Richards et al., 
2017). In my model both cell types within the spheroid are exposed to Gemcitabine 
which could stimulate exosome secretion in the CAFs. Recently it has been 
discovered that CAFs can behave as scavengers and remove Gemcitabine from the 
PDAC and tumour microenvironment to reduce its availability for epithelial cancer 
cells (Hessmann et al., 2017). In the 3D co-culture model the presence of CAFs which 
are able to scavenge Gemcitabine could be contributing to the reduction in the anti-
proliferative effect of Gemcitabine in this model. This is reminiscent of the PDAC 
tumour microenvironment. The presence of CAFs within the 3D co-culture model has 
been shown to have increase the denseness and compactness of the spheroids 
compared with the looser structures of the pancreatic cancer cell mono-cultures 
(Figure 3.7, Figure 3.8.). This suggests that the interactions between the cancer cells 
and CAFs leaves less exposed surface area for Gemcitabine uptake by PDAC cells 
which could also impact chemotherapeutic resistance. 
Taken together this provides evidence that the PDAC tumour microenvironment is 
dynamic in its response to chemotherapeutic agents and CAFs play a much more 
significant role in chemotherapy resistance than as just a physical barrier to 





PDAC remains one of the most aggressive cancer types and is the fourth leading 
cause of cancer-related death worldwide (Garrido-Laguna and Hidalgo, 2015). The 
overall 5-year survival rate for patients diagnosed with PDAC is less than 5% (Siegel 
et al., 2015) and it is predicted that PDAC will be the second most lethal cancer-
related malignancy by 2030 (Rahib et al., 2014). This poor prognosis is in part due to 
the fact that most patients are diagnosed with advanced disease. In addition, effective 
tools for screening for PDAC have not yet been developed which makes early 
detection of this disease unlikely. Once a patient has been diagnosed, there are 
limited treatment options available with tumour resection giving the most promising 
outlook for patients with 5-year survival rising to 15-20% (Oettle et al., 2007). However 
only 20% of patients presenting with PDAC have a resectable tumour (Malafa, 2015). 
Despite an increased understanding of PDAC tumour biology over the past 10-20 
years this has not translated to treatment breakthroughs against this malignancy. This 
is partly due to the lack of drug screening models which incorporate the tumour 
microenvironment. Considering the tumour microenvironment makes up over 80% of 
the PDAC tumour volume (Feig et al., 2012)  this is critical in understanding how 
drugs impact this tumour.   
The initial aim of this project was to isolate cells from the PDAC tumour 
microenvironment and use the cells to develop and characterise a 3D model of PDAC. 
The changes wrought on the architecture of the pancreas during tumorigenesis were 
shown using H&E staining (Figure 3.1A) and include the development of a 
desmoplastic stroma (Waghray et al., 2013). Activated CAFs are the most abundant 
cell type of the stromal reaction and are identified by their expression of αSMA, which 
distinguishes them from cancer cells which express pan-cytokeratin (Apte et al., 
1998)(Figure 3.1. B&C). CAFs were isolated using the outgrowth method (Bachem et 
al., 1998) and were characterised using the expression of markers and their 
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production of collagen 1a1 (Figure 3.2, Figure 3.3.). In order to accurately represent 
the PDAC tumour microenvironment it would have been preferable to use only cancer 
cells freshly isolated from tumour tissue samples in the creation of a 3D model, 
however after trialling various methods, this was not possible (Section 3.2.2.). The 
difficulties encountered with isolating PDAC cells is consistent with the findings of 
Ruckert et al. (2012) in which the isolation of pancreatic epithelial cancer cell lines 
was found to have a remarkably low success rate (~10%) with respect to other tumour 
cell isolates (Ruckert et al., 2012, Dangles-Marie et al., 2007, DeRose et al., 2011). 
One method of PDAC epithelial cell isolation which has been reported to have a high 
success rate is the use of patient derived xenografts (Pham et al., 2016). This method 
involves the implantation of tumour specimens into immune compromised mice; these 
xenografts are allowed to develop until they reach 1.5cm in diameter at which point 
they are passaged into new mice. This method has been shown to maintain epithelial 
cell markers (EpCAM, CK18 and CK19) and the isolated cells remain negative for 
CD68 and αSMA which is consistent with the original tumour (Pham et al., 2016). For 
future experiments, cells derived in this manner, in combination with the CAFs used 
in this project, would potentially allow for the most accurate in vitro modelling of CAF: 
Tumour cell interactions within the PDAC microenvironment. Given that it was not 
possible to isolate PDAC cells, commercially available cell lines were used.  
Commercially available pancreatic cancer cell lines have been suggested as a barrier 
to the development of new therapies as they do not represent the intra-patient tumour 
cell heterogeneity that exists in cells isolated from primary samples (Cassidy et al., 
2015). However, when modelling complex microenvironments with a particular focus 
on drug development, there exists a fine balance between best representing the 
complexity of the disease whilst also ensuring a cost effective and reproducible assay. 
Therefore, five PDAC cell lines were chosen with particular consideration made to 
best represent patient heterogeneity whilst also ensuring that the selected cell lines 
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were well characterised with respect to PDAC research (McConkey et al., 2010, Deer 
et al., 2010, Gradiz et al., 2016, Dalla Pozza et al., 2015). 
In furtherance of the development of a 3D model which incorporated CAFs it was 
necessary to investigate how CAFs and pancreatic cancer cell lines interacted when 
co-cultured in 3D. The use of 3D cell cultures in cancer research was first trialled by 
Sutherland and colleagues as early as 1970 (Sutherland et al., 1970). Since then it 
has been found that culturing cancer cells in 3D results in the maintenance of 
structures similar to those present in the primary tumour which differentiates these 
cultures from standard monolayer cultures (Mueller-Klieser, 1987). Indeed, 
pancreatic cancer cell lines (PANC1 and BXPC3) were shown to grow successfully 
in multicellular spheroids (Sipos et al., 2003). However, a 3D spheroid model does 
not accurately represent the tumour microenvironment as it does not incorporate the 
plethora of other cells present in the microenvironment such as CAFs, immune cells, 
nerves or blood cells. Given that the microenvironment plays such a key role in PDAC 
development and maintenance (Waghray et al., 2013, Wang et al., 2016a, Khan et 
al., 2015) it was necessary to characterise the effect that the addition of CAFs had on 
spheroids created from PDAC cell lines. In the case of BXPC3, PANC1 and ASPC1 
cells, spheroids formed in the absence of CAFs, however MIAPACA2 and SUIT2 cells 
formed loose structures which did not resemble spheroids. The addition of CAFs to 
MIAPACA2 and SUIT2 3D cultures allowed spheroids to form which indicates that the 
CAFs are able to provide structure, most likely in the form of extracellular matrix which 
allows the formation of spheroids which could not form when tumour cells are cultured 
alone. Moreover, there were differences in the diameter of the spheroids between 
spheroids created from mono and co-cultures (Figure 3.8.). Spheroid co-cultures 
showed a decrease in diameter compared to pancreatic cancer cell line mono-
cultures except in the case of MIAPACA2. However, it was difficult to measure a true 
diameter in the MIAPACA2 mono-culture spheroids as they did not form structurally 
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stable spheroids.  Circularity was increased in co-cultures of PANC1, SUIT2 and 
MIAPACA2 compared with mono-cultures of the cancer cell lines (Figure 3.9.). Of all 
five cell lines used in this project these three are the more rapidly proliferating which 
could be the reason they require the support of ECM produced by CAFs in order to 
form structurally stable spheroids in culture. Phenotypic observations show the 
spheroids which contain CAFs appear to be denser with less spaces observed 
between the cells in the co-cultures of PANC1, SUIT2 and MIAPACA2 with CAFs 
(Figure 3.7.). ASPC1 cells show clear structural differences in spheroids created from 
mono and co-culture with CAFs (Figure 3.7.). Thus, incorporating CAFs, which are 
responsible for the desmoplastic stromal reaction, into 3D culture clearly affected the 
morphology of spheroids. This work contributes to the development of in vitro models 
which incorporates the interactions between CAFs and PDAC cancer cells. 
The distribution of αSMA positive cells throughout the spheroids (Figure 3.10.) 
resembles the distribution of CAFs within the PDAC tumour microenvironment (Figure 
3.1.) and is consistent with previous reports (Ware et al., 2016b). Unfortunately, due 
to the time limitations of the project it was not possible to complete the staining 
necessary to fully elucidate the morphology of the cells within the spheroids. Were 
this to be investigated further it would require staining for pan-cytokeratin and E-
cadherin to visualise the location of the pancreatic cancer cell lines and the junctions 
between the cells. Nevertheless, the circularity, diameter and morphological 
differences shown when CAFs are incorporated into the spheroids demonstrate that 
CAFs markedly affect PDAC spheroids when grown in co-culture. The presence of 
αSMA positive fibroblasts throughout the co-culture suggests that the cells are 
distributed in a manner that reflects primary patient samples.    
Hh and Wnt/β-catenin signalling pathways are involved in the maintenance of the 
PDAC tumour microenvironment (Morris et al., 2010, Bai et al., 2016, Bailey et al., 
2008, Pilarsky et al., 2008). Consequently, the effect of co-culturing CAFs with PDAC 
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tumour cells had upon these aberrant embryonic signalling pathways was 
investigated.  
The Hh pathway is activated during the development of the gastro-intestinal (GI) tract. 
Activation of Hh pathway during GI tract development results in the formation of 
tissues with duodenal properties rather than pancreatic tissue (Hebrok, 2003). 
Interestingly the Hh pathway is downregulated during pancreatic development 
(Hebrok, 2003). Moreover, in the adult pancreas, the Hh pathway is found to be 
restrained to the β-cells of the endocrine pancreas where it is involved in the 
production of insulin (Thomas et al., 2000). The Hh pathway can become active in 
the exocrine pancreas in the event of pancreatic injury where it has a role in tissue 
regeneration (Fendrich et al., 2008). It is clear therefore, that with particular regard to 
the pancreas, the Hh pathway is tightly regulated such that its activation is not only 
limited to specific areas but also in response to specific stimuli, namely insulin 
secretion.  
Mutations in Hh pathway components which lead to constitutive activation of the 
pathway have been identified in some cancers such as basal cell carcinoma and 
medullablastoma (Fecher and Sharfman, 2015, Archer et al., 2012). In addition, a 
subset of solid tumours exhibit aberrant ligand-driven Hh pathway activation including 
colon, ovarian, small-cell lung and pancreatic cancer (Wang et al., 2013, Szkandera 
et al., 2013, Savani et al., 2012, Yauch et al., 2008). Various reports have shown that 
in the case of aberrant ligand expression, the tumour cells are resistant to Shh 
whereas mesenchymal cells of the stroma are Shh responsive as determined by their 
upregulation of GLI1 (Nolan-Stevaux et al., 2009, Tian et al., 2009, Yauch et al., 
2008). Activation of the Hh pathway in PDAC was initially reported by two 
independent studies (Nakashima et al., 2006, Kasperczyk et al., 2009). Shh 
expression is detected from PanIN1 throughout disease progression and this 
expression has been found to correspond directly with oncogenic Kras expression, 
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indicating that Shh is downstream of KrasG12D during pancreatic tumorigenesis (Ling 
et al., 2012). Kras is able to influence Shh expression through the NF-κB pathway; 
the activation of NF-κB signalling in vitro can promote transcriptional activity of Shh 
(Gu et al., 2016). It has been established that Shh expressed by the tumour cancer 
cells activate SMO-dependant downstream signalling in CAFs in the pancreatic 
stroma which leads to desmoplasia (Bailey et al., 2008, Feldmann et al., 2007, Olive 
et al., 2009). IHC visualisation of Shh ligand within the PDAC tumour 
microenvironment showed Shh expression in the tumour cells lining pancreatic ducts 
and was found to be absent in the stroma (Figure 4.2.). This is consistent with 
previous reports (Rucki et al., 2017, Damhofer et al., 2015) and demonstrates that 
Shh expression is restricted to the tumour cells of the tumour microenvironment. In 
2D culture PANC1, MIAPACA2 and SUIT2 cells expressed markedly more Shh than 
ASPC1, BXPC3 and CAFs. Moreover, the perinuclear pattern of Shh expression in 
PANC1, MIAPACA2 and SUIT2 is reminiscent of the Shh expression observed in the 
PDAC tumour microenvironment. This similarity suggests that, despite the inherent 
limitations associated with immortalized cell lines, PANC1, MIAPACA2 and SUIT2 
represented an appropriate PDAC model with respect to Shh signalling. 4/5 PDAC 
cell lines tested (PANC1, MIAPACA2 SUIT2 and ASPC1) secreted Shh whereas 
CAFs did not secrete Shh above the limit of detection of the ELISA. This level of Shh 
protein in cell supernatants was in broad agreement with the cellular expression level 
determined by IF, and is consistent with previous reports (Yamazaki et al., 2008). 
Together these data show that Shh is actively secreted by PDAC cells but not by 
CAFs suggesting that the tumour-supportive role of the stroma (Erkan et al., 2012b) 
is not mediated directly through Shh-driven proliferation. Rather through Shh, cancer 
cells are able to communicate with the surrounding microenvironment which supports 
cancer progression (Gu et al., 2016). 
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It was possible to activate Hh signalling in CAFs by treating them with rShh ligand 
(Figure 4.6). Moreover, Shh secreted by pancreatic cancer cells elicited a 
downstream signalling response in CAFs in vitro (Figure 4.7.) demonstrating the 
ability of pancreatic cancer cells to influence downstream Hh signalling in CAFs, a 
fact that was confirmed using a Transwell co-culture model (Figure 4.11.). Although 
GLI1 expression is accepted as a robust read-out for Hh signalling (Pandolfi and 
Stecca, 2015) other Hh pathway components such as PTCH11 and SMO are also 
activated in CAFs. The >5-fold upregulation of GLI1 and >8-fold upregulation of SMO 
mRNA which indicated an activation of Hh pathway in CAFs following co-culture of 
CAFs and PDAC cells. Likewise, the >9 fold upregulation of SMO and >7 fold 
upregulation PTCH11 expression also indicates Hh pathway activity. PTCH11 is not 
only the receptor for Shh but is an inhibitor of the Hh pathway through inhibition of 
SMO (Choudhry et al., 2014, Rimkus et al., 2016), however it is also a target of GLI1 
(Shahi et al., 2010)  suggesting an auto-inhibitory feedback mechanism is active in 
this pathway. Nevertheless, the upregulation of SMO, GLI1 and PTCH1 indicate that 
CAFs are able to respond to a physiologically relevant level of Hh stimulation provided 
by PANC1 cells. Introducing SMO inhibitors to the transwell co-culture model resulted 
in a loss of the upregulation of GLI1 which shows that this co-culture model of CAFs 
and PDAC cancer cell lines exhibits regulated and active Hh signalling which can be 
effectively utilised to assess the efficacy of small molecule inhibitors of Hh pathway 
components. This may therefore provide a model for exploring the underpinning 
mechanisms of the signalling pathways involved in the PDAC tumour 
microenvironment, and whether these pathways can be manipulated to produce a 
clinical benefit. The ability of these cell types to influence one another in vitro provides 
evidence that models of PDAC need to include CAFs to bridge the gap between in 
vitro and in vivo testing. Hh pathway inhibitors (SMO antagonists) have been shown 
to reduce the growth of pancreatic tumours in mice (Olive et al., 2009, Ozdemir et al., 
2015), which emphasizes a role for Hh pathway in PDAC tumour development. SMO 
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inhibitors trialled in the past have not had positive outcomes in the clinic for PDAC; 
IPI-926 was combined with Gemcitabine in a clinical trial (IPI-926-03 trial; 
NCT01130142). Unfortunately, the KPC model used in this study was not able to 
effectively predict the outcome of the long term effects of stromal depletion. Evidence 
suggests that depletion of the stroma results in more aggressive and metastatic 
tumour types (Rhim et al., 2014, Ozdemir et al., 2015). Once the stroma was depleted 
there was an approximate 3-fold upregulation of blood vessels which is responsible 
for the transient positive effects of increased drug delivery however eventually the 
increased blood supply led to an increased metastatic phenotype (Rhim et al., 2014). 
Nevertheless, such a key paracrine signalling mechanism may therefore represent 
an ideal drug target for PDAC as evidenced by the ability of Redx small molecule 
SMO inhibitors to disrupt the induction of GLI1 expression in CAFs. Therefore before 
any further therapies targeting stromal depletion are developed careful consideration 
needs to given to other components of the PDAC tumour microenvironment such as 
vasculature and perhaps stromal depletion in combination with angiogenesis 
inhibition would be more effective. Perhaps, modelling the complexity of the PDAC 
tumour microenvironment in in vitro models will aid in our understanding of the 
molecular mechanisms which underpin PDAC tumour maintenance and progression, 
and whether targeted therapies can be translated to a clinical benefit for patients. 
Furthermore, in light of the limitations of the KPC mouse model perhaps Hh pathway 
inhibitors in combination with inhibitors of other pathways which are involved in the 
PDAC tumour microenvironment, such as Wnt pathway still represent a viable 
targeted therapy approach for treatment of PDAC.  
More recently studies have been published which showed that genetic or 
pharmacological (Hh inhibitors) depletion of the stroma in KPC mice resulted in poorly 
differentiated tumours which were found to be phenotypically more aggressive and 
metastatic (Rhim et al., 2014, Ozdemir et al., 2015). This phenomenon had also been 
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reported in bladder cancer (Shin et al., 2014). Combined these data indicate that the 
role of the stroma is variable in PDAC progression and metastases. However, what 
is clear is that tumour cells and CAFs are part of a dynamic signalling network that 
allows crosstalk between these cell types.  
Unlike the Hh signalling pathway, the role of the Wnt signalling pathway in PDAC is 
poorly understood. Similar to the Hh signalling pathway, mutations which result in 
constitutive Wnt pathway activation are rare (Jiang et al., 2013, Weekes and Winn, 
2011). Despite this, cytoplasmic β-catenin accumulation (in approximately 65% of 
PDAC cases) is observed in both PanIn and PDAC (White et al., 2012) (Figure 5.1.). 
Inhibition of β-catenin using siRNA in pancreatic cancer cell lines has been found to 
significantly reduce proliferation and increase the apoptosis of cancer cells (Pasca di 
Magliano et al., 2007) indicating a role for the Wnt pathway in maintenance of PDAC 
tumorigenesis. The mechanism by which β-catenin relates to disease severity is not 
clear; Wnt ligands which correspond to canonical Wnt signalling have been found to 
be over expressed in PDAC (Pasca di Magliano et al., 2007, Sano et al., 2016). 
Wnt7B and Wnt5A have also been found to be present in the PDAC tumour 
microenvironment; these Wnt ligands are commonly associated with autocrine Wnt 
signalling (Arensman et al., 2014, Ripka et al., 2007).  In contrast, Wnt5A has also 
been implicated in playing a paracrine role within the PDAC tumour 
microenvironment, and co-culture experiments showed that pancreatic cancer cell 
lines could induce Wnt5A expression in CAFs (Ripka et al., 2007). In order for Wnt5A 
to activate canonical Wnt signalling it interacts with FZD5 which is typically associated 
with conditions which result in a dysregulation of tissue homeostasis such as the 
tissue fibrosis commonly observed during liver cirrhosis (Katoh and Katoh, 2007). 
This could be a potential mechanism by which Wnt signalling is involved in the 
desmoplastic reaction of PDAC.  
191 
 
Pancreatic development occurs initially in hypoxic conditions which causes the 
activation of hypoxia inducible factor-1α (HIF-1α) which in turn activates Notch 
signalling, this is responsible for the proliferation of naive endocrine cells from 
progenitor cells (Apelqvist et al., 1999). At approximately day 14 neovascularisation 
of the pancreas occurs which creates normoxic conditions which inhibits Notch 
signalling and Wnt/β-catenin signalling is activated this results in the proliferation of 
cells which form the exocrine pancreas (Wells et al., 2007). The interplay between 
these developmental signalling pathways which exists during pancreatic development 
could represent a mechanism by with these pathways are involved in pancreatic 
tumorigenesis. The Notch signalling pathway has been implicating in controlling 
epithelial to mesenchymal transition (EMT) and Wnt/β-catenin signalling has been 
implicated in acinar-ductal metaplasia (ADM) (Gungor et al., 2011, Zhang et al., 
2013). It is believed that the crosstalk between these pathways has a role in PDAC 
development (Hindriksen and Bijlsma, 2012) however the interplay between these 
pathways has not been elucidated. The β-catenin independent Wnt pathway has also 
been implicated in the development of vasculature during pancreatic tumour 
development, in particular Wnt5A has been associated with capillary sprouting 
(Masckauchan et al., 2006). Targeting angiogenesis in PDAC has been ineffective to 
date; it has been suggested that one way to overcome this is to target both Hh and 
Wnt pathways to inhibit the stroma and angiogenesis to increase the efficacy of 
chemotherapy (Weekes and Winn, 2011). I therefore sought to investigate whether 
the Wnt pathway had any involvement in the crosstalk between CAFs and pancreatic 
cancer cells. When CAFs and pancreatic cancer cell lines were exposed to external 
Wnt signals from Wnt3A producing cells there was an upregulation of AXIN2 mRNA 
which indicates an upregulation of the Wnt pathway (Figure 5.4, Figure 5.5.). 
However, this did not give any indication as to whether one cell type was more likely 
to be Wnt ligand responsive. A Transwell co-culture model, showed an upregulation 
of AXIN2 mRNA in PANC1 cells when they were cultured with CAFs (Figure 5.9.) 
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however there was no change in AXIN2 in CAFs (Figure 5.10.) indicating that Wnt 
ligands are produced by CAFs in the PDAC tumour microenvironment. This paracrine 
signalling mechanism is the opposite to the observations regarding the Hh pathway 
wherein the Shh is produced by tumour cells and induces downstream signalling in 
the CAFs. This is interesting as both Hh and Wnt pathways have similar roles in tissue 
homeostasis in the adult organism especially with regard to maintenance of stem cell 
populations and wound repair (Petrova and Joyner, 2014, Mohammed et al., 2016, 
Bai et al., 2016). That a difference exists in the tumour microenvironment suggests 
that the tight regulation of these pathways which exists during development and 
homeostasis is lost when the pathways become aberrantly activated in the tumour.  
An array of Wnt pathway associated genes found SFRP4 to be differentially 
expressed in CAFs compared to NAFs (Figure 5.3.). Furthermore, culturing CAFs and 
PANC1 cells in the same well resulted in an upregulation of SFRP4 mRNA in CAFs 
(Table 5.1, Figure 5.11). As SFRP4 has been shown to be an inhibitor of Wnt pathway 
(Ford et al., 2013, Kawano and Kypta, 2003) this indicates the potential presence of 
antagonists of Wnt signalling in the PDAC tumour microenvironment. In order to fully 
understand the role of Wnt signalling in PDAC a much more in-depth study is 
required. Specifically the determination of which Wnt ligands are present in the PDAC 
tumour microenvironment and whether they are consistent with canonical or non-
canonical Wnt pathway activation is needed. Once it is established which pathway or 
if all are active in the PDAC tumour microenvironment it would be possible to establish 
the role of Wnt signalling in PDAC. Different combinations of Wnt ligands and Fzd 
receptors result in the activation of different downstream Wnt pathways which have 
different consequences within the cell (van Amerongen, 2012).  For example the PCP 
pathway has a role in tumour cell proliferation and resistance to cell death whereas 
the Wnt/ β-catenin pathway has been linked with anchorage independent growth and 
invasion of tumour cells (Daulat and Borg, 2017, Sano et al., 2016). 
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 Nevertheless, the discovery that culturing CAFs and pancreatic cancer cells in the 
same well induced changes in Wnt pathway activation through upregulation of AXIN2 
in PANC1 cells was sufficient to show these cell types are able to signal to one 
another in an in vitro model. It was also possible to inhibit the upregulation of the Wnt 
pathway in PANC1 resulting from them being cultured with CAFs in a Transwell co-
culture model. This inhibition of Wnt pathway was achieved using a Redx PORCN 
inhibitor (Figure 5.9.), suggesting that this model can be effectively utilised to assess 
the efficacy of small molecule inhibitors of the Wnt pathway. The identification of the 
Wnt pathway being dysregulated in a number of human tumours including pancreatic, 
has led to the development of pharmacological inhibitors of the pathway. PORCN is 
an o-acetyl transferase which is required for the palmitoylation of Wnt ligands, a 
process which is required for their secretion. PORCN inhibitors have been identified 
as a potential therapeutic to target tumours such as colorectal cancer which is driven 
by the Wnt pathway (Schatoff et al., 2017) but also tumours which have a propensity 
to metastasize, such as pancreatic and lung (Zeng et al., 2006, Stewart, 2014). This 
is due to aberrant Wnt pathway activation being detected in cells identified as cancer 
stem cells (CSCs) which are believed to be involved in resistance to chemotherapy 
(de Sousa and Vermeulen, 2016).  
The ability of a Transwell co-culture model of CAFs and pancreatic cancer cell lines 
to cause an upregulation of both Hh and Wnt pathways indicates the importance of 
models which incorporate CAFs and potentially other aspects of the tumour 
microenvironment. In order to develop new therapies an agent must undergo rigorous 
testing in cells and animal models; this process can take over 10 years to complete 
and cost in excess of £500 million (Dickson and Gagnon, 2004). The development of 
new therapies in cancer is challenging due to the heterogeneity of tumours and the 
presence of a complex microenvironment which can affect resistance to therapies 
and overall disease progression. Drug discovery in the field of solid cancers still relies 
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heavily on testing the efficacy of new drugs on cancer cell lines grown in 2D, which 
then progresses to subcutaneous xenograft models (Unger et al., 2014). However, 
these reductionist models often give results which differ from those achieved in 
clinical trials (Mak et al., 2014). One reason for this is their inability to predict the effect 
of the tumour microenvironment on the therapies being tested. Therefore traditional 
methods of testing drug candidates has been under increasing examination and the 
development of more clinically relevant models which more effectively predict the 
clinical outcomes is of great importance in drug development (Santo et al., 2017). The 
overall aim of this project was to create a reproducible model which incorporated 
aspects of the PDAC tumour microenvironment to be used to screen new therapies.  
All of the pancreatic cancer cell lines tested (PANC1, MIAPACA2, SUIT2, BXPC3 and 
ASPC1) were sensitive to the anti-proliferative effect of chemotherapies such as 
Gemcitabine and Paclitaxel, however CAFs were found to be resistant at 72 and 96h 
(Figure 6.2, 6.3, 6.4. and 6.5.). This is consistent with previous reports detailing the 
efficacy of Gemcitabine in vitro in cancer cell lines from many tumour types including 
pancreatic, non-small cell lung, ovarian and bladder cancers (Rathos et al., 2012, Zoli 
et al., 1999, Boven et al., 1993, Pace et al., 2000, Hayashi et al., 2011). Gemcitabine 
targets the rapidly proliferating cancer cells, however in the PDAC tumour 
microenvironment approximately 80% of the tumour mass is composed of CAFs (Xie 
and Xie, 2015). Richards and colleagues also found CAFs to be intrinsically resistant 
to Gemcitabine, and CM from CAFs improved the survival of cancer cell lines treated 
with Gemcitabine (Richards et al., 2017). 2D co-culture models containing CAFs and 
PANC1 cells show a reduction in the anti-proliferative effect of Gemcitabine on 
PANC1 cells in the presence of CAFs (Figure 6.8, Figure 6.9.). Furthermore, 3D co-
culture models of CAFs and pancreatic cancer cell lines showed a marked effect on 
the efficacy of Gemcitabine (Figure 6.12.). There are intrinsic mechanisms of 
Gemcitabine resistance in PDAC such as levels of hENT1 or dCK expression in 
tumour cells (Giovannetti et al., 2006, Kroep et al., 2002). However, the data 
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presented herein suggests that CAFs also have an impact on Gemcitabine resistance 
which is more complex than simply providing a physical barrier to treatment. 
Fibroblast drug scavenging is one method by which CAFs affect gemcitabine 
resistance in PDAC. Hessman and colleagues show that the intracellular 
concentration of Gemcitabine in CAFs is higher than in tumour cells, suggesting that 
they remove Gemcitabine from the PDAC tumour microenvironment. This reduces 
the overall exposure of tumour cells to high concentrations of Gemcitabine and its 
anti-proliferative effect on cancer cells is therefore diminished (Hessmann et al., 
2017). Gemcitabine treatment has also been found to promote secretion of exosomes 
in CAFs which contain factors which induce expression of SNAIL in tumour cells 
(Richards et al., 2017). SNAIL expression has been found to promote tumour growth, 
metastases and chemotherapy resistance (Namba et al., 2015, Kaufhold and 
Bonavida, 2014). Both the exosome secretory role and the scavenging capacity of 
CAFs could explain the marked reduction in gemcitabine sensitivity when CAFs were 
co-cultured with PDAC cancer cell lines. Furthermore, 2D models which are 
commonly used in drug discovery provide an environment wherein every tumour cell 
has access to oxygen and nutrients which does not reflect the PDAC tumour 
microenvironment (Mehta et al., 2012). The deposition of collagen by the isolated 
CAFs contributed to the dense spheroids formed when in co-culture with PDAC cells. 
A more compact spheroid (with respect to PDAC cells alone) may help this model 
mimic the nutrient and oxygen restricted environment of the PDAC microenvironment.  
The lack of CAFs and 3D models may therefore offer an explanation as to why the 
ability to rapidly screen compounds in 2D cell assays has not resulted in a 
corresponding increase in approved drugs from the drug development industry. 
Developmental signalling pathways such as the Hh and Wnt pathways, which have 
been shown to be active in the PDAC tumour microenvironment, have also been 
implicated in mechanisms of Gemcitabine resistance (Jia and Xie, 2015). The efflux 
transporter ABCB2 is a downstream target of Shh and is believed to be involved in 
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resistance to Gemcitabine in PDAC (Xu et al., 2013). Wnt signalling has been 
implicated in increased resistance to Gemcitabine in lung cancer cell lines (Zhang et 
al., 2013); an increase in Wnt5a expression has been associated with increased 
resistance to apoptosis in response to Gemcitabine treatment in PDAC (Griesmann 
et al., 2013). Therefore the models presented in this project provide an accurate 
method by which compounds could be screened in an assay that takes into account 
the active Hh and Wnt paracrine signalling between CAFs and epithelial cells. 
Furthermore, this system accounts for the close 3D interaction and potential 
scavenging role of CAFs within PDAC. Taking such factors into account is necessary 
in understanding the molecular mechanisms which contribute to chemotherapy 
resistance in the PDAC tumour microenvironment.  
Models which take into consideration the complexity of the tumour microenvironment 
are necessary to fully understand the factors which will impact the efficacy of 
chemotherapies.  Together the data presented in this project indicate the intricacies 
of the signalling cross-talk network between CAFs and pancreatic cancer cell lines. 
To develop therapies to treat this complex disease it is necessary to utilise models 





Figure 7.1. Spheroid co-culture model summary 
The spheroid co-culture model presented is a mixed culture of CAFS and PDAC cancer cells which more 
accurately represents the PDAC tumour microenvironment than the standard 2D mono-culture which is 
most commonly utilised in drug discovery. I have demonstrated that culturing CAFs and PDAC cell lines 
in the same well (Chapter 5,6) results in active signalling (Hh, Wnt) between CAFs and tumour cells. 
Therefore it is likely that active signalling exists in the 3D co-culture model presented herein (Black/Red 
arrows). Additionally, the presence of CAFs in the model will result in the deposition of ECM mimicking 
the PDAC tumour microenvironment.  
 
Future Directions 
In order to continue with this project it is necessary to characterise this model further, 
I would have liked to stably transfect both the CAFs and tumour cell lines to express 
an easily identifiable marker such as (GFP or RFP). Once this had been 
accomplished it would be possible to quantify the proliferation of each cell type over 
time in the model and on the addition of chemotherapeutic agents, identify which cell 
type was most affected. In addition it would be interesting to investigate the efficacy 
of chemotherapies using different dosing methods such as the pulsing method 
described in chapter 6 (Figure 6.5, Figure 6.6) when they were used in the spheroid 
co-culture model. The pulsing dosing method more closely mimics the exposure of 
cells in the PDAC tumour than traditional dosing methods and the more closely we 
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can recapitulate what is happening in vivo the more chance we have of being able to 
predict how patients will respond to the chemotherapies.  
I was able to establish that culturing CAFs and tumour cells in the same well resulted 
in active Hh and Wnt signalling. Firstly, I would have like to investigate the levels of 
Hh and Wnt signalling in the spheroid co-culture model. Then eventually to use the 
spheroid co-culture model to test investigate combination therapies such as Hh and 
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